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ABSTRACT 
Biodegradable Hydrogel Composites for Growth Factor and Stem Cell 
Delivery in Osteochondral Tissue Engineering 
by 
Steven Lu 
Cartilage has a limited endogenous ability for self-repair and current clinical treatments 
for damaged or diseased cartilage tissue are insufficient. Additionally, there is a 
biological and mechanical interplay between cartilage and the underlying subchondral 
bone, linking the pathogenesis/regeneration of both tissues. Thus, this thesis seeks to 
develop hydrogel composites as growth factor and cell delivery vehicles to study the 
regeneration of osteochondral tissue. First, we investigated the release of growth factors 
from acellular hydrogel composites containing gelatin microparticles (GMPs) to 
stimulate the repair of cartilage tissue in an in vivo osteochondral defect model. 
Transforming growth factor-β3 (TGF-β3) with varying release kinetics and/or insulin-like 
growth factor-1 (IGF-1) were delivered from the chondral layer of bilayered hydrogel 
composites while the subchondral layer remained growth factor-free. Results 
demonstrated that dual delivery of TGF-β3 and IGF-1 did not synergistically enhance 
cartilage repair, regardless of release kinetics, and the delivery of IGF-1 alone positively 
stimulated osteochondral tissue repair. Subsequently, we focused on improving the repair 
of the subchondral bone. The second part of this thesis investigated the delivery of IGF-1 
and bone morphogenetic protein-2 (BMP-2) from the chondral and subchondral layers, 
respectively, of bilayered scaffolds in vivo. Results showed that BMP-2 enhanced 
subchondral bone repair, and that while the dual delivery of both growth factors did not 
improve cartilage repair, they synergistically enhanced subchondral bone formation over 
the delivery of IGF-1 alone. Using the results from this study, we also investigated 
relationships between specific cartilage and bone repair metrics to provide a fuller 
understanding of the osteochondral repair process. Correlation analysis revealed an 
intrinsic association between the degree of subchondral bone formation and cartilage 
surface regularity. Lastly, the third part of this thesis investigated the hydrogel 
composites as stem cell delivery vehicles. Degradable GMPs were used as temporary 
adherent substrates for anchorage-dependent mesenchymal stem cells (MSCs). MSCs 
were seeded onto GMPs and subsequently encapsulated in hydrogels to investigate their 
role on influencing MSC differentiation and aggregation. Non-seeded MSCs co-
encapsulated with GMPs in the hydrogels were used as a control for comparison. Results 
revealed that MSC-seeded GMPs exhibited more cell-cell contacts, greater chondrogenic 
potential, and a down-regulation of osteogenic markers compared to the controls. Overall, 
these hydrogel composites demonstrate potential as growth factor and cell delivery 
vehicles for the stimulation and study of osteochondral tissue regeneration. 
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Chapter 1 
Specific Aims 
Overview 
The overall objective of this thesis is to develop a biodegradable hydrogel 
composite as a growth factor and stem cell delivery vehicle for the study and regeneration 
of osteochondral tissue. These hydrogel scaffolds, fabricated from oligo(poly(ethylene 
glycol fumarate) (OPF) macromers, include gelatin microparticles as digestible porogens, 
carriers for the controlled release of growth factors, and moieties for stem cell interaction. 
Accordingly, the work in this thesis is divided into three specific aims. 
Specific Aim 1 
The first aim investigates the dual delivery of insulin-like growth factor-1 (IGF-1) 
and transforming growth factor-β3 (TGF-β3) from acellular hydrogel composites on 
articular cartilage repair in an osteochondral defect. Specifically, the release kinetics of 
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IGF-1 and TGF-β3 from the chondral layer of OPF hydrogel composites are studied in 
vitro and the effects of dual release on cartilage repair in vivo are assessed.  
Specific Aim 2 
The second aim investigates the dual delivery of IGF-1 and bone morphogenetic 
protein 2 (BMP-2) from bilayered hydrogel composites on osteochondral tissue repair. 
Specifically, IGF-1 and BMP-2 are incorporated in the chondral and subchondral layers, 
respectively, of bilayered scaffolds and the influence of the enhanced subchondral bone 
repair on cartilage regeneration is examined in vivo. 
Specific Aim 3 
The third aim investigates the use of degradable GMPs as temporary adherent-
substrates for MSCs within hydrogel composites. Specifically, the degradation rate of 
GMPs is tuned by modulating crosslinking density, and the differentiation and 
condensation potential of MSCs seeded onto GMPs of varying crosslinking densities and 
sizes are assessed in vitro. 
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Chapter 2 
Background 
 Cartilage damage and cartilage-related diseases are the most common cause of 
disability in the United States today, affecting more than 21% of adults at a cost of $128 
billion in medical bills and lost earnings to the economy [1-3]. 27 million adults, more 
than 10% of the United States adult population, alone have clinical osteoarthritis, and was 
the fourth most common cause of hospitalization in 2009 [4]. Articular cartilage’s low 
friction surface and high capacity to bear loads makes it indispensible in joint movement. 
However, its poor intrinsic capacity for self-repair has necessitated numerous therapeutic 
strategies, none of which have yet to provide a consistent and sustained healing response. 
Clinical therapeutic interventions have often resulted in only transient pain relief or 
inconsistent spontaneous healing [5]. As a result, tissue engineering has emerged as a 
valuable strategy to recapitulate the functional requirements of native articular cartilage. 
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2.1. Osteochondral Tissue 
2.1.1. Articular Cartilage 
2.1.1.1.  Function and Composition 
 Articular cartilage is a multiphasic tissue consisting primarily of 70-80% water by 
weight [6]. The solid fraction of the tissue is composed of 50-75% collagens, 15-30% 
proteoglycans, chondrocytes, and other protein macromolecules [3, 6]. Cartilage is an 
alymphatic, aneural, and avascular tissue, and as a result, has a limited potential for self-
repair. Due to its avascularity, the interstitial fluid within the pores of the extracellular 
matrix (ECM) plays an important role in transporting nutrients and waste within the 
tissue. In addition, due to its high water content, articular cartilage exhibits viscoelastic 
properties, allowing it to support high compressive loads [6]. 
 Collagen types present in articular cartilage include type II, VI, IX, X, and XI, of 
which type II makes up 90-95% of all collagen present in cartilage ECM [7]. Collagen 
type II fibers form complex networks to provide tensile strength and are essential to the 
tissue’s shape and volume. In addition, these fibers form a mesh with collage type XI and 
IX that entrap other macromolecules such as proteoglycans [7]. Proteoglycans are large 
macromolecules consisting of a protein core and glycosaminoglycan (GAG) side chains. 
The primary articular cartilage proteoglycan is aggrecan, comprising GAG chains of 
keratin sulfate and chondroitin sulfate linked to a protein core. Aggrecan, in turn, can 
bind to a long hyaluronan chain to form large proteoglycan aggregates. Due to the 
presence of highly negatively charged GAG chains, cartilage ECM has a net negative 
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charge known as the fixed charge density, which attracts ions from the interstitial fluid to 
create an osmotic pressure and causes the matrix to swell [6, 8]. 
 Another proteoglycan abundant in articular cartilage is perlecan. Found in the 
pericellular matrix of cartilage, perlecan bears heparin sulfate chains that have high 
affinity for growth factor binding [9]. While the mechanistic actions of perlecan in 
cartilage remains elusive, the presence of perlecan in cartilage condensation, maturation, 
and homeostasis is essential [10]. Perlecan provides cell-cell and cell-matrix interactions, 
which suggests its role in mechanotransduction processes, and plays a role as a ligand 
reservoir for the protection, storage, and release of growth factors [11, 12]. 
Articular cartilage can be modeled as a tissue with four structurally distinct layers 
as seen in Figure 2.1, each playing a role in its tensile, shear, and compressive properties 
[13]. The superficial/tangential layer comprises the upper 10-20% of articular cartilage 
and is the primary articulating surface with collagen fibers aligned parallel to the joint 
surface [6, 14]. This layer also has a high water content with compressive strains reaching 
up to 50% [3]. Due to fluid flow and matrix consolidation, chondrocytes present in this 
layer are flattened oriented along the collagen fibers [3]. 
 The middle/intermediate layer experiences little strain and occupies 40-60% of 
the total cartilage thickness [6]. Cell density in this layer is lower than the superficial 
layer and assume a more spherical morphology. These chondrocytes also produce high 
amounts of proteoglycans and collagen type II in random orientation [6]. 
 In the deep/radial zone, collagen fibers are packed tightly into large bundles 
oriented perpendicular to the articular surface and are anchored to the underlying 
subchondral bone. Proteoglycan content here is lower than the middle layer, and cell 
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density is the lowest of the three cartilaginous layers [6]. These cells often form a 
columnar arrangement in groups of four to eight cells and have high metabolic activity 
[14]. 
 The calcified zone marks the transition from pliable cartilage to stiff bone 
and is responsible for attaching the non-calcified cartilage to the underlying subchondral 
bone. Chondrocytes in this region are larger and are referred to as hypertrophic [14]. 
2.1.1.2. Injury and Repair 
 Injury to articular cartilage can occur through trauma, mechanical injury, and/or 
wear and tear. Three main types of injury occur: cartilage microfracture/matrix 
disruption, chondral defect/partial thickness defect, or osteochondral defect/full thickness 
defect. If a cartilage microfracture injury is minimal, remaining chondrocytes can 
increase their synthetic activity to repair the tissue. If the injury is more extensive and the 
collagen network is disrupted, altered load distribution of the cartilage matrix may occur, 
resulting in propagation of forces to the bone. This can result in thicker subchondral bone 
and thinner cartilage, leading to further degeneration of articular cartilage [15]. This type 
of injury can also lead to chondral fissures. 
 Chondral fissures are defects contained within the cartilage layer and do not 
extend to the subchondral bone. These types of defects often lead to an osteochondral 
defect due to limited metabolic activity for healing. Osteochondral defects comprise both 
the chondral and subchondral layer due to penetration of the underlying bone. As a result, 
access to the bone’s vasculature enables a spontaneous healing response by tapping into 
growth factors and progenitor cells present in the bone marrow [16].  
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 Following the creation of an osteochondral defect, permeation of blood into the 
defect site forms a fibrin clot and a classic wound healing response ensues [7]. Factors 
from the fibrin clot recruit MSCs and in the following two weeks, MSCs proliferate and 
differentiate. In rabbit osteochondral defect models, differentiated cells continue to 
produce collagen type II and I after two weeks, and by week 4-8, a well demarcated 
cartilage layer is developed [17-19]. Presence of hyaline cartilage can been seen by week 
4-12 depending on the type of defect created: in a femoral patellar groove defect, neo-
cartilage with Safranin O staining was seen as early as week 4 [19], whereas in a femoral 
head defect, hyaline cartilage was observed between 8 and 12 weeks [18]. However, 
regenerated cartilage all defect types often consists of both hyaline cartilage and 
fibrocartilage and degeneration of the neo-tissue can be observed as early as 12 weeks 
[19]. A number of factors may contribute to the degeneration of the newly formed 
cartilage. Fibrocartilage is mechanically inferior to hyaline cartilage and fissures may 
occur due to matrix degeneration and GAG loss [6]. In addition, the collagen fibrils of the 
repair tissue have been seen to be poorly integrated with the native cartilage adjacent to 
the defect site [19]. This could lead to micromotion and vertical shear stresses between 
the repair and residual cartilage, exacerbating cartilage degeneration [16]. Between 6 and 
12 months, matrix and cells of the repaired tissue continually regress to fibrocartilage, 
leading to chronic degeneration [16, 17]. 
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2.1.2. Subchondral Bone 
2.1.2.1. Function and Composition 
 Bone is a highly anisotropic material that continually adapts to changes in its 
physiological and/or mechanical environment through a cyclic process of bone formation 
and resorption [20, 21]. The primary elements of bone tissue consist of collagen and 
hydroxyapatite crystals, with collagen type I comprising approximately 95% of the total 
collagen content and about 80% of the total proteins present in bone [22]. Like articular 
cartilage, the mechanical properties of bone reflect the inherent material properties of its 
constituents: collagen grants bone its toughness and capacity to absorb energy while the 
mineral content helps determine the bone’s stiffness [21]. Three types of cells also exist 
within bone: osteoclasts which resorb bone, osteoblasts which produce calcified tissue, 
and osteocytes which continue to calcify surrounding tissue [23]. 
 The subchondral bone itself can be classified into two types: cortical 
bone/subchondral plate and trabecular bone. Cortical bone is dense, lies adjacent to 
calcified cartilage, and has low porosity and vascularity while trabecular bone is 
approximately 80% porous [23]. Due to differences in bone structure and organization, 
these two tissues adapt to mechanical loads in different ways and have distinct 
mechanical properties.  
2.1.2.2. Injury and Repair 
 Penetrative injuries to subchondral bone often results from continued 
degeneration of chondral fissures that reach the underlying bone as mentioned above. 
However, degenerative changes in subchondral bone can occur prior to the appearance of 
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an osteochondral defect. Certain studies have shown that a biphasic phenomenon is seen 
with early and late stage osteoarthritis. Early osteoarthritis is associated with thinning of 
the subchondral plate (the cortical bone) and overall decrease in bone volume [24, 25], 
whereas late stage osteoarthritis is associated with a thickening of the subchondral plate, 
increased stiffness, and increased density [26, 27]. An increase in trabecular bone volume 
also occurs with an increase in trabecular number and reduced separation between 
trabeculae [20]. However, while apparent (overall bone tissue) density increases, the 
matrix itself is not well mineralized leading to a reduced material density [20, 28]. 
Research has indicated that 6-12 months are required before new bone is fully 
mineralized [20, 29]. An increase in denatured collagen content has also been seen in 
subchondral bone in osteoarthritis [28]. Understanding these changes in subchondral 
bone during injury and repair can help interpret the mechanisms involved in the overall 
repair of osteochondral tissue. 
 
2.1.3. Interaction between articular cartilage and subchondral bone 
 Given the contact between cartilage and bone, total joint homeostasis will 
ultimately rely on the functional restoration of both tissues. Injury to articular cartilage 
can propagate to the underlying bone, and the health of cartilage tissue has been linked to 
the maintenance of normal biomechanics of the subchondral bone [30, 31]. It has been 
hypothesized that changes in subchondral bone may precede cartilage deterioration [32], 
and many studies have showed that changes in underlying bone occur early in 
osteoarthritis [33]. However, both cartilage and bone respond to biological and 
mechanical signals at different paces [33, 34]: bone has the capacity to rapidly remodel 
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its matrix, while chondrocytes in cartilage have a much lower synthetic activity [33]. The 
mechanisms of osteochondral tissue degeneration are complex and still unclear. Yet, with 
these challenges in mind, numerous tissue engineering strategies are being developed to 
address the biological, mechanical, and temporal interplay between articular cartilage and 
subchondral bone. 
 
 
2.2. Osteochondral Tissue Engineering 
 The regeneration of osteochondral tissue is a unique, albeit complicated endeavor; 
one that involves two anisotropic structures, both with distinct layers and biological 
constituents. Reviews on the tissue engineering of either cartilage or bone are extensive 
and are listed as follows [3, 5, 7, 16, 35-46]. While the generation of osteochondral tissue 
involves many of the same cell types, bioactive molecules, and scaffolds used for 
cartilage and bone tissue repair, osteochondral engineering requires more intricate 
designs to target the two layers. A general overview of these strategies are outlined 
below. 
 
2.2.1. Scaffold Design 
 Currently, there are four different approaches in designing scaffolds for 
osteochondral tissue as seen in Figure 2.2: (A) a scaffold for the subchondral layer but no 
scaffold for the chondral layer, (B) different scaffolds for the chondral and subchondral 
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layer which are combined at the time of implantation, (C) a single, heterogeneous 
composite scaffold, or (D) a single, homogenous scaffold for both layers [13, 47, 48]. 
Type (A) scaffolds generally involve seeding of cells on top of the subchondral 
component. For Type (B) scaffolds, cartilage-like and/or bone-like tissues are engineered 
in vitro and then combined through suturing or adhering. In contrast, Type (C) scaffolds 
are heterogeneous with two distinct, yet integrated, layers. These scaffold types also 
include continuous material gradient designs [49]. Type (D) scaffolds involve a single 
homogenous scaffold that may or may not incorporate distinct chondrogenic and 
osteogenic cells/bioactive molecules. Each scaffold type has its pros and cons and have 
shown promise in regenerating osteochondral tissue. 
 
2.2.2. Scaffold Materials 
 Osteochondral tissue engineering often requires a biocompatible and 
biodegradable scaffold to provide structural support for neo-tissue formation [50]. These 
scaffolds can also be designed to match the mechanical properties of surrounding tissue 
as well as control the delivery of cells and/or bioactive molecules [51]. In addition, these 
three-dimensional scaffolds can be highly porous with an interconnected pore network to 
facilitate cell migration and transport of nutrients and waste [52]. Scaffold materials for 
the subchondral layer usually fit in one of three categories: natural polymers, synthetic 
polymers, and inorganic materials. These materials in turn can be used to make a variety 
of matrices with unique cell/bioactive molecule delivery properties [50]. Similarly, 
natural and synthetic polymers have been used as materials to develop numerous three-
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dimensional scaffolds, hydrogels, micro- or nanoparticles, and/or composites for the 
chondral layer [50].  
 
2.2.3. Cells 
 Cells are another key component of tissue engineering. While cells are necessary 
for the in vitro generation of osteochondral tissue, an exogenous cell source is not 
essential for in vivo regeneration. This is especially true for osteochondral defects which 
penetrate the subchondral bone and access progenitor cells in the marrow space. 
However, studies have shown that delivering exogenous cells to chondral and 
osteochondral defects accelerates regeneration [6]. A number of cell types exist for 
osteochondral repair, the most prevalent being MSCs. These cells are capable of 
differentiating down a number of mesenchymal tissue lineage pathways including bone 
and cartilage [41], making it the most versatile cell type for osteochondral tissue 
engineering. Chondrocytes have also been used for osteochondral tissue repair, not only 
because of their cartilage-specific phenotype, but due to their ability to re-differentiate 
into osteoblasts [14]. Similarly, osteoblasts, the primary bone-forming cells, have been 
used for bone repair. However, both chondrocytes and osteoblasts must be isolated from 
an autologous biopsy, which can cause damage to the harvest site. Additionally, 
availability of such cells are often limited and in the case of chondrocytes, ex vivo 
expansion can result in de-differentiation [47]. Embryonic stem cells have also been 
investigated due to their pluripotent nature and capacity for unlimited proliferation. 
However, results have been tenuous and the political, legal, and ethical questions 
surrounding the use of embryonic stem cells deters their use [6, 51]. 
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2.2.4. Bioactive Factors 
 The growth and development of osteochondral tissue heavily relies on 
biochemical signals, of which the intensity, temporal, and spatial stimulation all play a 
role in determining specific ECM synthesis and tissue formation. Among these 
biochemical signals include growth factors which control a wide variety of cellular 
responses through transmembrane receptor binding [46]. A summary of the most 
common growth factors used for bone and cartilage tissue engineering are listed in Table 
2.1 with their effects on MSCs. BMPs, particularly BMP-2, are the most extensively 
studied osteogenic factors due to their powerful osteoinductive properties. On the other 
hand, TGF-β has been shown to be effective at inducing chondrogenic differentiation of 
MSCs and retaining the chondrogenic phenotype of chondrocytes in vitro [36]. However, 
mixed results have been reported on TGF-β delivery to osteochondral defects in vivo with 
potential deleterious effects [36].  
 The effects of TGF-β, BMP, and other growth factors such as vascular endothelial 
growth factor, platelet-derived growth factor, fibroblast growth factor, and insulin-like 
growth factor all have cartilage- and bone-specific responses. For example, BMP-2 can 
reverse chondrocyte de-differentiation and can increase cartilage-specific ECM 
production while decreasing collagen type I expression [36, 39]. Yet, BMP-2 also 
stimulate MSCs towards an osteogenic lineage and are an important osteoinductive factor 
[45, 50]. Harnessing the tissue-specific effects of these growth factors can be an 
important tool in osteochondral tissue engineering. 
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2.3. Background Summary 
 Due to articular cartilage’s low propensity for self-repair and the shortcomings of 
clinical therapies, tissue engineering strategies have emerged as an alternative to 
regenerating articular cartilage. In studying the injury and repair of articular cartilage, 
research has shown a close functional relationship with the underlying subchondral bone. 
These two distinct tissues comprise the osteochondral unit. As such, unique 
osteochondral tissue engineering constructs have been implemented, combining both 
cartilage and bone tissue engineering strategies. One of these constructs is the 
oligo(poly(ethylene glycol) fumarate) (OPF) hydrogel. OPF hydrogels have been utilized 
for a myriad of regenerative medicine applications, notably the regeneration of cartilage 
and bone. Previous research has validated the use of bilayered OPF hydrogels containing 
GMPs to create composites for the generation of osteochondral tissue. Most recently, 
these composites have dual delivered IGF-1 and TGF-β3 in vitro and investigated their 
combined effects on MSCs. In addition, MSCs have been encapsulated in OPF hydrogel 
composites to evaluate the potential of cellular composites for osteochondral tissue 
repair. Taking these previous results into account, the following Specific Aims will 
outline growth factor and cell delivery strategies in bilayered OPF hydrogel composite 
systems for osteochondral tissue engineering. 
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2.4. Tables and Figures 
 
Figure 2.1 A diagram depicting the different layers and components of articular cartilage 
and subchondral bone.  
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Figure 2.2 A schematic of the different scaffolding strategies used for the fabrication of 
osteochondral grafts [47]. 
 
 
Table 2.1 Summary of the effect of growth factors on MSCs [36, 45, 53] 
Growth Factor  Source  Effect on MSCs 
Transforming growth 
factor beta (TGF-β) 
 
Platelets, bone ECM, 
cartilage matrix 
 
Pleiotropic factor 
Increases proliferation and ECM production 
Bone morphogenetic 
proteins (BMP) 
 
Osteoprogenitor cells, 
osteoblasts, bone ECM 
 
Promotes differentiation of MSCs into 
chondrocytes and osteoblasts 
Fibroblast growth 
factors (FGF) 
 
Macrophages, MSCs, 
chondrocytes, osteoblasts 
 
Mitogenic factor 
 
Insulin-like growth 
factors (IGF) 
 
Bone matrix, osteoblasts, 
chondrocytes 
 
Mitogenic factor 
Increases expression of ECM 
Platelet-derived 
growth factor 
(PDGF) 
 Platelets, osteoblasts  
Mitogenic factor 
Chemotaxis factor 
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Chapter 3 
Fumarate-based hydrogels in regenerative 
medicine applications* 
The past several years have seen the development of novel fumarate-based 
hydrogels for tissue engineering applications.  These biocompatible and biodegradable 
hydrogels include poly(propylene fumarate-co-ethylene glycol), oligo(poly(ethylene 
glycol) fumarate), and poly(lactide-co-ethylene oxide-co-fumarate).  They have the 
capacity to be injectable and crosslinked in situ, and each hydrogel has its own unique set 
of physical properties that can be tailored to meet the requirements of a specific function.  
Such versatile functionality situates fumarate-based hydrogels as excellent scaffolds for 
numerous regenerative medicine applications. 
                                                        
 
* This chapter was published as Lu S, Kim K, Lam J, Kasper FK, Mikos AG. Fumarate-based 
hydrogels in regenerative medicine applications. In Biomaterials and Regenerative Medicine, Ma 
PX, editor: Cambridge University Press, New York, 279-294, 2014. 
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3.1. Introduction 
 Hydrogels are an excellent scaffold structure for numerous applications in tissue 
engineering and regenerative medicine. In particular, they can be used as cell and drug 
carriers to deliver such therapeutic components directly and locally [54].  Hydrogels can 
be injectable and crosslinked in situ, reducing the need for risky invasive surgeries [55].  
In addition, hydrogels can mimic the natural extracellular matrix (ECM) environment and 
allow for control of cellular and tissue functions as well as the transport of nutrients and 
bioactive molecules [56, 57].  
Fumarate-based hydrogels are synthetic polymers, allowing for flexible control of 
physical, mechanical, and degradative properties for a desired application [57].  Fumaric 
acid, the fundamental component of these hydrogel scaffolds, is an unsaturated organic 
acid commonly found in the human body and can be metabolized through the Krebs cycle 
[58-60].  Polymer chains that contain fumarate units crosslink easily via the unsaturated 
double bonds and degrade through hydrolysis of the ester bonds in the fumarate group 
[59-62].  Furthermore, the biodegradable nature of these hydrogels allows for neotissue 
ingrowth and eliminates the need for another surgery to remove the implanted scaffold 
[58, 63].  
Current research on fumarate-based hydrogels as tissue engineering scaffolds for 
regenerative medicine applications include poly(propylene fumarate-co-ethylene glycol) 
(P(PF-co-EG)), oligo(poly(ethylene glycol) fumarate) (OPF), and poly(lactide-co-
ethylene oxide-co-fumarate) (PLEOF). These hydrogel scaffolds have been well 
characterized with a number of in vitro and/or in vivo studies proving them to be non-
cytotoxic and biocompatible to surrounding tissues [64-67].  In addition, the ease in 
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crosslinking modulation of fumarate-based hydrogels is a testament to their versatility. 
As biodegradable and biocompatible materials, each hydrogel has its unique physical and 
mechanical properties that can be tailored to meet the needs of specific regenerative 
medicine applications including drug delivery and regeneration of bone, cartilage, and 
nerve tissue.  This chapter will illustrate the chemistry and characterization behind these 
fumarate-based hydrogels in addition to their applications in regenerative medicine.   
 
 
3.2. Poly(propylene fumarate-co-ethylene glycol) hydrogel 
Macroporous hydrogels based on poly(propylene fumarate-co-ethylene glycol) 
(P(PF-co-EG)) have been investigated over the past decade as an injectable, 
biodegradable scaffolding material for the modulation of cellular behavior [68-71]. 
 
3.2.1. Chemistry 
P(PF-co-EG) is a block copolymer of poly(propylene fumarate) (PPF) and 
poly(ethylene glycol) (PEG). It is formed via a multistep reaction that begins with the 
synthesis of PPF, a biodegradable polyester previously characterized and investigated for 
applications in orthopaedic and craniofacial tissue engineering [72-75]. First, diethyl 
fumarate and propylene glycol are reacted in the presence of catalytic zinc chloride to 
create bis(2-hydroxypropyl) fumarate, a diester intermediate. The intermediate can then 
be transesterified under vacuum to yield a linear unsaturated form of PPF [76]. Once PPF 
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is obtained, it can be reacted with PEG or methoxy-PEG to form the P(PF-co-EG) 
copolymer via a transesterification reaction as seen in Figure 3.1 [61, 69]. The use of 
methoxy-PEG allows for a more controlled synthesis of P(PF-co-EG) and ensures that at 
most two PEG block attach to the linear PPF chain [61].  
Due to the presence of fumarate double bonds in the PPF blocks, P(PF-co-EG) is 
a highly unsaturated copolymer. As a result of this intrinsic property, the raw copolymer 
material can undergo crosslinking to produce amphiphilic hydrogels [64]. The 
amphiphilic nature of P(PF-co-EG) also permits the copolymer to undergo reversible 
thermal gelation via changes in intermolecular behavior upon fluctuations in temperature 
[61]. The thermal initiation system for crosslinking can leverage a crosslinker, such as 
poly(ethylene glycol) diacrylate (PEG-DA), in combination with a radical initiator (e.g., 
the redox radical initiators ammonium persulfate (APS) and ascorbic acid (AA)) [77]. 
Sodium bicarbonate can be added to the reaction to interact with AA to generate carbon 
dioxide gas. The generated gas allows the production of macroporous hydrogel materials 
[78, 79].  
 
3.2.2. Characterization 
3.2.2.1. Swelling and degradation 
P(PF-co-EG) consists of alternating hydrophobic PPF and hydrophilic PEG 
polymer blocks. Due to the hydrophilic nature of the PEG component, P(PF-co-EG) 
materials can retain water to form amphiphilic hydrogels after crosslinking. By altering 
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the amounts of the hydrophilic and hydrophobic components, the swelling properties of 
P(PF-co-EG) hydrogels can be tuned [70]. Indeed, previous swelling studies have 
demonstrated that equilibrium swelling ratios of P(PF-co-EG) hydrogels are increased 
with higher PEG amounts and decreased with higher PPF amounts [70]. Additionally, 
physical properties such as compressive and tensile moduli can be modulated by 
adjusting the PPF:PEG ratio [70]. Because PPF retains the bulk structural integrity, 
higher PPF amounts are correlated with materials of greater mechanical strength. For 
example, hydrogels prepared with a 1:2 weight ratio of PPF to PEG had a tensile modulus 
of 1.90 ± 0.67 MPa while the same hydrogels prepared with a 2:1 weight ratio of PPF to 
PEG had a significantly higher tensile modulus of 20.66 ± 2.42 MPa [16]. 
With regard to the degradation characteristics of P(PF-co-EG) hydrogels, several 
studies have observed the mechanism by which these amphiphilic hydrogels degrade [64, 
79]. Due to the presence of hydrolytically cleavable ester bonds in PPF, P(PF-co-EG) 
hydrogels are expected to undergo bulk degradation following the absorption of water. 
Typically, bulk degrading materials maintain their shape and volume but lose mechanical 
strength as their internal polymeric networks undergo hydrolysis. However, this may not 
apply to hydrogels that undergo bulk degradation, as increased water penetration will 
affect the shape and volume of these materials over time. The gradual loss of mechanical 
strength over time was observed in both in vitro and in vivo conditions as measured by 
decreases in complex dynamic flexural and tensile moduli [64, 79].  
Like the swelling properties, the degradation rate of P(PF-co-EG) can be altered 
as well. For instance, greater amounts of mass loss are observed in hydrogels with higher 
PPF content [64]. Although PPF is responsible for a majority of the mechanical strength 
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attributed to P(PF-co-EG) hydrogels, the ester linkages make it most susceptible to 
hydrolytic cleavage [79]. As a result, increasing weight percentages of PPF initially 
increase tensile strength of the hydrogel but ultimately increase the rate of bulk 
degradation. Since the current system uses PEG-DA as the crosslinker, the crosslinking 
density can be modified by changing the P(PF-co-EG):PEG-DA ratio to also affect the 
degradation of P(PF-co-EG) hydrogels. Purportedly, smaller P(PF-co-EG):PEG-DA 
ratios, or higher crosslinking densities, result in slower degradation [79]. This is because 
more ester linkages need to be cleaved in hydrogels with greater crosslinking densities, 
ultimately leading to a slower degradation rate. Unlike other polyester scaffolds, 
however, the degradation of P(PF-co-EG) hydrogels is not heavily influenced by porosity 
[79]. While hydrophobic scaffolds may not swell in aqueous environments, P(PF-co-EG) 
hydrogels are already swollen with water and as a result, the rate of hydrolytic 
degradation for these materials is not influenced by an increase in surface area due to 
porosity.  
3.2.2.2. Cytocompatibility and biocompatibility  
Investigations of the in vitro cytotoxicity and in vivo biocompatibility of P(PF-co-
EG) hydrogels revealed favorable biological responses. Specifically, cytotoxicity was 
evaluated by exposing monolayer endothelial cell cultures to leachable materials from 
P(PF-co-EG) hydrogel films and then measuring their levels of viability and proliferation 
[80]. As determined by an MTT assay, the viability of exposed monolayers to gel 
compositions with high PEG amounts was not significantly different from that of 
negative controls [80]. Since P(PF-co-EG) based hydrogels are intended for injectable, 
biodegradable applications within the body, in vivo biocompatibility is also crucial. A 
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cage implant system was employed as the in vivo model to assess biocompatibility [80]. 
Briefly, dehydrated gel films were placed inside sterilized small cylindrical cages and 
implanted subcutaneously into Sprague Dawley rats [80]. Biochemical and histological 
analyses of exudates and extracted copolymer films revealed that the biocompatibility of 
P(PF-co-EG) hydrogels is dependent on the copolymer composition. In particular, 
increasing amounts of uncrosslinked PPF elicited more toxic responses in vivo [80]. 
Hence, cytotoxicity and inflammation can be attenuated with higher weight percentages 
or molecular weights (MWs) of the PEG component. Overall, P(PF-co-EG) hydrogels 
exhibited excellent biocompatibility upon implantation, demonstrating their suitability as 
effective tissue engineering scaffolds.   
3.2.2.3. Modification with biomimetic peptides 
With regard to biocompatibility, P(PF-co-EG) hydrogels were able to 
accommodate varying levels of cell adhesion. Copolymer modifications via changing the 
PEG amount can influence the physicochemical properties of hydrogels and thus cell 
adhesion. Tanahashi et al. reported that the adhesion of smooth muscle cells and human 
endothelial cells was dependent on the hydrophilicity of the hydrogels; less hydrophilic 
P(PF-co-EG) hydrogels elicited smaller amounts of cell adhesion [68]. However, cells 
bound to macroporous P(PF-co-EG) hydrogels alone do not display any morphological 
signs of activity [68]. In order to affect changes in cellular behavior, ECM adhesion 
peptides such as the arginine-glycine-aspartic acid (RGD) sequence have been 
incorporated into the bulk macroporous hydrogel, imparting properties that are 
biomimetic of the natural ECM [71]. Behravesh et al. incorporated RGD adhesion 
peptides into P(PF-co-EG) hydrogels by crosslinking P(PF-co-EG) with acryloyl-PEG-
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GRGDS, which was synthesized by reacting the oligopeptide GRGDS with acryloyl-
poly(ethylene glycol) N-hydroxysuccinimide (Ac-PEG-NHS) [15]. Adhesion and 
migration assays studying the behavior of bone marrow stromal cells, also referred to as 
mesenchymal stem cells (MSCs), on macroporous P(PF-co-EG) hydrogels demonstrated 
that cell specific binding can be achieved and that the cells bound are biologically active 
[71]. For instance, marrow-derived osteoblasts have been shown to bind, spread, and 
migrate on RGD-functionalized P(PF-co-EG) hydrogels, revealing the ability of these 
scaffolds to activate anchorage-dependent behaviors in this particular cell type [71]. By 
incorporating RGD peptide sequences into P(PF-co-EG) copolymers using PEG spacers 
and PEG blocks of specific MWs, only cell types with receptors for the RGD sequence 
are selected for binding. Additionally, biomimetic P(PF-co-EG) hydrogels can sustain the 
differentiation of progenitor cells [71]. Utilizing RGD-functionalized P(PF-co-EG) 
hydrogels as three-dimensional scaffolds for culture of bone marrow-derived MSCs, the 
biomimetic hydrogel was used as a vehicle for osteoblastic differentiation [81]. One can 
imagine the utility of such technologies for the ex vivo modulation of bone marrow-
derived MSCs to develop cell-inspired therapeutics for orthopedic tissue engineering 
applications.  
Another way P(PF-co-EG) hydrogels were modified involved the tethering of 
positively charged  agmatine to the PEG copolymer blocks [82]. Agmatine is a compound 
naturally synthesized from the amino acid arginine and is naturally metabolized by the 
body to form putrecine and urea [82]. Its cationic properties can be used to enhance the 
adhesion of vascular smooth muscle cells via the adsorption of anionic ECM molecules. 
To incorporate agmatine into P(PF-co-EG) hydrogels, Tanahashi et al. first generated 
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PEG-tethered fumarate (PEGF) groups by reacting PEG with diethyl fumarate in the 
presence of catalysts [29]. Next, PEGF was reacted with succinic anhydride to generate 
succinylated PEGF, which was further reacted with N-hydroxysuccinimide (NHS) to 
generate NHS-PEGF. The NHS group was then leveraged for the attachment of agmatine 
sulfate to PEGF via the NHS ester linkage to yield agmatine-PEGF. Finally, agmatine-
PEGF was crosslinked with P(PF-co-EG) to fabricate agmatine modified P(PF-co-EG) 
hydrogels in the presence of ascorbic acid [29]. Interestingly, P(PF-co-EG) hydrogels 
modified in the bulk with agmatine possess the ability to accommodate cell binding while 
maintaining high levels of hydrophilicity [83]. This property, along with the ability for 
these cationic hydrogels to biodegrade, makes agmatine modified P(PF-co-EG) hydrogels 
very suitable for cell carrier applications in tissue engineering.  
3.2.2.4. Thermoreversibility 
Hydrogels based on certain compositions of P(PF-co-EG) copolymers possess 
thermoreversible properties. Such thermoreversible behavior, as indicated by the 
presence of a lower critical solution temperature (LCST), arises from the amphiphilic 
nature of the P(PF-co-EG) copolymers. Behravesh et al. reported the appearance of 
LCSTs for P(PF-co-EG) copolymer solutions that were synthesized using PEG of low 
MWs [61]. Indeed, the block length of the PEG components in the copolymer played a 
crucial role in determining the LCST and sol-gel transition temperatures. Copolymers 
comprising PEG with high MWs may not exhibit any thermoreversible properties due to 
their high hydrophilicity. P(PF-co-EG) hydrogels have been formulated to achieve 
LCSTs that increase from 25 °C (near room temperature) to 35 °C (near body 
temperature) by decreasing the salt concentration of aqueous sodium chloride solutions in 
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which the P(PF-co-EG) hydrogels are immersed [77, 78]. The presence of salts alters the 
hydrogen bonding between the hydrophobic PPF and hydrophilic PEG blocks to affect 
changes in LCST [8]. These properties make P(PF-co-EG) hydrogels advantageous for 
the minimally invasive delivery of cells or other therapeutics for tissue engineering 
applications. Furthermore, these hydrogels can be chemically crosslinked utilizing a 
water-soluble redox initiator system that incorporates a basic and an acidic initiator to 
form macroporous P(PF-co-EG) hydrogels [78].   
 
3.2.3. Regenerative medicine applications 
3.2.3.1. Bone regeneration  
Using several in vitro models, P(PF-co-EG) based hydrogels have been 
investigated for potential applications in bone tissue engineering [68, 71, 81]. One such 
study seeded marrow-derived osteoblasts within biomimetic P(PF-co-EG) hydrogels and 
observed their subsequent adhesion and migration [71]. From the results, incorporating 
RGDS into P(PF-co-EG) hydrogels permitted the adhesion of up to 84% of the initial 
seeding density of marrow-derived osteoblasts [71]. Using a megacolony migration 
assay, Behravesh et al. detected increasing cell surface area coverage that occurred as a 
result of cell migration on RGD and not proliferation of cells [71]. By employing such 
behavior, it becomes feasible to apply biomimetic P(PF-co-EG) based hydrogels for the 
guided regeneration of orthopaedic or dental tissues.  Cells would mechanistically bind to 
implanted biomimetic scaffolds and migrate according to biological cues (like RGD 
peptides) engineered to therapeutically direct these cells to the defect site. It was also 
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demonstrated that MSCs seeded in P(PF-co-EG) based hydrogels could undergo 
osteoblastic differentiation when treated with osteogenically conditioned media [81]. 
Specifically, MSCs seeded in macroporous three-dimensional P(PF-co-EG) hydrogels 
exhibited substantial calcium deposition [81]. Using macroporous P(PF-co-EG) 
hydrogels that are biomimetic of the bone environment, marrow-derived progenitor cells 
may be harvested from patients with minimal donor site morbidity and expanded ex vivo 
for subsequent autologous cellular therapies.       
3.2.3.2. Cartilage regeneration  
Injectable and thermoreversible P(PF-co-EG) based hydrogels have also been 
investigated for cartilage regeneration. Due to the hydrophilicity of the PEG blocks, 
synthetic scaffolds based on P(PF-co-EG) copolymers inherently retain water to yield 
water-laden materials. Such properties are biomimetic of natural cartilage tissues. In an 
effort to assess the potential of applying P(PF-co-EG) hydrogels for cartilage 
regeneration, Fisher et al. encapsulated bovine articular chondrocytes within 
thermoreversibly gelled P(PF-co-EG) hydrogels and examined their viability [84]. 
Accordingly, the chondrocytes maintained satisfactory levels of proteoglycan and 
collagen type II syntheses. The proliferation of these cells was also increased with the 
addition of bone morphogenetic protein-7 [84].  
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3.3. Oligo(poly(ethylene glycol) fumarate) hydrogel 
While P(PF-co-EG) showed promise as a hydrogel scaffold for regenerative 
medicine applications, oligo(poly(ethylene glycol) fumarate) (OPF) macromers were 
developed for the fabrication of hydrogels with improved control over hydrogel 
parameters. P(PF-co-EG) macromers contain multiple PPF blocks, with each PPF block 
comprising several fumarate groups [70, 76, 77]. However, these multiple fumarate 
groups can result in varying MW between crosslinks and mesh sizes in fabricated 
hydrogel networks [77]. OPF macromers consist of fumarate groups separated by PEG 
chains of defined molecular weight. As a result, hydrogels with different mesh sizes can 
be easily fabricated by varying the molecular weight of the PEG employed in the 
synthesis of the macromer [62]. OPF hydrogels with tailored and controlled physical 
properties have great potential in a myriad of tissue engineering applications. 
 
3.3.1. Chemistry 
 OPF macromers consist of alternating units of fumarate groups and PEG chains, 
with the macromers capped by end PEG chains [59, 85]. These macromers are 
synthesized in a one-pot reaction, as seen in Figure 3.2, through the addition of distilled 
fumaryl chloride (FuCl) and triethylamine (TEA) dropwise to distilled PEG in a molar 
ratio of 1:0.9 PEG:FuCl. The molar ratio of FuCl to TEA is 1:2 in order to remove 
chlorine from the ends of FuCl. Upon completion of the reaction, the mixture is filtered, 
purified, and dried to obtain the macromer in powdered form [59]. 
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OPF macromers have been crosslinked in a variety of ways to form hydrogels 
through its fumarate groups.  Crosslinking can occur by radical polymerization through 
photo-initiation or thermal initiation. Photo-crosslinking has been achieved with a 
commercialized photo-initiator such as Irgacure 2959 and N-vinylpyrrolidone (NVP) as a 
comonomer [86].  Thermal crosslinking has been implemented in the presence of either 
APS and AA or APS and N,N,N’,N’ –tetramethylethylenediamine (TEMED) as seen in 
Figure 3.3. While both initiator systems have previously been used, the APS/TEMED 
initiator mix remains near neutral pH whereas the APS/AA system is acidic [66, 87]. 
Poly(ethylene glycol)-diacrylate and N,N’-methylene bisacrylamide (BISAM) have been 
used as crosslinkers in combination with the initiator systems just described to form OPF 
hydrogels [62, 88]. 
 
3.3.2. Characterization 
3.3.2.1. Swelling and degradation 
 Numerous swelling and degradation studies have been performed to investigate 
changes in physical properties as the OPF macromer length is varied [55, 62, 65]. Since 
OPF macromers consist of alternating units of fumarate groups and PEG chains, it is 
expected that longer PEG chains incorporated into the macromers would increase the 
hydrophilicity of the hydrogels, and thus greater swelling would occur. As the PEG chain 
MW increased from 1K to 35K, equilibrium swelling of chemically crosslinked 
hydrogels increased [62, 89, 90]. In addition, molecular weight between crosslinks and 
mesh size also increased as the initial PEG MW in OPF macromers increased [62].  For 
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example, as the PEG MW increased from 1K to 10K, mesh size of the resulting hydrogel 
increased from 76 to 160 Å respectively [62].  
As previously mentioned, degradation of OPF hydrogels is induced by cleavage 
of ester bonds within the polymer network by hydrolysis. The degree of degradation is 
extrapolated through mass loss and swelling ratio data over time and has been shown to 
be a function of PEG chain length in OPF macromers as well as crosslinking density [65]. 
There is an inverse relationship between crosslinking density and mass loss with greater 
mass loss occurring over time with a lower crosslinking density [65, 89].  
 When OPF hydrogels were crosslinked through photo-initiation, increasing the 
concentration of the comonomer NVP decreased the swelling ratio [86]. Over a period of 
21 days, a significant increase in sol fraction for low NVP concentrations in comparison 
to high NVP concentrations was also seen [86].  
 Composite OPF hydrogels have also been fabricated that have their own distinct 
swelling and degradation characteristics. Composite hydrogels comprising OPF and 
gelatin microparticles (GMPs) have been investigated using GMPs as growth factor (GF) 
delivery vehicles and an enzymaticaly digestible porogen [88]. When comparing OPF 
hydrogels and OPF-GMP composite hydrogels, no significant difference in swelling ratio 
and mass loss was observed by day 28 in PBS [55]. However, a significant increase in 
swelling ratio of composite hydrogels over simple hydrogels was observed by day 28 in 
collagenase-PBS [55]. This increase in degradation highlights the potential enzymatic 
effects of an in vivo environment on OPF-GMP composite hydrogels. 
 Mixed-mode OPF hydrogels crosslinked with PEG-dithiol produced hydrogels 
with distinct degradation and swelling properties. Hydrogels containing 20 wt% PEG-
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dithiol had increased swelling and decreased degradation time in comparison to 10 wt% 
PEG-dithiol and 0 wt % PEG-dithiol containing OPF hydrogels [91]. Due to the complex 
nature of these mixed-mode hydrogels involving chain and step polymerization, 20 wt% 
PEG-dithiol hydrogels may have a lower crosslinking density than 10 wt% or 0 wt % 
PEG-dithiol containing OPF hydrogels [91]. In addition, the presence of sulfide bonds 
located near the ester groups may promote faster ester hydrolysis [91, 92]. 
3.3.2.2. Cytocompatibility and biocompatibility 
 Before utilizing OPF hydrogels in tissue engineering, evaluation of its in vitro 
cytotoxicity and in vivo biocompatibility need to be investigated. Cytotoxicity of 
hydrogel constituents including the linear macromer, crosslinking agents, and initiators 
were examined. In addition, leachable substances from crosslinked hydrogels (i.e., sol 
fraction) were tested. Results showed that while OPF macromers were found to be non-
cytotoxic with no significant difference between high and low MW OPF macromers, 
shorter chain PEG-DA was more cytotoxic than longer chain PEG-DA [66]. Unreacted 
leachable components from crosslinked hydrogels were also found to be non-cytotoxic 
[66]. Also, the chemical initiators used to fabricate crosslinked hydrogels exhibited 
favorable cytocompatibility at concentrations relevant to hydrogel formation [66, 93].  
 Since the intended applications for OPF hydrogels include injectable scaffolds, 
studies investigating in vivo biocompatibility are essential. Research on the bone and soft 
tissue behavior of OPF hydrogels in rabbit models demonstrated positive results [65, 94]. 
Cranial and subcutaneous implants resulted in formation of a thin fibrous capsule 
regardless of varying hydrogel fabrication parameters [65]. Also, in vivo degradation 
products from hydrogels with 8K PEG MW elicited a minor inflammatory response, 
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whereas hydrogels with 1K PEG MW had limited degradation [65]. Overall, minimal 
cytotoxicity and favorable biocompatibility establish OPF hydrogels as excellent 
synthetic scaffolds for tissue engineering applications. 
3.3.2.3. Modification with biomimetic peptides 
 OPF hydrogels have been functionalized with biomimetic peptides with the intent 
to modulate cellular functions in guided tissue regeneration [95]. These peptides, 
including RGD and osteopontin-derived peptide (ODP), were incorporated in OPF 
hydrogels through bulk modification: by coupling the peptides to an Ac-PEG-NHS 
spacer, the resulting acrylated peptides could be crosslinked within the OPF network [96, 
97]. In a comparison between hydrogels modified with ODP and Gly-Arg-Gly-Asp-Ser 
(GRGDS), osteoblasts migrated faster on ODP modified hydrogels [98]. Also, increased 
migration occurred with increasing peptide concentration. In addition, bone marrow-
derived MSCs showed greater alkaline phosphatase (ALP) activity and greater OPN 
secretion on ODP-modified hydrogels in comparison to RGD-modified hydrogels [99]. 
These peptide modification techniques support the versatility of OPF hydrogels to 
enhance cellular functions and direct tissue-specific regeneration. 
 
3.3.3. Regenerative medicine applications 
3.3.3.1. Bone regeneration 
In a number of experiments, OPF hydrogels have been used as biomaterial 
scaffolds to support osteogenic differentiation of bone marrow-derived MSCs. In 
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particular, OPF hydrogels modified with RGD and ODP peptides exhibited greater OPN 
production and calcium deposition by seeded bone marrow-derived MSCs in comparison 
to unmodified hydrogels [97]. In addition, bone marrow-derived MSC adhesion, 
migration, and differentiation into osteoblasts are regulated by the concentration of 
incorporated adhesion peptides [98, 99].  Encapsulated bone marrow-derived MSCs also 
exhibit osteogenic differentiation when cultured in osteogenic media with greater OPN 
and calcium deposition in higher swelling hydrogels [54, 87]. Similarly, OPF gels with 
greater pore sizes enhanced osteogenic differentiation of bone marrow-derived MSCs 
[100].  
3.3.3.2. Cartilage regeneration 
Besides osteogenesis, OPF hydrogels have been used to mimic a native articular 
cartilage environment to support cartilage tissue formation. Several in vitro studies 
investigated chondrogenesis of encapsulated cells in hydrogels through a myriad of cell 
and GF combinations. By combining marrow-derived MSCs or chondrocytes with 
transforming growth factor-β1 (TGF-β1) released from GMPs, greater chondrogenesis 
was observed with the release of TGF-β1 in comparison to the absence of TGF-β1 [101, 
102]. An insulin-like growth factor-1 (IGF-1) and TGF-β1 dual growth factor release 
system was also investigated with encapsulated MSCs. Results showed upregulation of 
chondrocyte-specific genes for MSCs with TGF-β1 and promotion of cell aggregation 
with IGF-1 [103]. The physical properties of OPF hydrogels also affect chondrogenesis 
with a larger mesh size correlating to a larger PEG chain in OPF macromers increasing 
chondrogenesis of encapsulated MSCs [89].  In addition, a hydrogel co-culture system 
utilizing osteogenic cells in the bottom layer and MSCs in the top layer of bilyared OPF 
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constructs suggests a synergistic effect between the two layers to promote 
chondrogenesis in the top layer [104, 105]. In vivo studies utilizing OPF hydrogels to 
repair a full-thickness osteochondral defect have also been carried out. In these 
experiments, successful regeneration of subchondral tissue was seen employing OPF 
hydrogel scaffolds [106-108]. In addition, OPF hydrogels comprising GFs, including 
IGF-1 and TGF-β1, as well as MSCs show great potential for the repair of cartilage 
tissue.  
3.3.3.3. Tendon/ligament regeneration 
In a series of studies delivering fibroblasts for tendon/ligament regeneration, OPF 
based hydrogels were used as a template biomaterial to investigate cellular responses 
from mechanical stimuli [91, 109, 110]. Fibroblasts harvested from cruciate ligaments 
and patellar tendons of bovine knee joints have been encapsulated in OPF/PEG-DA/PEG-
dithiol mixed-mode hydrogels [91].  This research revealed that incorporation of 20 wt% 
PEG-dithiol can promote cell clustering and aggregation within hydrogel environments.  
Additionally, the differentiation of encapsulated human MSCs in OPF hydrogels into 
fibroblasts can be induced under cyclic tensile culture conditions [109].  Upregulated 
expression levels of tenascin-C, collagen type I and collagen type III were exhibited over 
21 days in the presence of mechanical stimuli.  Another study also investigated spatial 
controllability of photo-lithographically patterned OPF hydrogels with high spatial 
fidelity and thickness [110].  By utilizing serial steps of photocrosslinking and lamination 
in a simple, inexpensive microfluidic device, tissue-scale (1-2 mm in thickness) OPF 
hydrogels encapsulating multiple primary cell types could be patterned with high spatial 
control.   
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3.3.3.4. Lens regeneration 
One of the recent investigations of OPF hydrogels for tissue engineering 
applications is pigment epithelial cell encapsulation for lens regeneration [111].  Newt 
iris pigment epithelial cells were encapsulated in OPF hydrogels for implantation into 
lentectomized newts in vivo. Histological examination after 30 days indicated that 
encapsulated cells in hydrogel beads (1 mm in diameter) trans-differentiated into lens 
tissues. This was confirmed by lens fiber tissue formation without adverse side effects by 
hydrogel degradation [111].   
3.3.3.5. Nerve tissue regeneration 
Fumarate-based biomaterials have also been investigated for spinal cord and 
nerve regeneration in neural tissue engineering [112-115].  In order to overcome the 
drawbacks of autologous nerve grafts for the treatment of segmental peripheral nerve 
defects, such as malfunction in donor nerve site and size mismatch between a nerve graft 
and an implanted site, a variety of hydrogel systems have recently been investigated 
[112].  Among these degradable synthetic biomaterials, OPF hydrogels with the aid of 
electrically charged reagents have been developed for preliminary applications in neural 
tissue engineering [112, 114].  By copolymerization with [2-(methacryloyloxy) ethyl]-
trimethylammonium chloride (MAETAC), OPF hydrogels can be positively charged to 
support dorsal root ganglion neuron attachment and differentiation in a MAETAC 
monomer amount-dependent manner [112].  Another study investigated the incorporation 
of an electrically conductive polymer, polypyrrole (PPy) [114].  In order to achieve high 
conductivity in a nerve guidance conduit and to stabilize the positive charge, three anions 
36 
 
were incorporated with the OPF-PPy hydrogel system; naphthalene sulfonic acid, docecyl 
benzene sulfonic acid, and dioctyl sulfosuccinate. This composite hydrogel system was 
not cytotoxic to PC12 cells over 7 days in vitro. More importantly, neurite extension 
analysis after 24 hrs indicated that OPF-PPy hydrogels with naphthalene sulfonic acid 
promoted PC12 cell attachment and neurite length extension [114]. These recent studies 
demonstrate the potential use of electrically conductive fumarate-based hydrogel 
composites for nerve regeneration [113, 115].  
3.3.3.6. Delivery of bioactive molecules 
The delivery of bioactive molecules from OPF hydrogel composites has been researched 
for medicinal and regenerative applications. Using an OPF hydrogel carrier composite, 
the delivery of a chemotherapeutic anti-cancer drug, doxorubicin (Dox), was investigated 
[116].  An ionic monomer, sodium methacrylate, was crosslinked with OPF to form 
negatively charged hydrogels which could then couple with positively charged Dox 
through electrostatic interactions. This research demonstrated that controlled release 
kinetics of Dox from OPF hydrogels depended on the charge density of the hydrogel as 
well as the ionic strength of the surrounding environment [116]. In addition, released Dox 
maintained its anti-cancer activity to MG63 cells.  Precise control in the concentration of 
incorporated drugs could be achieved by modulation of OPF hydrogel chemical 
composition, subsequent changes in polyelectrolyte properties, and interactions with the 
ionic strength and pH of the surrounding environment [116].  
With the aid of poly(lactic-co-glycolic acid) (PLGA) microparticles, therapeutic 
proteins and drugs can be delivered in vivo in a controlled manner using OPF hydrogel 
platforms [117]. One such therapeutic protein, dibutyryl cyclic adenosine monophosphate 
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(dbcAMP), has been encapsulated in PLGA microparticles in OPF hydrogels for spinal 
cord transection studies [117]. This study demonstrated that sustained delivery of 
dbcAMP reduced capillary formation and the volume of cyst and scar formation in the 
presence of Schwann cells and MSCs. A functional recovery of motor skills in an animal 
model was significantly improved when dbcAMP was delivered with only MSCs [117]. 
Therapeutic proteins have also been released from OPF hydrogels and OPF-GMP 
composites. Due to innate charge differences, IGF-1 and TGF-β1 with isoelectric points 
(IEPs) of 7.5 and 9.5 respectively can bind to acidic GMPs with an IEP of 5.0 through 
ionic complexion at physiologic pH [118]. By complexing TGF-β1 to GMPs, burst 
release of the GF was reduced in comparison to release from simple OPF hydrogels . 
Dual GF delivery systems have also been employed using OPF-GMP composites with no 
deleterious effects of one GF release on the other [118]. Such systems offer spatial and 
temporal control on GF release for regenerative medicine applications [102-104].  
Plasmid DNA can also be delivered using OPF hydrogels [119, 120] and OPF-
GMP composites [121-123]. The release of plasmid DNA from an OPF hydrogel can be 
controlled by the PEG chain MW and subsequent degradation profile of the hydrogel 
[120, 121]. A study involving co-encapsulation of plasmid DNA and cells in OPF 
hydrogels demonstrated that bone tumor cells in hydrogels could be transfected by 
plasmid DNA encoding green fluorescent protein (GFP) and the transfected cells 
continuously expressed GFP protein over 21 days [119]. In the same study, estrogen 
receptor (ER)-negative human fetal osteoblasts were transfected by plasmid DNA 
encoding ER, and increased ALP activity and estrogen-dependent luciferase activities 
with the estrogen treatment were seen [119]. When plasmid DNA-GMP complexes were 
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encapsulated in OPF hydrogels, a sustained release of plasmid DNA over 42 days was 
observed in mice in vivo relative to a direct injection of DNA solution and the delivery of 
non-embedded DNA [122]. Another study also investigated the potential of OPF 
composite hydrogels encapsulating plasmid DNA encoding human bone morphogenetic 
protein-2 (BMP-2) complexed to GMPs to enhance bone regeneration in a critical sized 
rat cranial defect model [123].  
 
 
3.4. Poly(lactide-co-ethylene oxide-co-fumarate) hydrogel 
In addition to OPF, another fumarate-based hydrogel has been developed with 
controlled physical properties as an alternative for specific regenerative medicine 
applications. Poly(lactide-co-ethylene oxide-co-fumarate) (PLEOF) comprises an 
ultralow molecular weight poly(ʟ-lactide) (PLA) block that offers greater tunability of the 
fabricated hydrogel water content and degradation rate [124]. Preliminary studies show 
PLEOF hydrogels have potential as a fumarate-based tissue engineered scaffold with 
such added modifications. 
 
3.4.1. Chemistry 
PLEOF is also a PEG-based terpolymer modified using a fumarate unit to control 
crosslinkability [60].  In situ crosslinkable PLEOF macromers can be synthesized with a 
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co-polymer of PLA and diethylene glycol (produced by ring opening polymerization of ʟ-
lactide with diethylene glycol as an initiator), PEG blocks, and FuCl by condensation 
polymerization [60, 124].  The degradation products of the terpolymer include lactic acid 
and fumaric acid that can be metabolized, as well as PEG which can be excreted by the 
body [60]. 
For the crosslinking reaction, BISAM was used as a crosslinker while an acidic 
initiator, APS, and basic radical catalyst, TEMED, were utilized for a neutral redox 
initiation [60].  Crosslinking properties of PLEOF hydrogels are dependent on the 
concentrations of initiator/accelerator. As such, increasing APS/TEMED concentrations 
increased the rate of the crosslinking reaction, decreased gelation time, and increased the 
ultimate storage modulus of PLEOF hydrogels [60].  Increasing the concentration of 
BISAM also increased the ultimate modulus of the gels [60].  An increase in crosslinking 
density of PLEOF hydrogels was achieved by increasing the density of fumarate groups 
in PLEOF [60, 67].  In addition to chemical crosslinking, PLEOF can also be photo-
crosslinked with the aid of NVP, a photo-initiator, and UV radiation [125]. Like P(PF-co-
EG) and OPF macromers, PLEOF precursor chains can be crosslinked through the C=C 
double bond in the fumarate group. Crosslinking density and degradation of photo-
crosslinked PLEOF hydrogels are dependent of the composition (e.g., NVP 
concentration, PLA to PEG ratio, and PLEOF concentration) as well as the time and 
intensity of UV radiation [125].  
In addition to chemically crosslinked hydrogels using BISAM, a peptide 
crosslinker was also investigated to develop both hydrolytically and enzymatically 
degradable PLEOF hydrogels [67].  In this study, matrix metalloproteinase (MMP)-13 
40 
 
degradable peptide sequence QPQGLAK with acrylate end-groups functioned as the 
crosslinker polymerized with PLEOF macromers.  Peptide crosslinked PLEOF hydrogels 
showed higher water content and sol fraction compared to BISAM crosslinked hydrogels 
due to the relatively higher MW of the peptide crosslinker [67].  Using both peptide and 
BISAM crosslinkers, the degradation rate of PLEOF hydrogels were modulated by the 
ratio of the two crosslinkers, the amount of MMP-13 to cleave the peptide sequences, and 
the incubation time to expose to MMP-13 [67].  
 
3.4.2. Characterization 
A number of studies have been done to characterize the physical properties of this 
versatile terpolymer macromer.  The swelling ratio of PLEOF can be adjusted by varying 
the ratio of hydrophobic PLA blocks to hydrophilic PEG blocks as well as the PEG chain 
length [124, 126].  In addition, the degradation rate is controlled by the ratio of PLA to 
PEG blocks and the hydrogel mesh size is modified through the density of fumarate 
groups in the terpolymer [60].  In experiments with photo-crosslinked PLEOF hydrogels, 
hydrogels with greater PLA:PEG ratio exhibited decreased swelling and increased sol 
fraction.  Degradation experiments indicated that the PLA:PEG block ratio, and 
ultimately the ratio of lactide to fumarate units, affected the degradation rate of PLEOF 
hydrogels [124].  
The cytocompatibility of PLEOF hydrogels was also tested with MSCs. MSCs 
cultured in a medium containing BISAM crosslinker had a marked decrease in cell 
viability in comparison to those cultured in medium containing a peptide crosslinker [67].  
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The peptide crosslinked hydrogel network was shown to be cytocompatible with 
encapsulated MSCs (e.g., 90% viability), however, the sol fraction exhibited some 
adverse affects (e.g., 65% viability) [67].  
 
3.4.3. Regenerative medicine applications 
3.4.3.1. Bone regeneration 
Peptide incorporation in PLEOF hydrogels can enhance their osteoconductivity 
[127].  In order to conjugate various bioactive peptides in PLEOF hydrogels, acrylamide-
terminated RGD peptides were first crosslinked with fumarate groups in PLEOF 
macromers and PEGylated peptides derived from BMP-2 were grafted to the hydrogel 
surface by specific click chemistry between the azide group of the peptides and the 
propargyl group of the hydrogels [127].  As osteoblastic differentiation of encapsulated 
MSCs was observed in peptide-modified PLEOF hydrogels [67], MSCs seeded onto 
hydrogels conjugated with both RGD and BMP-2 derived peptides exhibited increased 
ALP activity and mineralization over 21 days of in vitro culture compared to hydrogels 
with single incorporation of either RGD or BMP-derived peptides [127].  Specifically, 
calcium deposition on PLEOF hydrogels with both peptides was significantly higher than 
solely RGD or BMP-2 derived peptide grafted hydrogels.  
Hydroxyapatite (HA) nanoparticles have also been incorporated for the 
fabrication of PLEOF nanocomposite hydrogels [128-130].  Interaction between HA 
nanoparticles with uncrosslinked PLEOF macromer chains [129] or incorporated peptides 
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[128] influenced the viscoelastic properties of PLEOF composite hydrogels.  Moreover, 
PLEOF/HA hydrogels conjugated with RGD peptides were utilized to coat electrospun 
PLA fiber-meshes to form multilayered fiber-reinforced laminated composite hydrogels 
[130].  In this study, MSCs seeded onto laminated PLEOF hydrogels with HA 
incorporation and RGD peptide conjugation exhibited enhanced osteoblastic 
differentiation, as evidenced by the expression of OPN and osteocalcin marker genes, and 
mineralization over 21 days of in vitro culture.   
3.4.3.2. Delivery of bioactive molecules 
Recently, the release kinetics of stromal derived factor-1α (SDF-1α) from PLEOF 
hydrogels and its effect on the migration of MSCs were investigated [126].  Increasing 
the PLA content in PLEOF macromers resulted in a decreased mesh size, increased SDF-
1α loading efficiency, and sustained release of SDF-1α [126]. In addition, the migration 
rate of MSCs was dependent on the release kinetics of SDF-1α from the PLEOF 
hydrogels.   
 
 
3.5. Conclusion 
The multitude of human tissues, each uniquely developed with specific function, 
calls upon versatile tissue engineered scaffolds with tailored and controlled properties. 
The synthetic hydrogels described here have been conceived to possess fumarate units. 
These fumarate units contain double bonds that allow the formation of a crosslinked 
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network, and ester groups that potentiate these hydrogels to degrade hydrolytically into 
biocompatible elements. P(PF-co-EG), OPF, and PLEOF have been synthesized with 
their own distinct physical properties and the development of these fumarate-based 
biomaterials has led to hydrogels with further adaptability over their physicochemical 
properties for specific tissue type regeneration. Future developments can illustrate the 
robust potential of these fumarate-based hydrogels as injectable, biodegradable, and 
biocompatible tissue engineered scaffolds. 
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3.6. Tables and Figures 
 
Figure 3.1 A schematic of the transesterification reaction between PEG and PPF to form 
the copolymer P(PF-co-EG) [69] 
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Figure 3.2 A schematic showing the synthesis of the OPF macromer from PEG and FuCl 
[59] 
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Figure 3.3 Chemical crosslinking of OPF with PEG-DA in the presence of initiators to 
form a hydrogel [62] 
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Chapter 4 
Strategies for Controlled Delivery of Biologics 
for Cartilage Repair* 
The delivery of biologics is an important component in the treatment of 
osteoarthritis and the functional restoration of articular cartilage. Numerous factors have 
been implicated in the cartilage repair process, but the uncontrolled delivery of these 
factors may not only reduce their full reparative potential and can also cause unwanted 
morphological effects. It is therefore imperative to consider the type of biologic to be 
delivered, the method of delivery, and the temporal as well as spatial presentation of the 
biologic to achieve the desired effect in cartilage repair. Additionally, the delivery of a 
single factor may not be sufficient in guiding neo-tissue formation, motivating recent 
research towards the delivery of multiple factors. This review will discuss the roles of 
                                                        
 
* This chapter was published as Lu S, Lam J, Kasper FK, Mikos AG. Strategies for controlled 
delivery of biologics for cartilage repair. Advanced Drug Delivery Reviews. 84:123-34 (2015). 
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various biologics involved in cartilage repair and the different methods of delivery for 
appropriate healing responses. A number of spatiotemporal strategies will then be 
emphasized for the controlled delivery of single and multiple bioactive factors in both in 
vitro and in vivo cartilage tissue engineering applications. 
 
 
4.1. Introduction 
The avascular and relatively acellular nature of articular cartilage complicates its 
natural capacity for regeneration upon damage. While numerous clinical therapies, such 
as microfracture, autologous chondrocyte implantation, and osteochondral grafts, have 
been developed for the treatment of cartilage injuries, they have been hampered by 
inferior cartilage repair and significant donor site morbidity [131]. Indeed, given the 
extensive literature presently highlighting the shortcomings of current clinical techniques 
for the management of chondral and osteochondral injuries, it is clear that the field of 
cartilage repair remains an area in critical need of innovative alternative therapies [132-
134]. In light of the disadvantages hindering the efficacy of currently available cartilage 
treatment options, the discipline of tissue engineering provides promising alternatives. 
Particularly, the area of osteochondral tissue engineering leverages the controlled 
combination of carefully engineered scaffolds, progenitor cells, and biochemical cues for 
replacing or restoring lost articular cartilage and subchondral bone function. While the 
selection of an optimal cell type and appropriate scaffold is necessary to reconstruct 
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specific tissues with a particular configuration and function, successful regeneration is 
greatly influenced by the cellular microenvironment in which cells and tissues grow 
[135]. Inspired by physiological events that occur during fetal development and long 
bone formation [136-138], the concept of growing articular cartilage has led to the 
integration of a wide variety of soluble cues in an effort to mimic natural signaling 
cascades in the wound healing environment.  
In cartilage tissue repair, the goal of eliciting the desired phenotypic responses 
from host and/or co-delivered progenitor cells remains. Yet, techniques for the delivery 
of soluble cues and other biologics for the treatment of cartilage and osteochondral 
defects have evolved over the years from simple bolus injections into the defect to more 
sophisticated and controlled multi-functional delivery systems. These engineered 
strategies, which permit localized drug delivery with controlled release kinetics, utilize 
delivery platforms that typically leverage at least one of several main delivery schemes 
developed for controlled release. The simplest approach involves the direct intra-articular 
injection of growth factors or palliative agents into the synovial space. While such 
injections represent an attractive and relevant option due to the lack of surgery, the 
frequencies of injections required and the supra-physiological dosages employed often 
complicate therapeutic efficacy. Additionally, the recapitulation of natural signaling 
cascades for proper healing and regeneration of damaged tissues would be near 
impossible with single injections [134, 138-141]. Nevertheless, the motivation to 
recapture the complexity of endogenous healing cascades into simplified and controlled 
forms has driven the evolution of materials-based delivery systems towards a range of 
modalities involving drug release from microspheres, bulk scaffolds, or a combination of 
50 
 
both. Although the type of modality employed for drug delivery can determine the 
mechanism of release, the method of agent incorporation also offers a significant form of 
modulation for controlled release. Conventional strategies for the incorporation of 
signaling molecules into engineered delivery systems typically involve either the physical 
entrapment or the chemical immobilization of factors into or onto a polymer matrix. 
Recent reviews by Mehta et al. and Santo et al. provide excellent summaries of modern 
controlled release strategies utilizing such means for bone and orthopedic therapies [142, 
143]. By carefully combining the physical entrapment of bioactive agents with the 
chemical conjugation of other bioactive factors, innovative and smart delivery systems 
can be engineered to sustain the release of single or multiple biologics in a 
spatiotemporally controlled fashion for effective cartilage therapy.  
This review begins with an overview of the various bioactive factors that have 
been utilized in delivery and controlled release strategies for cartilage repair. The aim is 
to first briefly enable an understanding of the different biological approaches available 
for both in vitro and in vivo cartilage repair applications. The following sections will 
discuss the methods of delivery and assess the current state of recent controlled release 
strategies developed for cartilage tissue engineering and cartilage repair. Special 
emphasis will be placed on combining materials-driven and biologically-driven strategies 
for cartilage repair in order to provide an outlook for future developments that are aware 
of the needs for both. 
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4.2. Cartilage Regenerative Factors 
The homeostasis and repair of articular cartilage is regulated by a number of 
growth factors, differentiation factors, systemic factors, and other biologics. The ultimate 
response from a specific biologic depends on its identity, and so a critical component in 
designing a controlled delivery system is the selection of an appropriate factor.  
 
4.2.1. Growth Factors 
Growth factors are a group of soluble signaling molecules that can stimulate 
cellular division, growth, and differentiation through specific binding of transmembrane 
receptors on target cells [144]. Among the biologics involved in cartilage repair, growth 
factors remain the most extensively studied due to their powerful proliferative, 
proanabolic, and/or anticatabolic properties [36]. These include select members of the 
transforming growth factor- (TGF-) superfamily, fibroblast growth factor (FGF) 
family, and insulin-like growth factor-1 (IGF-1). Another major growth factor, platelet-
derived growth factor (PDGF), plays a role in the wound healing of cartilage defects, but 
the direct effect of PDGF delivered to a cartilage defect has yet to be investigated [145]. 
It is most often used within platelet-rich plasma (PRP), which will be discussed in a later 
section.  
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4.2.1.1. Transforming Growth Factor- Superfamily 
The TGF- superfamily includes over 30 structurally related members and serves 
an important role in regulating embryogenesis as well as adult homeostasis [146]. Among 
the TGF- superfamily, the most heavily investigated growth factors for cartilage repair 
include prototypic members TGF-1, 2, and 3 and bone morphogenetic proteins (BMP) 
2, 4, and 7. Growth differentiation factors (GDFs), particularly GDF-5, have shown 
chondrogenic potential in vitro, but their ability to promote in vivo cartilage repair has yet 
to be evaluated [147-150].   
Transforming Growth Factor-s 
TGF-1, 2, and 3 are considered to be potent stimulators of chondrogenesis, 
inducing Sox9 expression and increasing cartilaginous extracellular matrix (ECM) 
production in bone marrow-derived mesenchymal stem cells (MSCs) as well as 
stimulating synthetic activity in chondrocytes [36, 138, 151]. In animal models, TGF-s 
are highly expressed during MSC condensation in the growth plate of long bones [138] 
and are also implicated in the early stages of cartilage repair [136]. As a result, TGF- 
isoforms, particularly TGF-1 and 3 have been used in a number of promising in vivo 
studies exploring the ability of TGF-s to promote the repair of cartilage defects [152]. In 
a rabbit full-thickness cartilage defect model, poly(lactic-co-glycolic acid) (PLGA)/fibrin 
gel scaffolds loaded with MSCs and TGF-1 resulted in better cartilage restoration than 
PLGA/fibrin gel scaffolds loaded with MSCs alone [153]. Additionally, TGF-1 in 
calcium alginate beads improved osteochondral tissue repair after 12 weeks compared to 
alginate scaffolds alone [154]. However, the effects of TGF-1 on cartilage repair in vivo 
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are not always consistent [107]. Guo et al. demonstrated that blank oligo(poly(ethylene 
glycol) fumarate) (OPF)-based scaffolds in a rabbit osteochondral defect model resulted 
in cartilage repair that was equal to or improved relative to OPF scaffolds with MSCs or 
OPF scaffolds with MSCs and TGF-1 [108]. Intra-articular injections of TGF- have 
also caused synovial fibrosis and endochondral ossification [155, 156]. Several reasons 
for the observed negative effects of TGF- delivery have been suggested, including the 
supra-physiological levels of growth factor employed as well as the relatively non-
specific effects of TGF- on MSC differentiation [108]. As a result, it is important to 
consider the dosage and presentation of TGF-s when delivered in vivo, understanding 
that TGF-s are multifunctional and induce gene responses in different cell types for 
proliferation and ECM synthesis [157]. 
Bone Morphogenetic Proteins 
Similar chondrogenic effects of TGF- have also been observed for several BMP 
molecules, likely due to the extensive crosstalk between TGF- and BMP signaling 
pathways [158]. Different BMPs, particularly BMP-2, 4, 6, 7, and 9, have been shown to 
stimulate chondrogenic differentiation of MSCs and/or adipose-derived stem cells 
(ASCs) either individually or with a TGF- prototypic member [159]. In a comparison 
between TGF-1 and BMP-2 delivery from PLGA microspheres in alginate gel, both 
groups resulted in greater histological scores for osteochondral repair compared to blank 
scaffolds at 12 and 24 weeks in a rabbit patellar groove defect [160]. BMPs also play a 
role throughout the MSC chondrogenic differentiation process, from MSC condensation 
to proliferation, differentiation, maturation, and calcification. In particular, BMP-2 is 
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expressed throughout the entire chondrogenic process, from proliferation to calcification 
[138], and hence, a long-term delivery of BMP-2 can be beneficial and has been shown to 
result in a higher quality repair of cartilage as opposed to short-term delivery [161]. 
Different BMPs also have different effects on osteochondral repair. In a study delivering 
BMP-2 or BMP-4 in alginate gels to a rabbit femoral condyle defect, delivering BMP-2 
alone resulted in better subchondral bone restoration while BMP-4 alone gave better 
cartilage tissue repair [162]. BMP-7 has also shown efficacy in vivo: BMP-7 delivered 
from a collagen sponge in conjunction with microfracture led to thicker repair cartilage, 
superior matrix and superior cell distribution compared to a collagen sponge plus 
microfracture alone in a rabbit chondral defect [163]. With the ability to induce both 
cartilage and bone formation, BMPs, particularly BMP-2, are attractive growth factors for 
the regeneration of the osteochondral tissue unit.  
4.2.1.2. IGF-1 
Within articular cartilage, IGF-1 is the main anabolic growth factor and plays a 
key role in cartilage homeostasis, balancing proteoglycan synthesis and breakdown by 
chondrocytes [145]. IGF-1 can decrease catabolic responses as well as increase 
proliferation and cartilaginous ECM production in MSCs and chondrocytes in vitro [36, 
164]. In vivo, IGF-1 has demonstrated the ability to improve filling of chondral defects 
[165], improve quality of cartilage repair [166, 167], and decrease the postoperative 
inflammatory response [168]. IGF-1 has also demonstrated an additive effect when 
combined with other growth factors such as TGF-1, BMP-2, and BMP-7 [164, 169, 
170]. However, achieving similar synergistic results when delivering IGF-1 with other 
growth factors in vivo is an area of much interest. IGF-1 delivered from gelatin 
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microparticles (MPs) in an OPF-based scaffold resulted in higher quality cartilage repair 
compared to OPF composites alone in a rabbit medial femoral condyle defect at 12 
weeks. But the benefits of IGF-1 were not maintained when co-delivered with TGF-1 
[107]. Similarly, the single delivery of IGF-1 from OPF composites showed an 
improvement in cartilage morphology over blank scaffolds alone, but the dual delivery of 
IGF-1 with TGF-3 did not have a synergistic effect [171]. Further study on combining 
IGF-1 with other growth factors as well as the appropriate presentation of IGF-1 in a 
multiple growth factor delivery strategy in vivo is needed. 
4.2.1.3. FGF-2 
Like IGF-1, the FGF family also plays an important role in the homeostasis of 
cartilage. In particular, FGF-2, or basic FGF (bFGF), has a potent mitogenic effect on 
MSCs and chondrocytes [172]. In addition, treatment with FGF-2 increased both the 
proliferative and chondrogenic potential of MSCs in vitro [164, 173, 174]. In vivo, the 
delivery of FGF-2 has been shown to improve both cartilage repair as well as the 
underlying subchondral bone [175, 176]. However, FGF-2 may have contraindications: 
FGF-2 induced chondrocyte proliferation in a cartilage explant, but resulted in 
chondrocyte clonal cluster formation, which is a histopathological feature of 
osteoarthritis (OA) [177]. Additionally, evidence suggests that FGF-2 may antagonize 
proteoglycan synthesis and upregulate matrix metalloproteinases (MMPs) [36]. Proper 
delivery and presentation of FGF-2 may help mitigate potential contraindicatory effects 
on cartilage repair. 
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4.2.2. Anti-Angiogenic Factors 
Full-thickness lesions that perforate the subchondral bone and bone-marrow 
spaces may trigger the onset of angiogenic and osteogenic processes in the cartilage 
layer, leading to conditions unfavorable for chondrogenesis. As a result, there has been 
interest in introducing anti-angiogenic factors to inhibit blood vessel growth and restore 
cartilage tissue to its natural state of avascularity [178]. This class of factors includes 
endostatin [179-181], suramin [182, 183], Flt-1 [184, 185], and bevacizumab [186]. 
While these factors demonstrate the ability to block vascularization and inhibit the 
activity of vascular endothelial growth factors (VEGFs), a clear benefit of this approach 
in a cartilage defect model remains to be seen.  
 
4.2.3. Systemic Factors and Notable Pharmaceuticals 
The therapeutic role of anti-inflammatory cytokines, chemokines, hormones, and 
other drugs have also been considered in the repair of cartilage. These biologics do not 
serve the primary role as a mitogenic or anabolic factor, but mediate the wound healing 
response through other mechanisms. Stromal cell-derived factor-1 (SDF-1) is a key 
chemokine in cell trafficking and homing of CD34+ stem cells, particularly MSCs [187], 
and has the potential to enhance cartilage repair through increased MSC migration to the 
site of a cartilage defect without the need for additional cell transplantation [188, 189]. In 
the parathyroid hormone (PTH) family, peptide segments of PTH have been shown to 
inhibit the progression of OA and advance the repair of shallow chondral defects [190, 
191]; and PTH-related proteins (PTHrP) are synthesized by chondrocytes and can 
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suppress induction of hypertrophy [192, 193]. However, the timing of PTH or PTHrP 
administration to cartilage defects remains an important parameter in affecting treatment 
outcome. Inhibitory factors on necrosis, apoptosis, MMPs, and aggrecanases have also 
shown potential in the treatment of cartilage defects [194-197]. Other notable systemic 
factors and pharmaceuticals are listed in Table 4.1. 
 
 
4.3. Biologic Delivery Methods 
Almost as important as the selection of an appropriate biologic is choosing a 
suitable delivery mechanism to enable an appropriately controlled release and elicit the 
intended response. The proper delivery of the biologic can affect the dosage as well as the 
release rate and ultimately determine whether or not a therapeutically effective 
pharmacokinetic release profile was achieved. 
 
4.3.1. Injection Delivery 
The delivery of a biologic through an intra-articular injection or systemic 
injection is perhaps the simplest method for minimally invasive administration. The 
ability to treat not only the articulating cartilage but also the entire joint is a relevant 
delivery strategy, particularly for the management of pain and degenerative processes in 
OA. Intra-articular injection of a chondroprotective agent, high-molecular-weight 
crosslinked hyaluronic acid (HA), was seen to improve joint lubrication and retard the 
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progression of OA in a rabbit anterior cruciate ligament transection model over lower 
molecular weight HA or a saline solution [198]. The benefit and potential of intra-
articular modalities for the presentation of chondroprotective agents has also been 
demonstrated in other studies [198-203]. In addition to palliative treatments, anti-
inflammatory agents have also been delivered through intra-articular means to treat OA 
inflammation [204-206]. By treating the synovial fluid and lining in addition to articular 
cartilage, the expression of major pro-inflammatory cytokines such as interleukin (IL)-1 
and tumor necrosis factor- (TNF-) can be addressed and reduced [207-213]. However, 
the delivery of chondrogenic growth factors such as TGF- and IGF-1 in an injection 
manner can effect unwanted changes in the host tissue due to uncontrolled presentation of 
these bioactive factors [214-218]. Growth factors have a short half-life in vivo and can 
result in rapid clearance when delivered systemically, hindering their potent mitogenic 
and/or anabolic effects [219-221]. Additionally, a bolus injection of growth factors gives 
supra-physiological doses, potentially resulting in pathological and non-specific effects, 
and an absence of a physiologically effective release profile.  
 
4.3.2. Bulk Phase Delivery 
Although the direct injection of bioactive agents has been used with some success 
for the treatment of OA, the rapid clearance of such drugs from the synovial capsule 
generally hinders therapeutic efficacy. Incorporation of biologics within a biomaterial 
carrier can address this issue by delivering the biologic in a concentrated and controlled 
fashion. Three-dimensional matrices and porous scaffolds are the most common delivery 
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vehicles, particularly for growth factors. By using a drug-delivering scaffold, focal 
chondral or osteochondral defects can be treated by releasing the factors to the 
surrounding tissue or promoting cell infiltration into scaffold. Many different techniques 
have been developed to regulate the release kinetics of soluble factors as well as retain 
the molecular bioactivity.  
One of the most common approaches for bulk phase delivery is a simple 
dispersion of the biologic within the matrix. The release of the bioactive factor is then 
dependent on the interaction between the factor and the matrix, either mediated by 
encapsulation [153, 175, 222], electrostatic interactions [163, 166, 176, 223-225], 
immobilization/tethering [226-228], or ECM affinity [229-231]. Biologics encapsulated 
or entrapped within bulk matrices often have a large burst release, which can be tuned by 
scaffold crosslinking density and pore size. However, particular natural materials have 
innate physical properties that can control the release of growth factors. Yang et al. 
delivered BMP-2 from fibrin gels and heparin-conjugated fibrin gels in a full-thickness 
trochlear groove defect in rabbits combined with microfracture [161]. An electrostatic 
interaction with heparin resulted in a sustained release of BMP-2 (82% over 13 days) 
compared to a burst release of BMP-2 from normal fibrin gels (88% in first 3 days). This 
long-term delivery of BMP-2 resulted in greater filling of cartilage as well as a higher 
quality of cartilage repair as opposed to short-term delivery [161].  
While many growth factors can adsorb onto scaffolds made of natural polymers 
through electrostatic interactions, hydrogen bonding, and/or van der Waals forces, non-
covalent binding methods may not enable a long-term sustained delivery. Fan and 
colleagues achieved stable localization of growth factors by crosslinking TGF-3 onto 
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PLGA/gelatin/chondroitin sulfate/HA scaffolds through a condensation reaction between 
the carboxyl group of the hybrid scaffold and amine group of TGF-3 [226]. Results 
indicated that the cumulative release of TGF-3 was reduced to 29.5% over 28 days and 
that TGF-3-immobilized scaffolds could induce similar levels of chondrogenic 
differentiation of seeded MSCs and in vivo cartilage repair compared to non-immobilized 
scaffolds cultured in medium with TGF-3. However, caution should be taken when 
tethering factors to monolithic scaffolds. Kopesky and colleagues demonstrated that 
adsorption of TGF-1 onto self-assembling peptide hydrogels stimulated chondrogenesis 
of seeded MSCs in vitro whereas biotin-streptavidin tethered TGF-1 hydrogels did not 
[232]. The authors suggested that the biotin-streptavidin affinity may exceed the strength 
of some covalent bonds and that tethering TGF-1 may have prevented internalization of 
the receptor-ligand complex [227, 228]. 
The release of growth factors can also be controlled through their innate affinity 
to certain ECM epitopes [229]. The use of an alginate-sulfate scaffold enhanced TGF-1 
attachment to the scaffold via heparin-like affinity interactions and resulted in a more 
sustained release of TGF-1 over 7 days as opposed to a >90% burst release from regular 
alginate scaffolds after 1 day [230]. Implantation of similar scaffolds with affinity bound 
TGF-1 and BMP-4 demonstrated the ability to induce endogenous regeneration of the 
osteochondral unit [231].  
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4.3.3. Microparticle and Nanoparticle Delivery 
Another method of delivery is releasing the selected biologic from micro- or 
nano-sized carriers. MPs and nanoparticles (NPs) are attractive drug delivery vehicles 
due to their small dimension, high surface area to volume ratio, high drug loading 
efficiency, and the ability to quickly respond to environmental stimuli such as 
temperature, pH, magnetic fields, or ultrasounds [138, 233, 234]. While MPs have been 
investigated for several decades, NPs as delivery vehicles for cartilage repair have been 
gaining interest [235-239]. NPs can be endocytosed by cells, allowing for the 
accumulation of NP-encapsulated drugs, and their exceptionally high surface area to 
volume ratio enhances their affinity to therapeutic drugs and external stimuli [240]. 
However, a high surface area to volume ratio may also reduce the stability of the nano-
sized delivery vehicle, and the tendency for certain NPs  to aggregate into microscale 
particles may mitigate the advantages of a NP system [240].  
MPs have traditionally been used as a delivery vehicle, either by dispersing the 
MPs in a continuous phase or using the MPs as building blocks without a surrounding 
matrix to form macroscopic scaffolds [138]. In particular, introducing MPs in a bulk 
scaffold, particularly hydrogels, adds a level of complexity and allows greater control 
over the growth factor release profile, spatial delivery, and leads to greater stability and 
bioactivity of encapsulated proteins [241, 242].  
Similar to bulk phase delivery, biologics can also be incorporated in MPs and NPs 
through entrapment, ionic interactions, or a combination of both. Ultimately, the 
subsequent release depends on the composition of the carrier as well as the factor 
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incorporation method. One popular material for the construction of MPs is synthetic 
PLGA due to its tunable degradation into lactic and glycolic acid [243], its ease of 
fabrication, and its established safety in other FDA-approved applications [244]. Several 
research groups have employed PLGA MPs for the delivery of anabolic growth factors to 
stimulate chondrogenesis/cartilage repair either in a hydrogel [242, 245-247] or as a 
building block to make PLGA MP plugs [248-250]. By dispersing growth factor-
delivering PLGA MPs in a hydrogel, near zero-order release kinetics of TGF-1 and 
BMP-2 were observed in vivo [245, 247]. However, despite the appeal of PLGA 
microcarriers for controlled drug release, the use of such hydrophobic materials can 
adversely affect the bioactivity of encapsulated factors [235, 251]. Growth factor delivery 
particulates have also been fabricated with other synthetic polymers, including heparin-
poly(L-lysine) NPs loaded with TGF-3 [237], Pluronic F68/heparin NPs for TGF-2 
immobilization [252], and poly(N-isopropylacrylamide) NPs for TGF-1 release [238]. 
Yet, different carrier matrices may be better suited for different biologics. Wang et al. 
demonstrated that PLGA MPs were better for releasing IGF-1 while silk MPs were more 
efficient in delivering BMP-2 [253]. 
Many natural polymers, notably gelatin [85, 103, 118, 234, 254-260], alginate 
[261], HA [261-264], chondroitin sulfate [236], and silk [253], have been used to create 
growth factor delivering MPs. Gelatin is a natural polymer derived from collagen, and by 
subjecting collagen precursors to either alkaline or acidic processing during the 
production of gelatin, basic or acidic gelatin with different isoelectric points can be 
obtained [254, 260]. Resultant gelatin carrier matrices can then achieve either a net 
negative or positive charge at physiological pH depending on the isoelectric point, 
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allowing for the ionic complexation of various growth factors during drug loading. 
Acidic gelatin MPs, which can be complexed with positively charged growth factors, 
were previously used for the controlled delivery of TGF-1 [258, 259], TGF-3 [256], 
IGF-1 [118] , and BMP-2 [260] for cartilage and bone tissue engineering applications. 
However, since natural materials like gelatin and alginate are not native to articular 
cartilage, new ventures are exploring the use of more chondromimetic carriers with the 
aim of leveraging potential synergistic effects between growth factors and orthotopically 
relevant materials.  
Ansboro and colleagues recently described a layer-by-layer approach for the 
fabrication of hollow HA microspheres as carriers of TGF-3 [264]. In their work, the 
authors reported that the delivery of TGF-3 from HA microspheres to human MSC 
pellets enhanced the expression of chondrogenic genes (type II collagen and aggrecan) 
while inhibiting the expression of hypertrophic markers (type X collagen) in vitro. Lim 
and colleagues reported the development of nanoscale and microscale particles using 
chondroitin sulfate, a negatively charged glycosaminoglycan (GAG) found in articular 
cartilage [236], where they were able to show the controlled release of TGF-1 from 
these particles. An interesting study by Bajpayee and colleagues modeled the effect of NP 
charge and size on particle uptake and binding in articular cartilage [265]. Using Avidin, 
a highly glycosylated protein with a high positive charge and a diameter of ~7 nm, as a 
model protein for the development of NPs as drug carriers, the authors demonstrated that 
while particles less than 10 nm in diameter were able to penetrate through the full-
thickness of bovine cartilage explants, particles that were 15 nm in diameter were 
confined only to the superficial cartilage layer. Of note, the presence of a positive fixed 
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charge density facilitated the rapid uptake of Avidin via electrostatic partitioning within 
24 hrs when compared to neutrally charged NeutrAvidin and enhanced Avidin retention 
time to over 15 days [265]. Such results indicate that charge properties can be leveraged 
in innovative nanoparticle designs for the rapid uptake and retention of nanocarriers 
throughout the entire cartilage layer. Within the context of anti-inflammatory strategies 
for cartilage repair, the use MP carriers as the controlled delivery vehicles for small anti-
inflammatory agents is also a subject of great interest [213, 235, 266-268]. 
  
 
4.4. Strategies for Controlling Delivery of Biologics 
The plethora of studies on single growth factor delivery to induce chondrogenesis 
and/or facilitate neo-cartilage growth have been indispensible in showing the complexity 
of the cartilage wound healing environment. The current research on biologics for 
cartilage repair sees a trend towards multiple growth factor delivery to mimic the 
numerous signaling cascades involved. Yet the lack of an overwhelming improvement for 
multiple growth factor delivery over single growth factor delivery exemplifies the need to 
modulate the temporal expression and spatial distribution of biologics for not only 
cartilage regeneration, but for the repair of the osteochondral unit as a whole. The 
following sections will discuss the recent progress in the delivery of multiple biologics 
and spatiotemporally controlled delivery strategies for cartilage repair applications, and 
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will highlight several advanced options for the design of biologic delivery platforms with 
potential for precise spatial and/or temporal control over the release of bioactive factors. 
 
4.4.1. Multiple Biologics Delivery 
Musculoskeletal development is an intricate process governed precisely by the 
activation and interplay of numerous biochemical cell-signaling pathways. In particular, 
the process of chondrogenesis alone involves the activation of chondrogenic adhesion 
molecules (integrins) and the up-regulation of chondrogenic growth factors (TGF- 
superfamily) and their signal regulators, followed by the up-regulation of anabolic factors 
(bFGF, IGF-1, VEGF) during hypertrophy [269]. While technically simple, it is 
extremely unlikely that the delivery of a single factor can stimulate the recapitulation of 
these signaling pathways for cartilage regeneration. As a result, strides have been made 
towards the development of controlled release systems for the delivery of multiple 
growth factors for cartilage repair in the hopes of increasing therapeutic potency. Since 
the work of Richardson and colleagues [270], which successfully demonstrated the 
controlled dual release of both VEGF and PDGF for the rapid formation of a mature 
vascular network, the field of controlled release has seen the advent of many 
sophisticated delivery systems for multiple bioactive agents. Indeed, by regulating the 
delivery of several bioactive factors, the induction of various biological responses in a 
fashion that promotes optimal cartilage repair becomes theoretically possible.  
A common chondrogenic strategy involves the sequential release of TGF-1 or 
TGF-3 to first chondrogenically stimulate a synthetic response by host/delivered 
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progenitor cells, followed by the release of an anabolic or maturation factor like IGF-1 to 
encourage cartilage matrix production. Our laboratory, as well as others, has previously 
established that the dual delivery of TGF-1 and IGF-1 can be achieved with distinct 
release kinetics [118, 271], and that the released growth factors stimulate the 
chondrogenic gene expression of MSCs in vitro [103]. In the case of bulk hydrogel and 
NP/MP composite scaffolds, varying the phase of incorporation can modulate the release 
kinetics of multiple growth factors. By loading TGF-1 directly into the bulk OPF 
hydrogel phase while loading IGF-1into highly crosslinked GMPs encapsulated within 
the OPF hydrogel, Holland and colleagues were able to attain a burst release of the 
former combined with the simultaneous but sustained release of the latter [118]. Another 
approach for the sequential delivery of TGF-1 and IGF-1 involves the use of 
biodegradable PLGA MPs [272]. Jaklenec and colleagues fused IGF-1 containing and 
TGF-1 containing PLGA microspheres using dichloromethane vapor in order to 
generate three-dimensional drug-eluting scaffolds [271]. Incorporating bovine serum 
albumin (BSA) into the organic phase during microsphere fabrication improved IGF-1 
internalization into the microspheres and hence, delayed the release of IGF-1. The release 
of TGF-1 was controlled by either capping or uncapping PLGA with a carboxylic acid 
chain, where uncapped PLGA led to delayed release of the growth factor due to increased 
secondary interactions between the PLGA, TGF-1, and BSA [271]. The development of 
such a modular design allowed for the combination of PLGA microspheres containing 
various growth factors or bioactive agents in order to generate custom dual or multiple 
biologic delivery systems. Indeed, a similar system utilizing PLGA microspheres of 
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different co-polymer ratios and spherical sizes was able to achieve multiple burst releases 
of encapsulated chondroitin sulfate for potential applications in treating OA [273]. 
A more recent system leveraged a NP-laden hydrogel composite for the dual 
delivery of BMP-7 and TGF-2. TGF-2-immobilized NPs were created by first mixing 
Pluronic F68 with heparin to permit hydrogen bonding between the two components 
[252]. TGF-2 was subsequently immobilized via ionic complexation with the heparin 
component. Chitosan and polyvinyl alcohol were then added to promote the formation of 
individual TGF-2 immobilized NPs, which were embedded into a BMP-7 immobilized 
alginate hydrogel bulk phase. The authors were able to show fast release of BMP-7 (up to 
80% cumulative release) coupled with the sustained release of TGF-2 (up to 30% 
cumulative release) over 21 days in vitro [252]. Interestingly, the delivery of both BMP-7 
and TGF-2 from the hydrogel phase, as opposed to delivery from the encapsulated NPs, 
was slower due to the potential aggregation between growth factors during hydrogel 
fabrication, highlighting the need to examine the potential interplay between biologics in 
multiple growth factor delivery systems. Nevertheless, these systems coupling the 
delivery of BMPs with TGF- are especially useful in applications involving MSCs 
derived from sources other than the bone marrow (i.e., adipose tissue), which require 
such growth factor combinations for chondrogenesis [274-277]. Despite our ability to 
tailor the release of multiple therapeutic agents in order to affect a desired cellular 
responses in vitro, one must consider the challenges of accurate preclinical translation in 
vivo. For instance, the dual delivery of TGF-2 and BMP-7 to trochlear groove defects in 
rabbits, even with the co-implantation of adipose derived MSCs, failed to elicit any 
histological improvement in osteochondral tissue repair over controls [225]. 
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Analogously, the co-delivery of TGF-1 and IGF-1 via OPF/gelatin MP hydrogel 
composites did not offer any additional benefits over the delivery of IGF-1 alone for 
osteochondral tissue regeneration in vivo [257]. Recently, it was investigated whether the 
lack of additive or synergistic effects could be due to differences in TGF- release 
kinetics between the in vivo environment and what was observed in vitro [171]. Using a 
similar OPF composite system, IGF-1 and TGF-3 were co-delivered to an osteochondral 
defect site to evaluate tissue repair, where changing the loading phase of TGF-3 varied 
its release kinetics. However, the results seemed to confirm a lack of synergy between 
these two growth factors in affecting a favorable healing response in vivo [171].  
Bian and colleagues recently described an alternative strategy with high potential 
for cartilage repair [261]. Their approach entailed the initial transient exposure of MSCs 
encapsulated in a HA hydrogel to TGF-3 released from co-encapsulated alginate 
microspheres to induce chondrogenesis, followed by the exposure to PTHrP to prevent 
hypertrophy. While the release of TGF-3 induced the chondrogenesis of MSCs in vivo 
(in a subcutaneous mouse model), the uncontrolled and rapid delivery of PTHrP was 
unable to inhibit hypertrophic calcification [261]. Another strategy described the 
combined use of anti-angiogenic agent suramin and TGF-1 for the generation of hyaline 
cartilage from periosteal cells on an agarose hydrogel implanted within a subperiosteal 
space [183]. Together, these studies highlight the complexity of the native joint 
environment and indicate that caution must be taken when combining multiple growth 
factors with similar chondrogenic stimulatory effects for controlled delivery in vivo. 
Indeed, it may prove advantageous to instead combine factors with varying anti-
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inflammatory, anti-angiogenic, chondrogenic, or anabolic biological effects in order to 
simulate biomimetic cascades and processes for more effective cartilage repair in vivo. 
Within the context of multiple growth factor delivery, an emerging field of 
interest comprises the application of PRP. PRP is an enriched blend of growth factors that 
can be autologously derived through the centrifugation of patient blood. Several protocols 
exist for the isolation and preparation of PRP for specific applications [143, 278]. In 
contrast to the rising potential of PRP for cartilage repair, information regarding its 
composition and mechanisms of action remain relatively scarce. Additionally, it remains 
unclear how different processing techniques and donor-to-donor variability affect the 
composition and effectiveness of PRP. Using protein antibody membrane arrays, Krüger 
and colleagues recently profiled the growth factor composition of human PRP and 
revealed a plethora of chondrogenic and anabolic growth factors including various BMPs, 
FGFs, PDGFs, IGFs, TGF-s and VEGFs [279]. Indeed, several studies of late have 
reported the positive effects of PRP on cartilage repair in both diseased and acute defect 
models [280].  
Sundman and coworkers treated osteoarthritic synovium and cartilage explants 
with PRP ex vivo and showed that PRP decreased the gene expression of inflammatory 
markers including TNF- and MMP-13 while enhancing endogenous HA production 
[281]. Raeissadat and colleagues evaluated the effects of PRP injections on functional 
improvement and quality of life of OA patients in a clinical study and found that even the 
direct intra-articular administration of PRP ameliorated joint pain and knee stiffness, and 
improved patients’ quality of life in the studied time frame of 6 months [282], which 
corroborates the results from similar investigations [283-285]. However, the lack of 
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proper controls necessitates further investigations regarding the clinical use of PRP for 
OA. In an acute femoral defect model, the treatment of osteochondral grafts with PRP 
prior to implantation actually led to the improvement of graft-host integration when 
compared to grafts treated with saline solution [286], further indicating that PRP can 
decrease cartilage degeneration via the inhibition of inflammatory signals and the 
induction of neo-cartilage integration. Given the multifarious properties of PRP, future 
combinatory strategies can aim to leverage specific PRP effects through the co-delivery 
of synergistic or inhibitory factors. One potential strategy could explore the possibility of 
releasing the anti-angiogenic drug Avastin [287] following the delivery of PRP in order 
to promote a hypoxic environment, which has been shown to be vital for non-
hypertrophic chondrogenesis [288] for articular cartilage repair.  
 
4.4.2. Spatially Controlled Delivery 
It is well known that the extracellular matrix structure of articular cartilage 
represents an intricate hierarchy of distinct layers that function together to meet the 
osmotic and viscoelastic demands of the tissue. While advances toward the utilization of 
multiple bioactive agents are beginning to address some of the complexities of cartilage 
regeneration in vivo, the presence of undefined and potentially negative cross-effects 
suggests that the method of growth factor presentation to defect sites still requires 
significant fine-tuning. Indeed, it is recognized that bioactive factors should ideally be 
delivered in a spatially and temporally controlled fashion in order to elicit maximum 
therapeutic efficacy. By first reviewing strategies for spatial control followed by 
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strategies for temporal control, this section primarily highlights recent advances made 
toward the development of technologies or platforms that can allow precise control over 
spatiotemporal release conditions for cartilage repair. 
For cartilage applications, spatial control over drug delivery can be mainly 
achieved via two distinct approaches: the conditional/permanent immobilization of 
chondrogenic growth factors to desired regions within a scaffold, or the directional 
release of chondrogenic growth factors from a reservoir. Within the context of 
osteochondral tissue repair, growth factor concentration gradients and multiphasic 
scaffolds are often applied. Out of the strategies available for spatial control, the physical 
entrapment or chemical conjugation of factors to a scaffold represents the most 
technically simple approach. Such methods for protein sequestration commonly offer 
several advantages including localized growth factor presentation, dosage control, and 
preservation of protein bioactivity. McCall and colleagues recently investigated a strategy 
for TGF-1 immobilization using clinically relevant materials [289]. TGF-1 was first 
thiolated by a reaction with 2-iminothiolane (via primary amine groups on the N-
terminus), and was subsequently functionalized into poly(ethylene glycol) (PEG)-
diacrylate hydrogels using mixed-mode photopolymerization. By changing the initial 
concentration of thiolated TGF-1 prior polymerization, it was shown that the growth 
factor dosage as well as bioactivity could be precisely controlled. Interestingly, co-
encapsulated human MSCs, when exposed to the lower dosages of immobilized TGF-1, 
actually exhibited equal or greater levels of chondrogenesis when compared to soluble 
TGF-1 in culture medium [289].  
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Implications for the utility of spatially tethered chondrogenic growth factors to act 
as chondrogenic stimulants or chemoattractants for host progenitor cells in cartilage 
defects in vivo were further provided by Griffin and colleagues, who recently reported the 
synthesis of photodegradable macromers for the conjugation and release of biologics 
[290]. In their work, the authors synthesized a class of photosensitive ortho-nitrobenzyl 
(o-NB) macromers that could be functionalized with different reactive groups at the 
benzylic position. These reactive groups, which included alcohols, alkyl halides, amines, 
carboxylic acids, N-hydroxysuccinyl ester, and biotin, permitted the conjugation of 
essentially any type of therapeutic agent for cartilage repair. The mechanistic release of 
such therapeutics could then be externally controlled by light exposure. Additionally, it 
was previously reported by the same group that o-NB macromers could be designed with 
different photodegradation rates, hence yielding external control over the multistaged 
release of multiple bioactive factors [291]. As a proof of concept, Griffin and coworkers 
incorporated o-NB macromers that were conjugated with TGF-1 into PEG hydrogels 
and demonstrated that photoreleased TGF-1 maintained high bioactivity and was able to 
effectively induce the chondrogenic differentiation of human MSCs in vitro. The 
development of such platforms confers researchers with not only options for the precise 
external control over the spatial presentation of bioactive factors in potential strategies for 
cartilage repair, but also the temporal patterning of bioactive factor delivery. 
While many systems have been designed for the spatially controlled delivery of 
growth factors to cartilage tissues as a whole, few studies if any have employed spatial 
gradients with high enough resolution to target the subtle inhomogeneity of the 
hierarchical articular cartilage makeup. However, as aforementioned, recent innovations 
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using Avidin as a model protein for articular cartilage drug uptake [265] indicate that the 
particle diameter and fixed charge density of drug-loaded NP systems could be finely 
tuned to affect NP uptake depth and retention time in order to target distinct zones within 
the cartilage layer. Currently, spatial concentration gradients usually consist of lower 
resolution biphasic or multiphasic systems built to stimulate the simultaneous repair of 
cartilage and subchondral bone in osteochondral composite tissues. In such cases, 
bilayered composites can easily be used to bias the local delivery of chondrogenic factors 
to the cartilage layer and osteogenic factors to the subchondral layer in osteochondral 
defects. As discussed earlier in the section describing the delivery of multiple biologics 
for cartilage repair, our laboratory has previously evaluated the utility of bilayered OPF 
composite systems for the spatially controlled delivery of chondrogenic factors IGF-1 
and TGF-1 or TGF-3 only to the chondral regions of an osteochondral defect [171, 
257].  
In line with the need for high spatial resolution scaffolds and interfacial 
considerations between the cartilage and bone layers of osteochondral composite tissues, 
Wang and colleagues developed a BMP-2 and IGF-1 gradient biopolymer system with 
the ability to elicit the corresponding osteogenic and chondrogenic response of MSCs 
[253]. Using an aqueous-derived silk porous scaffold, silk microspheres loaded with 
BMP-2 or IGF-1 were differentially mixed together via a gradient maker to generate 
either single BMP-2/IGF-1 gradients or dual reverse gradients of both growth factors in a 
single scaffold. However, it was found that only silk scaffolds delivering BMP-2 
gradients (i.e., single BMP-2 gradients or reverse BMP-2/IGF-1 gradients) were effective 
at promoting a gradient response [253], indicating that bioactive agents must be 
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compatible with the delivery platform. More recently, Dormer and coworkers described 
the creation of a PLGA microsphere-based bioactive plug with a continuous gradient 
transition between chondrogenic TGF-1 and osteogenic BMP-2 for osteochondral tissue 
repair in vivo [248]. When implanted into medial femoral defects in rabbits, it was shown 
that the presence of a reverse continuous gradient of chondrogenic and osteogenic growth 
factors led to improved histological repair over blank controls. While results highlight the 
potential of growth factor gradient design for osteochondral tissue regeneration, the lack 
of controls that test specifically the effect of the gradient on tissue repair necessitates 
future studies evaluating such an effect. 
In contrast to growth factor gradient designs, Li and coworkers developed a 
unique spatial control strategy based on inhomogeneous bilayered collagen scaffolds that 
could bias the direction of growth factor release [292]. The described construct 
comprised a dense collagen layer and a loose collagen layer sandwiching a reservoir of 
chitosan-heparin NPs loaded with growth factors for the directional release of the 
anabolic factor bFGF [292]. bFGF was preferentially released through the loose collagen 
layer, thereby making the loose layer a better cell-adhesive and proliferative substrate 
with potential for tissue repair in vivo. The same release of bFGF was not observed for 
the dense layer. When this bFGF release platform was utilized for articular cartilage 
repair in osteochondral defects in vivo, the authors showed that the directional release of 
bFGF toward the subchondral bone (i.e., loose layer facing subchondral bone) stimulated 
the early up-regulation of endogenous TGF-s, BMPs, and VEGFs as detected in the 
synovial fluid [293]. Additionally, the controlled and directional release of bFGF toward 
the subchondral bone in an osteochondral defect improved histological scores for 
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cartilage repair. Furthermore, such a spatially oriented approach limits the release of 
growth factors into the synovial space and hence, preserves the supply and longevity of 
growth factors for optimal therapeutic efficacy.  
 
4.4.3. Temporally Controlled Delivery 
Most, if not all, controlled release strategies enabling spatial control over the 
delivery of biologics also confer some degree of temporal control. Hence, the following 
will highlight several recent advances specifically emphasizing precise temporal control 
for the release of bioactive agents in the context of cartilage-related applications. 
Accordingly, one class of biomaterials that can offer improved temporal control over 
traditional delivery systems is self-assembling peptides. Kopesky and coworkers recently 
reported the slow and sustained release of TGF-1 from acellular self-assembled peptide 
formed from AcN-(KLDL)3-CNH2 custom peptide sequences [232]. Such KLD peptides 
were able to efficiently uptake growth factors, which could be loaded into the equilibrium 
peptide solution before or after self-assembly, with five times greater uptake before self-
assembly. This provided the ability to precisely modulate the dosage of growth factors to 
be released. It was shown that by day 3, only 18% percent of the total TGF-1 loaded 
was released, indicating the avoidance of a burst release [232]. By day 21, only 44% of 
cumulative TGF-1 was achieved, suggesting the utility of KLD hydrogels for long-term 
controlled growth factor release and for avoiding the dosage limitations of other single 
growth factor delivery systems. Furthermore, KLD hydrogels could theoretically 
maintain growth factors in their bioactive macromolecular form efficiently through 
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designed electrostatic interactions during peptide sequencing. Despite the advantages of 
such long-term release strategies, the efficacy of delivered peptides and proteins 
commonly face issues related to short half-lives. To address this problem, Ashley and 
colleagues developed a generic drug delivery platform based on a tetra-PEG porous 
hydrogel incorporating -eliminative linkers that could undergo -eliminative cleavage in 
the presence of an electron withdrawing modulator for the release of covalently tethered 
drugs [294]. The -eliminative linkers, which were not prone to enzymatic degradation, 
could be designed to have highly predictable half-lives and could be used to 
simultaneously conjugate bioactive factors and crosslink PEG hydrogels. The covalent 
fixation of therapeutics to and their subsequent release from the -eliminative linkers 
could then be directly controlled by the half-life of the linker, which can be designed to 
range from a few hours to over a year [294]. Hence, by combining -eliminative linkers 
with short half-lives for drug tethering and those with longer half-lives for hydrogel 
crosslinking, one can ensure the complete release of growth factors prior to hydrogel 
degradation. Such a strategy for osteochondral defect repair would allow one to take full 
biomechanical advantage of having hydrogel structural support while mitigating any form 
of release kinetics limitations associated with bulk material degradation. Additionally, the 
ability to fine-tune the temporal release of biologics and to potentially decouple spatial 
and temporal modulation should inspire future innovations toward the design of growth 
factor delivery patterns that mimic the cartilage signaling cascades during fetal 
development in order to stimulate robust cartilage regeneration. Table 4.2 lists various 
strategies that have leveraged the use of spatial and/or temporal control for the delivery of 
biologics for cartilage repair applications. 
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Other approaches toward achieving temporal control over growth factor 
presentation typically involve more indirect means via the use of gene therapy. Indeed, 
many pharmacotherapy strategies that currently exist in the literature describe the use of 
gene therapy, or the viral/non-viral conditioning of cells into endogenous growth factor 
depots, for cartilage and osteochondral repair. However, it is not clearly known how the 
effectiveness of such strategies compares with those that rely on the controlled delivery 
of exogenous factors. Using bovine articular chondrocytes, Shi and coworkers compared 
the effectiveness of exogenously and endogenously delivered IGF-1 and TGF-1 for in 
vitro chondrogenesis [295]. The authors showed no difference between exogenously or 
endogenously delivered IGF-1, but found that exogenously delivered TGF-1 elicited 
greater chondrogenic gene expression when compared to endogenously delivered TGF-
1. This was confirmed to be due to the non-covalent complexation of a latency-
associated peptide with TGF-1 during endogenous production to form a small latent 
complex, which was then bound by latent TGF-1 binding protein to form a large latent 
complex [295]. While this preserved growth factor bioactivity, the complex was shielded 
from TGF-1 receptors on the chondrocyte surfaces. These results suggests that while the 
endogenous delivery of certain bioactive factors via gene therapy may prove beneficial 
for cartilage repair, not all factors are suitable with this form of delivery. The current 
state of gene therapy as a means for temporally controlled chondrogenic growth factor 
delivery is aptly reflected by the work of Lu and colleagues, who recently reported the 
utility of a chitosan-based gene-activated matrix encapsulating chitosan/HA NPs carrying 
plasmids for the prolonged delivery of plasmid genes for transfection [296]. In their 
application, the authors leveraged a hybrid NP system for the delivery of plasmids 
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encoding TGF-1, where the presence of HA theoretically improved the transfection 
efficiency and also provided a substrate with which cells could interact. It was shown that 
the release of plasmids was sustained for over 120 days in vitro, and that the released 
plasmids stimulated the proliferation of seeded chondrocytes. These results demonstrate 
that the main advantage of sustained gene therapy when compared to conventional 
exogenous delivery is the ability to control the timely administration of growth factors in 
an endogenously relevant fashion, therefore highlighting the potential of such strategies 
for effective cartilage repair. 
 
 
4.5. Conclusion 
Despite its perceived simplicity, the consistent repair of articular cartilage still 
remains a significant clinical challenge. However, the advent of innovative tissue 
engineering technologies is beginning to address many of the major shortcomings of 
current clinical approaches. Specifically, tissue engineering approaches leveraging the 
use of release platforms that offer spatiotemporal control over the delivery of bioactive 
factors are eliciting favorable outcomes in vitro and in vivo. In a relatively short time 
span, release systems for the delivery of biologics have evolved from simple intra-
articular modalities into complex multifunctional and modular delivery platforms. While 
such systems have generally employed the benefits of chondrogenic growth factors in 
cartilage repair applications, new approaches are now finding utility in the use of 
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biologics with primary effects on progenitor cells other than chondrogenic or anabolic 
stimulation. As highlighted, therapeutic treatment of cartilage repair could also be 
garnered from the delivery of various anti-inflammatory, anti-angiogenic, or 
chondroprotective agents. The delivery of multiple factors simultaneously or in a 
spatiotemporally designed fashion for cartilage repair applications, as evidenced by the 
use of biphasic delivery scaffolds or growth factor gradients, is also becoming a popular 
area of research. Yet, as new findings show, the delivery of more factors may not 
necessarily elicit additive or synergistic effects in cartilage regeneration. Additionally, 
studies are now beginning to show that certain bioactive factors may only be compatible 
with certain delivery platforms. Hence, future efforts should aim to identify these key 
biologic-to-biologic and biologic-to-platform interactions as such information will be 
critical to the success of future strategies leveraging the delivery of various biologics for 
cartilage repair. 
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4.6. Tables and Figures 
Table 4.1 Biologics delivered for in vitro and in vivo cartilage repair applications 
Biologics Biological Effect Biologic Type 
In vitro/In vivo 
Model 
Comments References 
PTHrP Anti-Hypertrophy Growth Factor In vitro cultures; In 
vivo OC defect 
model 
Inhibited hypertrophy of chondrocytes and 
MSCs during differentiation in vitro; Reduced, 
but did not prevent, calcification in vivo  
[261] 
S-(+)-
ibuprofen 
Anti-inflammatory Small Molecule Ex vivo OA model Reduced prostaglandins synthesis at 50 µM.  
When released from PLGA-PEG microspheres, 
reduced cartilage degradation at 1 mM ex vivo 
[209, 266] 
Sulforaphane Anti-inflammatory Small Molecule In vitro cultures; In 
vivo OA model 
Inhibited inflammatory markers including 
COX-2, ADAMTS-5, and MMP-2 in vitro; 
Delayed progression of OA in vivo  
[213] 
IL-1Ra Anti-inflammatory Antigen In vitro cultures; In 
vivo OA model 
Bound to IL-1 surface receptors of 
synoviocytes in vitro; Retained in joint without 
inducing degenerative changes in vivo; Specific 
chondroprotective effects need to be evaluated 
[235] 
3,4,6-O-
Bu3GlcNAc 
Anti-
inflammatory/Chondroprotective 
Small Molecule In vitro cultures Decreased the expression of IL-1-stimulated 
NFkB target genes and increased GAG 
production and chondrogenic gene expression 
of IL-1 challenged chondrocytes 
[297] 
SDF-1 Cell Homing Chemokine In vitro cultures; In 
vivo OC model and 
intraperitoneal cell 
migration model 
Did not influence proliferation/chondrogenesis 
of MSCs in OC defect but resulted in ectopic 
cartilage formation when delivered with TGF-
1 at 4 weeks in vivo 
[188, 298] 
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PRP Chondrogenic/Anabolic/Anti-
inflammatory 
Growth Factor 
Cocktail 
In vitro and ex vivo 
cultures; In vivo 
OA and OC defect 
models 
Decreased the expression of inflammatory 
markers including TNF- and MMP-13 and 
enhanced endogenous HA production ex vivo; 
OC graft pre-treatment with PRP enhanced 
graft-host integration in vivo 
[281, 286] 
HA Chondroprotective Viscosupplement In vitro cultures; In 
vivo OA models 
High molecular weight HA resulted in 
improved histological scores and lower 
cartilage friction coefficients when compared 
to low molecular weight HA in vivo 
[198] 
Proteoglycan 
4 
Chondroprotective Viscosupplement In vitro cultures Supplementation of OA synovial fluid with 
proteoglycan 4 restored lubricating ability by 
reducing friction coefficient in cartilage-on-
cartilage tests 
[299] 
Prostaglandins 
E2 
Inflammatory/Anabolic Small Molecule In vitro cultures Low concentrations (10-9 M to 10-6 M) 
stimulated increased chondrogenic gene 
expression of articular chondrocytes in 3D 
[210] 
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Table 4.2 Selected spatiotemporally controlled delivery strategies for in vitro and in vivo cartilage repair applications 
 
Biologics Delivered Delivery Platform In vitro/In vivo Model Spatial Strategy Temporal Strategy Reference 
TGF-1, IGF-1 Gelatin microparticles 
encapsulated in bilayered 
OPF hydrogels 
Rabbit femoral medial 
condyle osteochondral 
defect 
Growth factors  delivered 
from the chondral layer of 
bilayered OPF construct 
Burst release of TGF-1 with 
sustained release of IGF-1 
[107] 
TGF-3, IGF-1 Gelatin microparticles 
encapsulated in bilayered 
OPF hydrogels 
Rabbit femoral medial 
condyle osteochondral 
defect 
Growth factors delivered 
from chondral layer of 
bilayered OPF construct 
Burst release or sustained 
release of TGF-3 with 
sustained release of IGF-1 
[171] 
TGF-1, IGF-1 PLGA microsphere-fused 3D 
scaffold 
In vitro N.A. Burst or sustained release of 
TGF-1; Burst or sustained 
release of IGF-1 
[271] 
BMP-7, TGF-2 Pluronic F68-heparin-
chitosan nanoparticles 
encapsulated in alginate 
hydrogel 
Rabbit trochlear 
groove osteochondral 
defect 
N.A. Burst release of BMP-2 with 
sustained release of TGF-2 
[252] 
TGF-3, PTHrP Alginate microspheres 
encapsulated in HA hydrogel 
Mouse subcutaneous 
model 
N.A. Burst release of TGF-3 with 
simultaneous release of 
PTHrP 
[261] 
BMP-2, IGF-1 Silk microspheres 
incorporated into aqueous-
derived silk porous scaffold 
In vitro Single BMP-2 gradient; 
Single IGF-1 gradient; 
Continuous BMP-2/IGF-1 
transitional reverse 
gradient 
N.A. [253] 
BMP-2, TGF-1 PLGA microsphere-based 
bioactive plug 
Rabbit femoral 
condyle osteochondral 
defect model 
Continuous BMP-2/TGF-
1 transitional reverse 
gradient 
N.A. [248] 
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bFGF Chitosan-heparin 
nanoparticles in loose/dense 
bilayered collagen scaffold 
Rabbit trochlear 
groove osteochondral 
defect model 
Directional bFGF release 
via the loose collagen 
layer - Compared release 
toward or away from 
subchondral bone  
Burst release followed by 
sustained release of bFGF 
[292, 293] 
BMP-2, microfracture Heparin-conjugated fibrin 
(long-term delivery) or fibrin 
(short-term delivery) 
Rabbit trochlear 
groove osteochondral 
defect model 
N.A. Burst or sustained release of 
BMP-2 with bone marrow 
exposure 
[161] 
TGF-1, BMP-4 Affinity binding bilayered 
alginate sulfate 
Rabbit trochlear 
groove osteochondral 
defect model 
TGF-1 affinity-bound 
into chondral layer; BMP-
4 affinity-bound into 
subchondral layer 
N.A. [230] 
BMP-2 or TGF-1 PLGA microspheres 
encapsulated in alginate 
matrix overlaid on porous 
PLGA cylinder 
Rabbit trochlear 
groove osteochondral 
defect model 
TGF-1, low dose (2.5 
µg) BMP-2, or high dose 
(5 µg) BMP-2 delivered 
from PLGA in chondral 
layer 
Burst release followed by 
sustained release of TGF-1 
or BMP-2  
[160] 
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Chapter 5 
Osteochondral tissue regeneration using a 
bilayered composite hydrogel with 
modulating dual growth factor release 
kinetics in a rabbit model*,^ 
Biodegradable oligo(poly(ethylene glycol) fumarate) (OPF) composite hydrogels 
have been investigated for the delivery of growth factors (GFs) with the aid of gelatin 
microparticles (GMPs) and stem cell populations for osteochondral tissue regeneration. 
In this study, a bilayered OPF composite hydrogel that mimics the distinctive hierarchical 
structure of native osteochondral tissue was utilized to investigate the effect of 
                                                        
 
* This chapter was published as Kim K, Lam J, Lu S, Spicer PP Spicer, Lueckgen A, Tabata Y, 
Wong ME, Jansen JA, Mikos AG, Kasper FK. Osteochondral tissue regeneration using a 
bilayered composite hydrogel with modulating dual growth factor release kinetics in a rabbit 
model. Journal of Controlled Release. 168:166-78 (2013). 
^ The candidate was involved in designing and executing the in vitro swelling and release kinetics 
studies, the design and animal surgery of the in vivo study, and writing and editing of the 
manuscript. 
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transforming growth factor-β3 (TGF-β3) with varying release kinetics and/or insulin-like 
growth factor-1 (IGF-1) on osteochondral tissue regeneration in a rabbit full-thickness 
osteochondral defect model. The four groups investigated included (i) a blank control (no 
GFs), (ii) GMP-loaded IGF-1 alone, (iii) GMP-loaded IGF-1 and gel-loaded TGF-β3, and 
(iv) GMP-loaded IGF-1 and GMP-loaded TGF-β3 in OPF composite hydrogels. The 
results of an in vitro release study demonstrated that TGF-β3 release kinetics could be 
modulated by the GF incorporation method. At 12 weeks post-implantation, the quality of 
tissue repair in both chondral and subchondral layers was analyzed based on quantitative 
histological scoring. All groups incorporating GFs resulted in a significant improvement 
in cartilage morphology compared to the control. Single delivery of IGF-1 showed higher 
scores in subchondral bone morphology as well as chondrocyte and glycosaminoglycan 
amount in adjacent cartilage tissue when compared to a dual delivery of IGF-1 and TGF-
β3, independent of the TGF-β3 release kinetics. The results suggest that although the dual 
delivery of TGF-β3 and IGF-1 may not synergistically enhance the quality of engineered 
tissue, the delivery of IGF-1 alone from bilayered composite hydrogels positively affects 
osteochondral tissue repair and holds promise for osteochondral tissue engineering 
applications.  
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5.1. Introduction 
Articular cartilage is a flexible connective tissue that facilitates the articulation of 
bone in major synovial joints via the dissipation of friction and physiological 
compressive forces [7, 15, 300-302]. With a limited endogenous ability for self-repair, 
damaged cartilage as a result of disease or trauma oftentimes leads to premature arthritis. 
Although current clinical methods are insufficient for long-term treatment [303], tissue 
engineering strategies provide promising alternatives for cartilage repair. To date, many 
research groups have adapted a wide variety of natural or synthetic polymers for the 
fabrication of scaffolds for cartilage tissue engineering. In particular, hydrogel scaffolds 
derived from these materials can be used as a vehicle to deliver biochemical factors that 
stimulate the chondrogenic differentiation of host progenitor cells within a tissue defect 
site [3, 304]. Our laboratory has developed a novel class of water-soluble synthetic 
macromers based on oligo(poly(ethylene glycol) fumarate) (OPF) that can be chemically 
crosslinked to yield hydrolytically degradable hydrogels. Injectable and biodegradable 
hydrogels formed from OPF have been leveraged for the controlled delivery of 
chondrogenic growth factors (GFs) with the aid of gelatin microparticles (GMPs), which 
serve as GF delivery vehicles and enzymatically digestible porogens [88, 89, 101-105, 
118]. Previously, such composite hydrogel systems have been utilized to deliver 
chondrogenic GFs for the elicitation of osteochondral tissue repair within osteochondral 
defect sites in animal models [106-108]. However, the simultaneous delivery of multiple 
GFs and how these GFs interact in vivo to repair osteochondral tissue remains an area of 
investigation.  
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In the present work, OPF composite hydrogels are used to deliver transforming 
growth factor-β3 (TGF-β3) and/or insulin-like growth factor-1 (IGF-1) to an 
osteochondral defect to facilitate cartilage regeneration and subchondral tissue formation. 
TGF-β3 is a potent GF that can induce the chondrogenic differentiation of progenitor cell 
populations in vitro [305-308] as well as augment cartilage tissue formation in vivo [152, 
261, 309, 310]. IGF-1 primarily acts as an anabolic maturation factor to stimulate the 
cellular synthesis of proteoglycans and type II collagen [36, 311]. Previously, OPF 
composite systems were employed to deliver TGF-β1, an isoform of TGF-β3 with similar 
chondrogenic effects, to the chondral space of an osteochondral defect [106]. Although 
the presence of TGF-β1 alone did confer some therapeutic advantage, such as the 
improvement of joint surface regularity over controls at 4 and 14 weeks, the GF did not 
effect a different overall healing response when compared to controls [106]. To achieve 
an overall improvement in osteochondral regeneration and to study the effects of a dual 
GF delivery system in a wound healing environment, the delivery of TGF-β1 with IGF-1 
on osteochondral tissue repair was evaluated [107]. This study was based on results in 
literature demonstrating the synergistic effects of TGF-β1 with IGF-1 on increased 
chondrogenic gene expression and proteoglycan synthesis by articular chondrocytes [312, 
313] and mesenchymal stem cells (MSCs) in vitro [314]. The in vivo study however, 
showed that an initial burst release of TGF-β1 during early stages of cartilage healing 
followed by a sustained release of IGF-1 was not effective at regenerating osteochondral 
tissue under the conditions investigated [107]. Despite the lack of synergy between TGF-
β1 and IGF-1, the controlled delivery of multiple GFs merits further investigation when 
one considers the complex interplay of GFs during different stages chondrogenesis and 
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cartilage regeneration [37, 39, 315]. Indeed, several in vitro studies have demonstrated 
that the anabolic effects of TGF-β isoforms on progenitor cells are dependent on the time 
of delivery [316, 317]. Recently, it was shown that the sequential exposure of umbilical 
cord-derived MSCs to TGF-β3 followed by IGF-1 enhanced their production of cartilage-
like extracellular matrix (ECM) components in vitro [318]. Moreover, our laboratory has 
found that the TGF-β3 isoform was more effective than TGF-β1 at inducing the 
chondrogenic differentiation of rabbit MSCs encapsulated within bilayered OPF 
composite hydrogels [104]. Therefore, we hypothesize that the delivery of TGF-β3, when 
combined with the sustained release of IGF-1, may influence the differentiation of host 
progenitor cell populations and thereby affect the degree of osteochondral tissue repair. 
It has been demonstrated that release kinetics of GFs from OPF composite 
hydrogels can be modulated by hydrogel construction parameters, which include the 
degree of crosslinking of GMPs, the molecular weight of the poly(ethylene glycol) block 
in the OPF macromer, the resultant mesh size of such crosslinked OPF hydrogels, and the 
method of GF incorporation within the composite hydrogel [88, 106, 107, 118]. Such a 
level of tunability with OPF composite hydrogels may be leveraged for the timed 
delivery of multiple chondrogenic GFs to progenitor cell populations in the host tissues to 
repair an osteochondral defect. Indeed, the release kinetics of TGF-β3 when delivered 
together with IGF-1 from OPF composite hydrogels might be an important parameter to 
regulate for the induction of high quality cartilage tissue remodeling and regeneration in 
vivo. The present study investigates how different release kinetics of TGF-β3, in the 
presence of IGF-1, from OPF composite hydrogels affect the tissue response in an 
osteochondral defect.  
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The global hypothesis of this study is that the release of TGF-β3, when combined 
with the sustained release of IGF-1, from OPF composite hydrogels will synergistically 
facilitate osteochondral tissue regeneration in a rabbit osteochondral defect model relative 
to the delivery of IGF-1 alone. Furthermore, it is hypothesized that the release kinetics of 
TGF-β3, when delivered together with a sustained release of IGF-1, will influence the 
degree and quality of osteochondral tissue repair. To this end, the specific objectives of 
this study are: (1) to characterize the in vitro release kinetics of IGF-1 and TGF-β3 from 
composite hydrogels over 28 days, (2) to investigate the synergistic effect of a dual 
delivery of TGF-β3 with IGF-1 on osteochondral tissue regeneration, and (3) to evaluate 
the effect of modulated TGF-β3 release kinetics with sustained IGF-1 release on the 
quality of cartilage and subchondral bone tissue regeneration in a rabbit full-thickness 
osteochondral defect model.  
 
 
5.2. Materials and Methods 
5.2.1. OPF synthesis 
According to a method developed in our laboratory [59, 85], poly(ethylene 
glycol) with a number average molecular weight (Mn) of 35,000 (Sigma-Aldrich, St. 
Louis, MO) was utilized to synthesize OPF. The resulting OPF with an Mn of 42,500 ± 
180 and a weight average molecular weight (Mw) of 120,300 ± 6,500 was used 
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throughout the study. Prior to hydrogel fabrication, OPF was sterilized by exposure to 
ethylene oxide (EO) for 12 hrs according to established methods [102, 103, 108]. 
 
5.2.2. Gelatin microparticle fabrication  
Gelatin microparticles (GMPs) were fabricated using acidic gelatin with an 
isoelectric point of 5.0 (Nitta Gelatin INC., Osaka, Japan) and were crosslinked with 10 
or 40 mM glutaraldehyde (Sigma-Aldrich, St. Louis, MO) according to previously 
established methods [118]. After lyophilization, GMPs with a diameter of 50 – 100 µm 
were selected by sieving and sterilized with EO prior to hydrogel fabrication. Sterile 
GMPs were swollen with phosphate buffered saline (PBS) or GF solutions at 4°C for 15 
hrs, according to previously described methods [88]. For equilibrium swelling of GMPs, 
55 µL of PBS or GF solution was applied to 11 mg of dried GMPs. For the degradation 
study, blank GMPs were swollen with PBS alone. For the in vitro release study and in 
vivo implantation, 40 mM GMPs were loaded with an IGF-1 solution with a 
concentration of 24.42 µg of human recombinant IGF-1 (R&D Systems, Minneapolis, 
MN) per mL PBS to achieve a concentration of 2000 ng IGF-1 per mL crosslinked OPF 
composite hydrogel prior to equilibrium swelling. Similarly, 10 mM GMPs were loaded 
with a TGF-β3 solution with a concentration of 21.97 µg of human recombinant TGF-β3 
(R&D Systems) per mL PBS to achieve 1800 ng TGF-β3 per mL crosslinked OPF 
composite hydrogel prior to equilibrium swelling. 10 and 40 mM GMPs, which have 
different degradation rates, were selected to deliver dual GFs in a fashion that first 
induces chondrogenic differentiation of progenitor cells by TGF-β3, followed by IGF-1 
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induced stimulation of the ECM production [107].  Furthermore, a 2.5 times higher 
concentration for both IGF-1 and TGF-β3 solutions was used in the preparation of 
additional groups for the in vitro release study. 
 
5.2.3. Bilayered composite hydrogel fabrication 
Bilayered composite hydrogels to deliver GFs were fabricated via a two-step 
crosslinking procedure as previously described [104, 105, 107]. The subchondral layer 
was partially crosslinked first and the chondral layer was fabricated on top of the 
subchondral layer. Specifically, 100 mg of sterile OPF and 50 mg of sterile poly(ethylene 
glycol) diacrylate (PEG-DA, Glycosan, Alameda, CA) with a molecular weight of 3400 
were dissolved in 468 µL PBS and mixed with 110 µL of blank GMPs swollen with PBS 
(GMP/PBS). Equal parts (46.8 µL) of the thermal radical initiators, 0.3 M of ammonium 
persulfate (APS, Sigma-Aldrich) and 0.3 M of N,N,N’,N’-tetramethylethylenediamine 
(TEMED, Sigma-Aldrich), were then mixed into the polymer solution. The polymeric 
mixture was quickly injected into a cylindrical Teflon mold (2.2 mm in diameter and 2.2 
mm in thickness) and partially crosslinked at 37°C for 4 min.  Subsequently, the 
polymer-GMP mixture for the chondral layer was prepared. 100 mg of sterile OPF and 50 
mg of sterile PEG-DA were dissolved in 468 µL PBS and mixed with 110 µL of blank 
GMP solution swollen with PBS for the control group, 55 µL of GMP/PBS and 55 µL of 
GMP solution swollen with IGF-1 (GMP/IGF-1) for Group 1, and 55 µL of GMP/IGF-1 
and 55 µL of GMP solution swollen with TGF-β3 (GMP/TGF-β3) for Group 3 (Table 
5.1). For Group 2 (Gel phase loading), the same amount of OPF/PEG-DA was dissolved 
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in 413 µL PBS, mixed with 55 µL of TGF-β3 solution, and subsequently mixed with 46.8 
µL of 0.3 M of APS and 46.8 µL of 0.3 M of TEMED. The mixture for the chondral 
layer was then injected onto the partially crosslinked subchondral layer, and crosslinked 
at 37°C for 8 min. 
 
5.2.4. Degradation  
For the swelling and degradation studies, two different sizes of bilayered 
composite hydrogels containing only GMP/PBS for both chondral and subchondral layers 
were fabricated as described above. The composite hydrogels were placed in either 3 mL 
of PBS or collagenase-PBS (370 ng collagenase 1A per mL PBS) in a 12 well plate, and 
incubated at 37°C for 28 days on a shaker table (70 RPM). At days 1, 4, 7, 14, 21, and 28, 
the swelling ratio, sol fraction, and mass remaining for OPF hydrogel composites were 
determined (n=4) using the following equations; swelling ratio = (Ws – Wd) / Wd, % sol 
fraction = (Wi – Wd) / Wi x 100 (%), and mass remaining = Wd / Wi x 100 (%), where Wi, 
Ws, and Wd represent the weight of dried hydrogel immediately after fabrication prior to 
swelling, the weight of wet hydrogel after swelling at each time point, and the weight of 
dried hydrogel after swelling at each time point, respectively.  
 
5.2.5. Quantification of in vitro release kinetics  
Release kinetics of the total amount of GFs from bilayered composite hydrogels 
was assessed by measuring the radioactivity of 125I-labeled GFs [106, 118]. Briefly, 125I-
93 
 
labeled IGF-1 and TGF-β3 (Perkin Elmer Life Sciences, Boston, MA) were incorporated 
with unlabeled GFs (Peprotech, Rocky Hill, NJ) for GMP swelling. 3% of the required 
GF solution volume for GMP swelling was replaced with 125I-labeled GF solution of the 
same concentration. Bilayered OPF composite hydrogels were fabricated as described 
above. For the IGF-1 release study, 40 mM GMPs were loaded with 125I-labeled IGF-1 
and unlabeled IGF-1 for the hydrogels in all groups, while unlabeled TGF-β3 was used 
for hydrogel samples in Group 2 (Gel phase loading) and Group 3 (GMP loading) (Table 
5.1). For the TGF-β3 release study, 10 mM GMPs were loaded with 125I-labeled TGF-β3 
and unlabeled TGF-β3 in the presence of unlabeled IGF-1 was used for the samples in 
Group 2 (Gel phase loading) and Group 3 (GMP loading). In addition, a 2.5 times higher 
GF amount (i.e., 2.5 times higher concentration of GF solution with same volume for 
GMP swelling or gel phase loading) was loaded in hydrogels to investigate the effect of 
GF concentration on release kinetics. After fabrication, hydrogels were placed in 3 mL of 
PBS or collagenase-PBS in a 12 well plate, and incubated at 37°C for 28 days on a shaker 
table (70 RPM). At 2 hrs, 12 hrs, days 1, 2, 4, 7, 10, 14, 18, 21, 24, and 28, the 
supernatant of each hydrogel was collected and replaced with fresh buffer solution. The 
amount of released GF was determined by the correlation of measured radioactivity to a 
standard curve using a gamma counter (Cobra II Autogamma, Packard, Meridian, CT) 
(n=5).  
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5.2.6. Bioactivity of released growth factors 
Release kinetics of biologically active GFs were assessed by cellular assays, as 
described in previous studies [271, 319]. Bilayered composite hydrogels 3 mm in 
diameter and 3 mm in thickness were utilized. For the IGF-1 activity assay, hydrogels in 
Group 1 were fabricated as described above. Hydrogels delivering both IGF-1 and TGF-
β3 were not examined with the cellular assays, as the presence of TGF-β3 may confound 
the results. Four hydrogels were placed in 1 mL of collagenase-PBS in a 12 well plate, 
and incubated at 37°C for 28 days on a shaker table (70 RPM). At 2 hrs, 12 hrs, days 1, 2, 
4, 7, 10, 14, 18, 21, 24, and 28, the supernatant of each hydrogel was collected and 
replaced with fresh buffer solution. Collected supernatants were stored at - 80°C until the 
assay time. A MCF-7 cell line proliferation assay was used to measure the biologically 
active fraction of released IGF-1 from the composite hydrogels [271]. 5,000 MCF-7 cells 
(HBT-22, ATCC, Manassas, VA) in serum-free DMEM:F12 medium (Life Technologies, 
Grand Island, NY) were plated in a 96 well plate. 25 µL of collected supernatant or 25 
µL of an IGF-1 standard (0.15 – 20 ng/mL range) were then added. The cells were 
cultured in an incubator (37°C, 5% CO2) for 72 hrs. Proliferative activity of plated cells 
was measured by a CellTiter Blue assay (Promega, Madison, WI) according to the 
manufacturer’s protocol. Fluorescence intensity was measured using a microplate reader 
(excitation 560 nm/emission 590 nm). A standard curve was generated by a 4 parameter 
fit and the active amount of released IGF-1 was calculated at each time point (n=4) [271]. 
The cumulative % active release was plotted based on the released amount of IGF-1 as 
measured with 125I-labeled GFs in the “Quantification of in vitro release kinetics” section. 
For the TGF-β3 activity assay, composite hydrogels in Group 2 and Group 3 were 
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fabricated as described above. Similarly, IGF-1 was not included in these composite 
hydrogels as its presence may confound the results of the TGF-β3 activity assay. Three 
gels in each group were placed in 1 mL of collagenase-PBS in a 12 well plate, and 
incubated at 37°C for 28 days on a shaker table (70 RPM). Sample collection and storage 
were the same as described above. A Mink lung epithelial cell line (CCL-64, ATCC, 
Manassas, VA) inhibition assay was used to measure the biologically active fraction of 
released TGF-β3 from OPF composites [319]. 10,000 CCL-64 cells (HBT-22, ATCC, 
Manassas, VA) in DMEM media (Life Technologies, Grand Island, NY) were plated in a 
96 well plate. 25 µL of collected supernatant or 25 µL of a TGF-β3 standard (0.005 – 5 
ng/mL range) were then added. The cells were cultured in an incubator (37°C, 5% CO2) 
for 72 hrs. The level of inhibition, the active amount of released TGF-β3, and the 
cumulative % release of active TGF-β3 were analyzed as described above.  
 
5.2.7. Animal surgery 
A total of 24 skeletally mature (i.e., 6 months old) male New Zealand white 
rabbits were utilized in this study based on a previously established full-thickness 
osteochondral defect model [106-108]. The number of defects and animals per each 
group were determined by power analysis and consideration of previous studies [106-
108]. All surgical procedures were approved by the Institutional Animal Care and Use 
Committees of Rice University and University of Texas Health Science Center at 
Houston. Animal surgeries for implantation in bilateral defects were performed as 
previously described [106-108]. Prior to surgery, anesthesia was induced by 
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subcutaneous injection of Ketamine (25-40 mg/kg) and Acepromazine (1-2 mg/kg). 
General anesthesia was then maintained through ventilator administration of a mixture of 
isoflurane and oxygen. Osteochondral defects (3 mm in diameter and 3 mm in thickness) 
were created on the medial femoral condyles. Pre-fabricated bilayered composite 
hydrogels were swollen in sterile PBS for 30 minutes and these swollen composite 
hydrogels with the same dimensions as the defect were press-fitted into the osteochondral 
defect. Then, the muscle and skin were closed. This procedure was repeated for the 
contralateral knee using a hydrogel of the same formulation. Therefore, each animal 
received two hydrogels (one per knee) and a total of 12 hydrogels (n=12) were implanted 
in 6 animals per experimental group. To minimize post-operative discomfort, Carprofen 
(4 mg/kg) was administrated for 2 days post-operatively.  
 
5.2.8. Tissue Processing 
Rabbits were euthanized by intravenous administration of Beuthanasia (0.22 
mL/kg) at 12 weeks post-surgery. The tissue surrounding the medial femoral condyle was 
retrieved en bloc, fixed in 10% buffered formalin (pH 7.4) for 1 week, decalcified in 
EDTA solution for 6 weeks, dehydrated through a graded series of ethanol baths, and 
then embedded in paraffin. Longitudinal sections of 6 µm thickness were taken from the 
center (within the central 1 mm), lateral edge (within the lateral 1 mm), and medial edge 
(within the medial 1 mm) of each defect using a microtome. Two sections from each 
location were stained with hematoxylin and eosin (H&E), Safranin O/Fast Green, and van 
Gieson’s Picrofuchsin.  
97 
 
 
5.2.9. Histological Scoring 
Histological sections were blindly and independently scored by three evaluators 
(J.L., P.P.S., and F.K.K.) using a previously established scoring system for osteochondral 
repair, as shown in Table 5.2 [108]. A total of 11 parameters to evaluate osteochondral 
repair were used to analyze the whole defect for both chondral (within the upper 1 mm of 
the defect) and subchondral (within the bottom 2 mm of the defect) regions.   
 
5.2.10. Statistical Analysis 
The data from the in vitro assays were analyzed by one-way analysis of variance 
(ANOVA) and Turkey’s multiple-comparison test. The means and the standard 
deviations were reported in each figure. For the histological analysis, ordered logistic 
regression of histological scores was performed to analyze the potential effect of 
experimental group, location within the defect, and knee joint [106-108]. p<0.05 was 
considered to indicate a significant difference. 
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5.3. Results 
5.3.1. Degradation of bilayered OPF composite hydrogels 
The swelling ratio of bilayered OPF composite hydrogels remained stable over 28 
days in PBS, but started to increase after 7 days in collagenase-PBS (Figure 5.1A). The 
sol fraction of composite hydrogels in PBS was also stable (about 40%) over 28 days 
(Figure 5.1B). However, the sol fraction in collagenase-PBS started to increase after 7 
days of incubation and maintained a gradual increase until day 28. Similarly, the fraction 
of the initial mass remaining continuously decreased over time in collagenase-PBS 
(Figure 5.1C).  
5.3.2. In vitro IGF-1 release kinetics 
The % cumulative release profiles of IGF-1 (as measured by radiolabeled IGF-1) 
over 28 days for Groups 1-3 are shown in Figure 5.2A-C, respectively, while the % 
cumulative release profile of the active amount of released IGF-1 for Group 1 (as 
measured by cellular assays) is shown in Figure 5.2D. The release kinetics of IGF-1 were 
similar between groups in both PBS and collagenase-PBS conditions as seen in Figure 
5.2A-C. Initial burst release of IGF-1 within the first 4 days in collagenase-PBS was 43.9 
± 3.4 % in Group 1 (GMP-loaded IGF-1 only), 46.2 ± 1.7 % in Group 2 (GMP-loaded 
IGF-1 and gel-loaded TGF-β3), and 40.8 ± 3.7 % in Group 3 (GMP-loaded IGF-1 and 
GMP-loaded TGF-β3). 28-day % cumulative IGF-1 release in collagenase PBS was 83.2 
± 1.4 % in Group 1, 85.0 ± 0.9 % in Group 2, and 85.2 ± 3.0 % in Group 3. In addition, 
the IGF-1 release rate (% release of IGF-1 per day) is shown in Table 5.3A. No statistical 
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difference was observed between groups in collagenase-PBS during all phases. For all 
groups, approximately 30% of IGF-1 was released in phase 1 (up to 24 hrs), while 
approximately 1% of IGF-1 was released each day in phase 4 (days 18 - 28) (Table 
5.3A). Biologically active IGF-1 released from the OPF composites (i.e., the released 
IGF-1 to actively enhance the proliferation of the MCF-7 cell line) was analyzed by using 
the same formulation in Group 1 in collagenase-PBS. Figure 5.2D showed that 36.6 ± 
8.8 % of active IGF-1 was released within the first 4 days and that a total cumulative 
release of 66.6 ± 15.5 % was achieved by day 28. Release rate of active IGF-1 in 
collagenase-PBS (Table 5.3B) was similar to release rate determined by gamma counter 
(Table 5.3A) in all phases.  
 
5.3.3. In vitro TGF-β3 release kinetics 
The % cumulative release profile of TGF-β3 over 28 days is shown in Figure 
5.3A-B, while the % cumulative release profile of the active amount of TGF-β3 is shown 
in Figure 5.3C. When comparing Group 2 and Group 3, a significantly higher burst 
release of TGF-β3 is seen within the first 2 days in Group 2 in collagenase-PBS (Figure 
5.3A). Specifically, the 2-day burst release of TGF-β3 is 26.4 ± 3.3 % in Group 2 (GMP-
loaded IGF-1 and gel-loaded TGF-β3) and 19.5 ± 3.5 % in Group 3 (GMP-loaded IGF-1 
and GMP-loaded TGF-β3), although the 4-day release for both groups has no statistical 
difference (32.2 ± 3.3 % in Group 2 and 36.5 ± 4.0 % in Group 3). From day 7 to day 28, 
the % cumulative release is higher in Group 3 than in Group 2 at each time point (Figure 
5.3A). The 28-day % cumulative TGF-β3 release in collagenase-PBS is 71.4 ± 9.2 % in 
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Group 2 and 84.8 ± 2.6 % in Group 3. Similar release kinetics were found in the standard 
PBS condition (Figure 5.3B). The release rate of TGF-β3 (% release per day) in Table 
5.4A also indicates the difference between Groups 2 and 3. The release rate in Group 2 is 
higher than that in Group 3 in phase 1, but the release rate in Group 3 is higher than that 
in Group 2 in phases 2 and 3 in collagenase-PBS. The release of a higher (2.5 times) 
concentration of TGF-β3 in composite hydrogels featured similar % cumulative release 
profiles and the release rate (data not shown).  
Biologically active released TGF-β3 (i.e., the released TGF-β3 to actively inhibit 
the proliferation of the CCL-64 cell line) was analyzed by using the same formulations 
for Groups 2 and 3 (Figure 5.3C) in collagenase-PBS. Initial burst release of active TGF-
β3 as measured by a cell assay is similar within the first 2 days for both formulations. 
The 28-day % cumulative release of active TGF-β3 is 58.4 ± 11.9 % in Group 2 and 69.0 
± 18.6 % in Group 3. The release rate of active TGF-β3 in Group 3 is higher than that in 
Group 2 for phases 2 and 3 from days 1 to 18 (Table 5.4B). 
 
5.3.4. Histological observation and scoring 
Sections from three locations (lateral edge, medial edge, and center) per sample 
were obtained for histological evaluation. Representative images from each group are 
shown in Figure 5.4 – Figure 5.7, respectively. Figure 5.8 shows the histological scores 
for the 11 parameters listed in Table 5.2. 
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In all groups, partially degraded OPF gels were observed in the subchondral layer 
(Figure 5.4 – Figure 5.7). No significant difference was observed in both overall tissue 
filling and overall hydrogel degradation (Figure 5.8A). In all formulations, a mean score 
of about 2 was recorded in overall filling  at the 12 week time point. This observation was 
closely related to a mean score of 2 in the percent degradation of the implant. Partially 
degraded gels in the subchondral layer in all formulations contributed to this score. In 
addition, statistical analysis revealed that location in the defect (lateral/medial/center) 
was a significant factor in overall degradation. Specifically, degradation in the lateral 
edge was greater than that in the center, which is correlated with the observation of 
remaining hydrogel in the center area. 
Although mean scores for overall hydrogel degradation in Figure 5.8A are similar 
in all groups, none of the samples in the control group (Figure 5.4), which lacked GF 
incorporation, showed complete degradation, while groups incorporating GF showed at 
least one sample with complete degradation (i.e., all three sections per sample with a 
score of 3; one sample in Group 1, one in Group 2, and two in Group 3). In particular, the 
size of partially degraded gels in the subchondral region in Group 1 was generally smaller 
than those found in the control (i.e., approximately less than 30% of subchondral area in 
all sections), as shown in Figure 5.5. Specimens in groups delivering both IGF-1 and 
TGF-β3 (Groups 2 and 3) showed similar subchondral characteristics to samples seen in 
the control group, such as the frequency of partially degraded gels, the presence of 
inflammatory cells, and the area covered with newly formed bone tissues in the defect 
site (Figure 5.6E and Figure 5.7E). 
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In the evaluations for subchondral bone regeneration including percent bone 
filling, bone morphology, and bonding between newly formed bone tissue and adjacent 
bone (Table 5.2), the mean score for bone filling was slightly above 2 (Figure 5.8B) in 
all groups. However, the frequency of complete bone filling in Group 1 is greater than the 
other groups (data not shown). Although inflammatory cells and surrounding fibrous 
tissue were also observed in samples from Group 1 (Figure 5.5E), the quality and 
frequency of trabecular bone formation was higher than the specimens in the control 
group. Location in the defect was also a significant factor in bone filling; scores for the 
lateral edge were significantly higher than those for the center.  
In subchondral bone morphology, a mean score (1.67 ± 0.96) for Group 1 (GMP-
loaded IGF-1 only) was higher than that (1.11 ± 0.62) for Group 3 (GMP-loaded IGF-1 
and GMP-loaded TGF-β3). In the blank control, the morphological characteristics of 
newly formed subchondral tissue in the defect were generally a mixture of compact bone 
with fibrous tissues (Figure 5.4 and Figure 5.9A).  As indicated by the score distribution 
in Figure 5.9A, sections in Group 1 showed higher levels of trabecular bone regeneration 
as well as less compact bone with fibrous tissue formation than other groups. However, 
the presence of partially degraded OPF gels that were surrounded by fibrous tissues 
maintained a mean score between 1 and 2 for each group. Despite this result, bone 
bonding between newly formed tissue and adjacent native bone within the subchondral 
region was found to be complete on both edges of the defect and received a score of 3 for 
all sections in all experimental groups (Figure 5.8B).  
Cartilage regeneration was evaluated in the categories of cartilage morphology, 
thickness of newly formed cartilage, surface regularity, chondrocyte clustering, 
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chondrocyte and glycosaminoglycan (GAG) amount in newly formed cartilage, and 
chondrocyte and GAG amount in adjacent cartilage tissue (Table 5.2). Histological 
analysis of the cartilage region indicated that the formulation significantly affected the 
cartilage morphology as well as the cell and GAG content in adjacent cartilage tissue 
(Figure 5.8C). However, location (lateral/medial/center) within the defect was not a 
significant factor. For cartilage morphology, all GF groups (Group 1, 2, and 3) received 
statistically higher mean scores when compared to the blank control (without GF 
loading). The score distribution for cartilage morphology (Figure 5.9B) indicated that 
higher levels of hyaline cartilage regeneration as well as less fibrous tissue formation 
were more frequent in Groups 1, 2, and 3 than the blank control. The cartilage layer in 
samples in the control group (Figure 5.4) was usually composed of thick fibrous tissue 
and fibrocartilage and the complete disruption of neo-cartilage surface or deep fissures in 
the cartilage layer was also observed in some samples. Neo-cartilage tissue in the 
chondral layer in GF groups (Figure 5.5 - Figure 5.7) was usually fibrocartilage (Figure 
5.9B). However, it should be noted that the frequency of hyaline cartilage accompanied 
with a smooth surface and zonal organization was higher in GF groups than the control 
(Figure 5.9C). Group 2 (GMP-loaded IGF-1 and gel-loaded TGF-β3) received the 
highest mean score (2.17 ± 0.61) (Figure 5.8C) and frequency of hyaline-like cartilage 
tissue formation (Figure 5.9B), which indicated the presence of a mixture of newly 
formed hyaline cartilage and fibrocartilage within the cartilage defect space. Samples 
with hyaline cartilage formation generally demonstrated intensive GAG staining and less 
chondrocyte clustering, as shown in Figure 5.6D. Overall cartilage morphology observed 
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in Group 3 was similar to that in Group 2, except with less GAG staining (Figure 5.7B 
and Figure 5.7D).  
Although no statistical differences were observed in cartilage thickness, surface 
regularity, and chondrocyte clustering (Figure 5.8C), all GF incorporating groups 
(Groups 1, 2, and 3) received higher mean scores for these parameters than the blank 
control. Mean scores for surface regularity (between 1 and 2) and chondrocyte clustering 
(around 1) reflected that newly formed cartilage tissues in all formulations contained 
some fissures and clustered chondrocyte populations, respectively. Scores for cell and 
GAG amount in neo-cartilage did not show any statistical difference between groups 
(Figure 5.8C). In cell and GAG amount in adjacent cartilage tissue, normal chondrocyte 
cellularity and normal Safranin O staining (i.e., a mean score close to 3) were observed 
for all formulations. Specifically, the mean score (3.00 ± 0.00) in Group 1 (GMP-loaded 
IGF-1 only) for this parameter was statistically higher than that (2.75 ± 0.50) in Group 2 
(GMP-loaded IGF-1 and gel-loaded TGF-β3). 
 
 
5.4. Discussion 
The main objective of this study was to determine the effect of dual GF delivery 
using IGF-1 and TGF-β3 in bilayered OPF composite hydrogels for osteochondral tissue 
regeneration. Specifically, we investigated (1) how the in vitro release kinetics of TGF-β3 
could be modulated by differing the incorporation method in OPF composite hydrogels, 
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in the presence of IGF-1, (2) whether the delivery of TGF-β3 in the presence of IGF-1 
would enhance the osteochondral tissue regeneration over delivery of IGF-1 alone, and 
(3) whether varied release kinetics of TGF-β3 when delivered with IGF-1 would affect 
the degree of osteochondral tissue regeneration in a rabbit defect model. While we have 
previously studied the effects of TGF-β1 delivery alone and the dual delivery of TGF-β1 
and IGF-1 in a rabbit osteochondral model [106, 107], questions regarding how 
interactions between multiple GFs and how varying the release kinetics of these GFs 
affect osteochondral tissue regeneration in vivo remain to be investigated. 
An increase in GF release (Figure 5.2 and Figure 5.3), especially in phase 3 (Day 
4-18) was related to GMP degradation by collagenase and subsequent mass loss (Figure 
5.1). The release profile demonstrated that the release kinetics of IGF-1 were not 
influenced by the incorporation of the other GF (i.e., TGF-β3) in the same layer of a 
bilayered hydrogel construct, while the release kinetics of TGF-β3 could be modulated by 
loading the GF in the GMP or OPF phase of the hydrogel composites (Figure 5.2 – 
Figure 5.3 and Table 5.3, Table 5.4). In addition, the release kinetics of TGF-β3 were not 
influenced by the concentration of GF solution used to swell the GMPs. It was 
hypothesized that the ionic complexation of GFs with GMPs would reduce any loss of 
their activity [320]. Indeed, higher amounts of active TGF-β3 released were detected in 
Group 3 (GMP-loaded TGF-β3) compared to Group 2 (gel-loaded TGF-β3) using a Mink 
lung epithelial cell line, especially in phase 2 and 3 (Table 5.4).  
Histological data demonstrated that improved cartilage morphology in the defect 
by GF incorporation was observed when compared to the control (Figure 5.8C), 
indicating a beneficial effect of GF delivery (TGF-β3 and/or IGF-1) using OPF 
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composite hydrogels. The released bioactive GFs may have contributed to the migration 
of host cell populations to the defect site, stimulated the chondrogenic differentiation of 
progenitor stem cells, and subsequently improved cartilage-like tissue regeneration. 
Histological data also demonstrated that TGF-β3 delivery in the presence of IGF-1 
(specifically, Group 2) resulted in a greater frequency of hyaline-like cartilage formation 
(Figure 5.8C and Figure 5.9B). No major degenerative effect on surrounding host tissues 
was observed throughout the samples in the dual delivery groups (i.e., Group 2 and 3). 
Highly localized TGF-β3 delivery in the present study did not influence fibrous tissue 
formation in both chondral and subchondral layers when histological sections in Group 2 
and 3 were compared to those in the blank control. Although a higher frequency of 
hyaline cartilage formation (Figure 5.9B) was observed in Group 2, any synergistic 
effect of dual GF delivery of TGF-β3 with IGF-1 over a single delivery of IGF-1 was 
limited. Both dual GF delivery groups (i.e., Group 2 and 3) did not show higher levels of 
osteochondral tissue regeneration over delivery of IGF-1 alone (Figure 5.8C). The 
significant differences between GF loading groups were found in bone morphology 
(Figure 5.8B) and adjacent GAG (Figure 5.8C). Delivery of IGF-1 alone (Group 1) 
showed an improved subchondral bone morphology over Group 3 (GMP-loaded IGF-1 
and GMP-loaded TGF-β3) as well as a higher cell and GAG amount in adjacent cartilage 
tissue over Group 2 (GMP-loaded IGF-1 and gel-loaded TGF-β3).  
These results show that delivery of IGF-1 alone for osteochondral tissue repair 
improves the subchondral bone morphology and the interaction with the surrounding 
chondral tissue over a dual GF delivery with IGF-1 and TGF-β3. Since TGF-β3 has been 
shown to have an inhibitory effect on the osteogenic differentiation of MSCs and 
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osteoblastic cells in vitro [104, 321, 322], it is possible that the amount of TGF-β3 
released in this study suppressed subchondral bone formation. Indeed, greater amounts of 
active TGF-β3 were released in Group 3 as compared to Group 2, potentially resulting in 
the significantly lower bone morphology score observed in Group 3 than in Group 1. 
Further research could help elucidate the effects of TGF-β3 on in vivo subchondral bone 
repair. Additionally, other in vivo studies using the dual delivery of IGF-1 and TGF-β1 in 
a rabbit full-thickness defect model for osteochondral tissue regeneration also 
demonstrated a lack of synergy despite the fact that different hydrogel materials and 
different types and doses of GF were applied [107, 323]. One study using self-assembled 
peptide hydrogels demonstrated that the incorporation of chondrogenic factors including 
IGF-1 and TGF-β1 did not significantly improve cartilage regeneration over hydrogels 
without chondrogenic factors [323]. In a previous in vivo study from our laboratory 
[107], the single sustained delivery of IGF-1 using OPF composite hydrogels showed 
significantly improved cartilage regeneration over the single burst delivery of TGF-β1 
within an osteochondral defect. IGF-1 alone also resulted in a significantly higher score 
for chondrocyte clustering when compared to the dual delivery of IGF-1 and gel-loaded 
TGF-β1 [107]. Furthermore, several in vivo studies showed a positive result of IGF-1 
delivery in cartilage tissue regeneration using other animal models [145, 165, 168]. 
Taken together, the delivery of TGF-β3 (at the varying release kinetics examined) with 
IGF-1 did not improve osteochondral tissue regeneration over the delivery of IGF-1 
alone, suggesting a lack of synergy between these two growth factors. Further research 
investigating the dose-dependent effect of IGF-1 alone on osteochondral tissue 
regeneration is warranted. 
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A comparison between Group 2 and Group 3 reveals no statistical differences in 
histological scores for subchondral bone evaluation and cartilage regeneration. While in 
vitro results demonstrate distinct release kinetics between gel-loaded and GMP-loaded 
TGF-β3, in vivo release kinetics may have been different. Indeed, previous studies have 
shown differences between in vitro and in vivo release kinetics of GFs from composite 
scaffolds using microparticles as delivery vehicles [324-326]. In one study, the release of 
BMP-2 from a poly(DL-lactic-co-glycolic acid)/calcium phosphate composite was found 
to be faster in vivo than from similar composites in vitro [326, 327]. This highlights the 
complexity of an in vivo environment and suggests that the release kinetics of TGF-β3 in 
vivo in this study may not have been sufficiently different to elicit a change in 
osteochondral regeneration.  As a result, with the amount of TGF-β3 incorporated within 
the OPF composite hydrogels for Groups 2 and 3, differing release kinetics of TGF-β3 
together with the presence of IGF-1 did not significantly influence the quality of 
regenerated osteochondral tissue in a full-thickness defect model.  
Compared to a series of previous in vivo studies using OPF composite hydrogels 
[106-108], PEG with a higher molecular weight (Mn of 35,000) was utilized to synthesize 
OPF in the present study. As the molecular weight of the PEG chain between crosslinks 
increases, one would expect that the crosslinking density of the hydrogels would 
decrease, thus resulting in an increased level of hydrogel degradation [89, 96, 97]. In 
addition to the faster degradation, it has also been reported that larger network mesh sizes 
and better transport of nutrients/signaling molecules as modulated by higher molecular 
weight of PEG enhanced the chondrogenic differentiation of encapsulated MSCs in OPF 
composite hydrogels [89]. Furthermore, such modulation in hydrogel properties offers a 
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mode of control over the diffusion of soluble components within hydrogel composites, 
which is a critical factor for determining the release kinetics of GFs that are incorporated 
in hydrogels. For instance, when compared to a previous study that used OPF synthesized 
from PEG with Mn of 25,000 and methylene bisacrylamide as a crosslinker [107], a 
higher cumulative release of IGF-1 on day 28 (Figure 5.2) was observed in the present 
study with the same crosslinking density of GMPs (67.4 % vs 83-85%).  
However, the in vivo degradation of implanted gels using OPF synthesized from 
PEG with a Mn of 35,000 and PEG-DA as a crosslinker in this study was not complete 
after 12 weeks. One possible factor to affect the degradation is the molar crosslinking 
ratio of OPF and PEG-DA. When compared to using a lower PEG block Mn at the same 
OPF:PEG-DA weight ratio and total polymer content for hydrogel fabrication [108], the 
current system had a higher molar crosslinking ratio of OPF and PEG-DA which explains 
the prolonged in vivo degradation. Although the newly formed subchondral bone tissue 
and neo-cartilage tissue at the site of implant edges were well integrated with the 
surrounding native tissues, partially degraded gels were often observed in the center of 
the subchondral region of the defect, regardless of GF loading formulation (Figure 5.4 – 
Figure 5.7). The observation suggests that bone infiltration begins from the defect margin 
toward the center of the implantation region in the subchondral layer, but bone 
remodeling in the core area is limited. In addition, the presence of inflammatory cells and 
fibrous tissue in the subchondral area resulted in low histological scores in bone 
morphology.  
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5.5. Conclusions 
IGF-1 and TGF-β3 were independently released from bilayered OPF composite 
hydrogels and the release kinetics of TGF-β3 could be modulated by the incorporation 
method. Higher amounts of active TGF-β3 were released when it was incorporated with 
GMPs as compared to gel phase loading. Single delivery of IGF-1 and dual delivery of 
both IGF-1 and TGF-β3 significantly enhanced cartilage morphology over a blank 
hydrogel control in a full-thickness osteochondral defect model after 12 weeks. Although 
IGF-1 delivery alone contributed to enhanced cartilage repair compared to the dual 
delivery of IGF-1 and TGF-β3, there was no significant effect of the TGF-β3 release 
kinetics on osteochondral tissue repair. The lack of synergy between IGF-1 and TGF-β3, 
regardless of TGF-β3 kinetics, demonstrates that the dual delivery of GFs does not 
necessarily confer an improved healing response over the single delivery of GFs in 
certain tissue engineering applications in vivo. 
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5.6. Figures and Tables 
(A) (B) 
 
 (C)  
 
Figure 5.1 Degradation profile of bilayered OPF composite hydrogels. Swelling ratio (A), 
sol fraction (B), and mass remaining (C) were measured over 28 days in collagenase 
containing PBS () and PBS () (n=4). Error bars correspond to standard deviation. 
  
0 
5 
10 
15 
20 
25 
30 
0 5 10 15 20 25 30 
S
w
e
ll
in
g
 R
a
ti
o
 
Days 
Collagenase-PBS 
PBS 
0 
10 
20 
30 
40 
50 
60 
70 
80 
0 5 10 15 20 25 30 
S
o
l 
F
ra
c
ti
o
n
 (
%
) 
Days 
0 
10 
20 
30 
40 
50 
60 
70 
80 
0 5 10 15 20 25 30 
F
ra
c
ti
o
n
 I
n
it
ia
l 
M
a
s
s
 R
e
m
a
in
in
g
 (
%
) 
Days 
112 
 
(A) (B) 
 
 (C) (D) 
 
 
Figure 5.2 % cumulative IGF-1 release from a bilayered OPF composite hydrogels in 
Group 1 (A), Group 2 (B), and Group 3 (C) over 28 days (n = 5). Solid line indicates 
collagenase-PBS condition while dashed line indicates PBS condition. % cumulative 
active IGF-1 release from a hydrogel in Group 1 (IGF-1 only) in collagenase-PBS is 
shown in (D) (n = 4). Error bars correspond to standard deviation. (*) indicates a 
significant difference between groups (p < 0.05). 
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(A) (B) 
 
 (C) 
 
 
Figure 5.3 % cumulative TGF-β3 release from a bilayered OPF composite hydrogels in 
Group 2 (solid line) and Group 3 (dashed line) in collagenase-PBS (A) and PBS (B) over 
28 days (n = 5). % cumulative active TGF-β3 release from a hydrogel in Group 2 (solid 
line) and Group 3 (dashed line) in collagenase-PBS is shown in (C) (n = 4). Error bars 
correspond to standard deviation. (*) indicates a significant difference between groups 
(p < 0.05). 
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Figure 5.4 Representative histological sections of osteochondral tissue formation after 
12 weeks of implantation of OPF composite hydrogels in control (blank without GFs). 
Sections were stained with H&E (A), Safranin-O/Fast Green (B), and van Gieson's 
Picrofuchsin (C) (scale bar: 1000 μm). Images indicate a thick fibrous layer with a 
discontinuity in morphology compared to adjacent host cartilage tissue and incomplete 
degradation of hydrogels in the subchondral area along with inflammatory cell 
infiltration. Boxed regions are shown with a higher magnification (D, E) (scale bar: 
250 μm). (*) indicates some partially degraded OPF composite hydrogels remaining in 
the defect site. 
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Figure 5.5 Representative histological sections of osteochondral tissue formation after 
12 weeks of implantation of OPF composite hydrogels in Group 1 (IGF-1 only). Sections 
were stained with H&E (A), Safranin-O/Fast Green (B), and van Gieson's Picrofuchsin 
(C) (scale bar: 1000 μm). Images with higher magnification indicate hyaline-like 
cartilage morphology with a hierarchical aligning of chondrocytes in the cartilage region 
(D) and a small fraction of partially degraded OPF composite hydrogels (indicated by *) 
in the subchondral area (E) (scale bar: 250 μm). 
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Figure 5.6 Representative histological sections of osteochondral tissue formation after 
12 weeks of implantation of OPF composite hydrogels in Group 2 (IGF-1 and gel-loaded 
TGF-β3). Sections were stained with H&E (A), Safranin-O/Fast Green (B), and van 
Gieson's Picrofuchsin (C) (scale bar: 1000 μm). Images with higher magnification 
indicate hyaline-like cartilage morphology with GAG staining in the cartilage region (D) 
and partially degraded OPF composite hydrogels (indicated by *) that are surrounded by 
regenerated bone tissue in the subchondral area (E) (scale bar: 250 μm). 
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Figure 5.7 Representative histological sections of osteochondral tissue formation after 
12 weeks of implantation of OPF composite hydrogels in Group 3 (IGF-1 and GMP-
loaded TGF-β3). Sections were stained with H&E (A), Safranin-O/Fast Green (B), and 
van Gieson's Picrofuchsin (C) (scale bar: 1000 μm). Images with higher magnification 
indicate fibrocartilage formation in the cartilage region (D) and a similar subchondral 
bone morphology with large volume of partially degraded OPF composite hydrogels 
(indicated by *) compared to the control specimen (E) (scale bar: 250 μm). 
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(A) (B) 
 
(C) 
 
Figure 5.8 Histological scoring for overall defect (A), subchondral region (B), and 
cartilage region (C). Overall evaluation (A) includes overall tissue filling and overall 
implant degradation; subchondral evaluation (B) includes bone filling, bone morphology, 
and bonding to adjacent tissue; cartilage evaluation (C) includes cartilage morphology, 
cartilage thickness, surface regularity, chondrocyte clustering, chondrocyte and GAG 
amount in neocartilage, and chondrocyte and GAG amount in adjacent cartilage. Data are 
shown as average scores with error bars representing standard deviation. (*) indicates a 
significant difference between groups (p < 0.05). 
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Figure 5.9 Histological score distribution for subchondral bone morphology (A) and 
cartilage morphology (B) for the four groups tested. 
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Table 5.1 Bilayered OPF composite design for the four experimental groups tested in this 
study. Growth factor loading concentration is shown as ng of incorporated growth factor 
per mL of crosslinked OPF composite hydrogels before swelling. 
 
  
121 
 
Table 5.2 Histological scoring system for evaluation of (A) overall tissue evaluation, (B) 
subchondral bone evaluation, and (C) cartilage evaluation in rabbit osteochondral defects.  
 Score 
(a) Overall defect evaluation (throughout the entire defect depth)  
1. Percent filling with newly formed tissue  
100% 3 
>50% 2 
<50% 1 
0% 0 
2. Percent degradation of the implant  
100% 3 
>50% 2 
<50% 1 
0% 
 
0 
 
(b) Subchondral bone evaluation (within the bottom 2 mm of defect)  
3. Percent filling with newly formed tissue  
100% 3 
>50% 2 
<50% 1 
0% 0 
4. Subchondral bone morphology  
Normal, trabecular bone 4 
Trabecular bone, with some compact bone 3 
Compact bone 2 
Compact bone and fibrous tissue 1 
Only fibrous tissue or no tissue 0 
5. Extent of new tissue bonding with adjacent bone  
Complete on both edges 3 
Complete on one edge 2 
Partial on both edges 1 
Without continuity on either edge 
 
0 
 
(c) Cartilage evaluation (within the upper 1 mm of defect)  
6. Morphology of newly formed surface tissue  
Exclusively articular cartilage 4 
Mainly hyaline cartilage 3 
Fibrocartilage (spherical morphology observed with ≥ 75% of cells) 2 
Only fibrous cartilage (spherical morphology observed with < 75% of 
cells) 
1 
No tissue 0 
7. Thickness of newly formed cartilage  
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Similar to the surrounding cartilage 3 
Greater than the surrounding cartilage 2 
Less than the surrounding cartilage 1 
No cartilage 0 
8. Joint surface regularity  
Smooth, intact surface 3 
Surface fissures (<25% of new surface thickness) 2 
Deep fissures (≥25% of new surface thickness) 1 
Complete disruption of the new surface 0 
9. Chondrocyte clustering  
None at all 3 
<25% chondrocytes 2 
25-100% chondrocytes 1 
No chondrocytes present (no cartilage) 0 
10. Chondrocyte and GAG content of new cartilage  
Normal cellularity with normal Safranin O staining 3 
Normal cellularity with moderate Safranin O staining 2 
Clearly less cells with poor Safranin O staining 1 
Few cells with no or little Safranin O staining or no cartilage 0 
11. Chondrocyte and GAG content of adjacent cartilage  
Normal cellularity with normal Safranin O staining 3 
Normal cellularity with moderate Safranin O staining 2 
Clearly less cells with poor Safranin O staining 1 
Few cells with no or little Safranin O staining or no cartilage 0 
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Table 5.3 (A) Release kinetics (% release per day) of IGF-1 (n = 5) and (B) release 
kinetics (% release per day) of active IGF-1 in Group 1 in collagenase-PBS (n = 4) from 
OPF composite hydrogels in phase 1 (~ 24 h), phase 2 (1–4 days), phase 3 (4–8 days), 
and phase 4 (18–28 days). (*) indicates a significant difference between groups in the 
same phase (p < 0.05). 
(A) 
Experimental 
Groups 
Phase 1 (%/day) 
(~ 24 hrs) 
Phase 2 (%/day) 
(Days 1 - 4) 
Phase 3 (%/day) 
(Days 4 - 18) 
Phase 4 (%/day) 
(Days 18 – 28) 
 
Collagenase-
PBS 
PBS 
Collagenase-
PBS 
PBS 
Collagenase-
PBS 
PBS 
Collagenase-
PBS 
PBS 
Group 1 31.1 ± 2.8 27.3 ± 2.8 4.3 ± 0.4 2.4 ± 0.3 2.1 ± 0.2 2.5 ± 0.5 0.9 ± 0.1 1.1 ± 0.6 
Group 2 31.7 ± 1.8 31.7 ± 1.8* 4.8 ± 0.3 2.5 ± 0.2 1.9 ± 0.3 
1.8 ± 
0.4* 
0.9 ± 0.1 1.8 ± 0.5 
Group 3 28.1 ± 2.3 27.6 ± 2.3 4.2 ± 0.6 2.7 ± 0.2 2.1 ± 0.2 2.8± 0.2 1.0 ± 0.1 1.0 ± 0.2 
 
(B) 
 
Phase 1 (%/day) 
(~ 24 hrs) 
Phase 2 (%/day) 
(Days 1 - 4) 
Phase 3 (%/day) 
(Days 4 - 18) 
Phase 4 (%/day) 
(Days 18 – 28) 
Active IGF-1 Release 
(Group 1, collagenase-PBS) 
26.2 ± 13.4 3.5 ± 2.3 1.7 ± 0.6  0.6 ± 0.1 
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Table 5.4 (A) Release kinetics (% release per day) of TGF-β3 (n = 5) and (B) release 
kinetics (% release per day) of active TGF-β3 (n = 4) from OPF composite hydrogels in 
phase 1 (~ 24 h), phase 2 (1–4 days), phase 3 (4–8 days), and phase 4 (18–28 days). (*) 
indicates a significant difference between Group 2 (Gel loading) and Group 3 (GMP 
loading) in the same phase (p < 0.05). 
(A) 
Experimental 
Groups 
Phase 1 (%/day) 
(~ 24 hrs) 
Phase 2 (%/day) 
(Days 1 - 4) 
Phase 3 (%/day) 
(Days 4 - 18) 
Phase 4 (%/day) 
(Days 18 – 28) 
 
Collagenase-
PBS 
PBS 
Collagenase-
PBS 
PBS 
Collagenase-
PBS 
PBS 
Collagenase-
PBS 
PBS 
Group 2 25.0 ± 3.1* 28.8 ± 3.3* 2.5 ± 0.4 1.7 ± 0.3 2.1 ± 0.3 2.1 ± 0.3 1.3 ± 0.7 1.2 ± 0.3 
Group 3 17.1 ± 3.2  19.5 ± 1.0 6.5 ± 1.2* 1.7 ± 0.3 3.1 ± 0.1* 
3.3 ± 
0.4* 
1.1 ± 0.2 0.9 ± 0.1 
 
(B) 
Experimental 
Groups 
Phase 1 (%/day) 
(~ 24 hrs) 
Phase 2 (%/day) 
(Days 1 - 4) 
Phase 3 (%/day) 
(Days 4 - 18) 
Phase 4 (%/day) 
(Days 18 – 28) 
Group 2 25.6 ± 2.7 1.6 ± 0.6 1.0 ± 0.3 1.4 ± 0.6 
Group 3 24.4 ± 5.1 3.1 ± 0.6* 1.8 ± 0.1* 1.0 ± 0.1 
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Chapter 6 
Dual growth factor delivery from bilayered, 
biodegradable hydrogel composites for 
spatially-guided osteochondral tissue repair* 
 The present work investigated the use of biodegradable hydrogel composite 
scaffolds, based on the macromer oligo(poly(ethylene glycol) fumarate) (OPF), to deliver 
growth factors for the repair of osteochondral tissue in a rabbit model. In particular, 
bilayered OPF composites were used to mimic the structural layers of the osteochondral 
unit, and insulin-like growth factor-1 (IGF-1) and bone morphogenetic protein-2 (BMP-
2) were loaded into gelatin microparticles and embedded within the OPF hydrogel matrix 
in a spatially controlled manner. Three different scaffold formations were implanted in a 
                                                        
 
* This chapter was published as Lu S, Lam J, Trachtenberg JE, Lee EJ, Seyednejad H, van den 
Beucken JJJP, Tabata Y, Wong ME, Jansen JA, Mikos AG, Kasper FK. Dual growth factor 
delivery from bilayered, biodegradable hydrogel composites for spatially guided osteochondral 
tissue repair. Biomaterials. 35:8829-39 (2014). 
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medial femoral condyle osteochondral defect: 1) IGF-1 in the chondral layer, 2) BMP-2 
in the subchondral layer, and 3) IGF-1 and BMP-2 in their respective separate layers. The 
quantity and quality of osteochondral repair was evaluated at 6 and 12 weeks with 
histological scoring and micro-computed tomography (micro-CT). While histological 
scoring results at 6 weeks showed no differences between experimental groups, micro-CT 
analysis revealed that the delivery of BMP-2 alone increased the number of bony 
trabecular islets formed, an indication of early bone formation, over that of IGF-1 
delivery alone. At 12 weeks post-implantation, minimal differences were detected 
between the three groups for cartilage repair. However, the dual delivery of IGF-1 and 
BMP-2 had a higher proportion of subchondral bone repair, greater bone growth at the 
defect margins, and lower bone specific surface than the single delivery of IGF-1. These 
results suggest that the delivery of BMP-2 enhances subchondral bone formation and 
that, while the dual delivery of IGF-1 and BMP-2 in separate layers does not improve 
cartilage repair under the conditions studied, they may synergistically enhance the degree 
of subchondral bone formation. Overall, bilayered OPF hydrogel composites demonstrate 
potential as spatially-guided, multiple growth factor release vehicles for osteochondral 
tissue repair. 
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6.1. Introduction 
 The osteochondral unit is a multiphasic tissue comprised of two main tissue types: 
the articulating cartilage responsible for nearly frictionless movement and shock-
absorbance, and the subchondral bone indispensible for underlying mechanical support 
[328-330]. Within the knee, the health of cartilage tissue has been linked to the 
maintenance of the natural biomechanics of the subchondral bone, and given the contact 
between cartilage and bone, total joint homeostasis will ultimately rely on the functional 
restoration of both tissues [331-334]. As a result, tissue engineering strategies to 
regenerate the osteochondral unit have evolved over the years from monolithic structures 
to gradient/bilayered scaffolds as a means of controlling treatment to repair the cartilage-
bone interface or to target each tissue separately [335-337]. In addition to selecting an 
appropriate scaffold design, successful regeneration of osteochondral tissue is greatly 
influenced by the microenvironment in which cells and tissues grow [135]. A number of 
soluble cues have been implicated in osteochondral wound healing environment [337], 
and the goal of eliciting the desired phenotypic response from co-delivered and/or host 
progenitor cells in vivo remains a difficult challenge. Due to the numerous signaling 
pathways involved in osteochondral repair, the delivery of multiple growth factors to 
improve therapeutic potency is an area of great interest, particularly when both cartilage 
and bone tissues are considered [338]. 
 The present work seeks to repair osteochondral tissue through the dual delivery of 
growth factors from acellular, bilayered hydrogel composites. These hydrogel composites 
are fabricated from a synthetic macromer, oligo(poly(ethylene glycol) fumarate) (OPF), 
which is synthesized by the esterification of poly(ethylene glycol) (PEG) and fumaryl 
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chloride. The resulting macromer can be crosslinked via the double bonds of the fumarate 
group to form a hydrogel as well as degrade through hydrolysis of the ester groups [59, 
339]. Gelatin microparticles (GMPs) are also embedded within the crosslinked hydrogel 
matrix to act as both an enzymatically digestible porogen and a delivery vehicle for 
growth factors [258, 259, 340]. These OPF-based hydrogel composites have been used in 
a number of in vitro and in vivo studies as growth factor delivery vehicles, and allows for 
comparisons between growth factor types and delivery methods for cartilage and 
osteochondral tissue repair applications [171, 257-259, 340, 341]. In an effort to mimic 
the osteochondral unit, these hydrogels are laminated to form two distinct layers as a 
means of tailoring scaffold composition and drug loading to the cartilage and bone areas 
of the defect [256, 341, 342]. With this design, the current study incorporates a 
chondroinductive factor and an osteoinductive factor into the bilayered hydrogels in 
separate layers to facilitate simultaneous cartilage and subchondral tissue repair within an 
osteochondral defect. 
 The strategy of spatially incorporated biologics for simultaneous in vivo cartilage 
and bone repair is a growing area of research: Chen et al. delivered plasmids encoding for 
transforming growth factor-1 (TGF-1) and bone morphogenetic protein-2 (BMP-2) in 
separate layers of a chitosan-gelatin scaffold [343], Re'em et al. spatially presented TGF-
1 and BMP-4 in an alginate-sulfate hydrogel [231], and Mohan et al. and Dormer et al. 
created sintered poly(D,L-lactic-co-glycolic acid) microsphere scaffolds with reverse 
gradients of TGF-1 and BMP-2 [249, 344]. However, an optimal combination of 
chondrogenic and osteogenic growth factors has yet to be achieved for osteochondral 
regeneration. 
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 As a result, the main hypothesis of this study is that insulin-like growth factor-1 
(IGF-1) delivered from the chondral layer and BMP-2 delivered from the subchondral 
layer of bilayered OPF hydrogel composites can act synergistically to promote 
osteochondral tissue repair over the delivery of either growth factor alone. Additionally, 
it is hypothesized that earlier subchondral bone repair, stimulated by the release of BMP-
2, will affect the degree of cartilage repair. IGF-1 is the main anabolic growth factor in 
articular cartilage and plays a key role in homeostasis by balancing synthesis and break 
down of proteoglycans by chondrocytes [218]. Additionally, previous studies have 
demonstrated similar or improved cartilage repair with the single delivery of IGF-1 over 
the dual delivery of IGF-1 with TGF-1 or TGF-3 from bilayered OPF composites in a 
medial femoral condyle osteochondral defect model [171, 257]. BMP-2 is a potent 
osteogenic growth factor for inducing de novo bone formation in ectopic and orthotopic 
sites and has been shown to improve subchondral bone formation when delivered to 
osteochondral defects [219, 222, 345-349]. Additionally, BMP-2 is expressed throughout 
the entire chondrogenic process of mesenchymal stem cells (MSCs), from condensation 
to proliferation, differentiation, maturation, and calcification [337]. With the ability to 
induce the growth of both cartilage and bone tissue, several research groups have 
delivered BMP-2 from monolithic scaffolds to osteochondral defects and have improved 
cartilage repair over blank scaffolds [348-350]. However, the current study isolates the 
incorporation of BMP-2 to the subchondral layer to maximize its osteoinductive potential 
and reduce its direct morphogenetic effects on progenitor cell chondrogenesis in the 
chondral layer.  
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 To test the two hypotheses aforementioned, the current study 1) investigates the 
repair of cartilage and subchondral bone tissue in an osteochondral defect facilitated by 
bilayered hydrogel composites delivering IGF-1 and/or BMP-2 incorporated in a spatially 
controlled manner, 2) evaluates the degree of subchondral bone repair with micro-
computed tomography (micro-CT) and osteochondral tissue repair through histological 
scoring, and 3) compares the extent of cartilage and subchondral bone repair at 6 week 
and 12 week time points.  
 
 
6.2. Materials and Methods 
6.2.1. Oligo(poly(ethylene glycol) fumarate) synthesis 
 OPF was synthesized from PEG (Sigma-Aldrich, St. Louis, MO) with a nominal 
molecular weight (MW) of 35,000 according to methods previously developed in our 
laboratory [59, 339]. Gel permeation chromatography was used to characterize the OPF 
macromer to give a number average molecular weight of 50,400 ± 900 Da and a weight 
average molecular weight of 127,400 ± 3,200 Da. Prior to the fabrication of hydrogel 
implants, OPF was sterilized for 12 hours by exposure to ethylene oxide (EO) according 
to established protocols [171, 351].  
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6.2.2. Gelatin microparticle fabrication and growth factor loading 
 Using established methods, GMPs were fabricated using acidic gelatin (Nitta 
Gelatin, Osaka, Japan) with an isoelectric point (IEP) of 5.0 and crosslinked in 40 mM 
glutaraldehyde (Sigma-Aldrich, St. Louis, MO), followed by glycine quenching of 
unreacted glutaraldehyde [340, 352]. Following lyophilization, GMPs of 50-100 m in 
diameter were obtained through sieving and EO sterilized for 12 hours prior to GF 
loading. GMPs were then partially swelled with either phosphate buffered saline (PBS) or 
a GF solution at a ratio of 5 L solution to 1 mg dried GMP for 15 hrs at 4ºC before 
hydrogel encapsulation according to previously described methods [258, 259]. In 
particular, 225 L of PBS, IGF-1 solution, or BMP-2 solution was combined with 45 mg 
of GMPs. Recombinant human IGF-1 (Peprotech, Rocky Hill, NJ) was reconstituted with 
PBS to a GF loading concentration of 7.95 g per mL solution and loaded onto GMPs to 
give a total of 5.6 ng IGF-1 per hydrogel construct. Recombinant human BMP-2 
(Peprotech, Rocky Hill, NJ) was reconstituted with a mixture of ddH2O and PBS to a GF 
loading concentration of 712 g per mL solution to give a total of 1 g BMP-2 per 
hydrogel construct.  
 
6.2.3. Bilayered hydrogel composite fabrication 
 Bilayered hydrogel composites were fabricated via a two-step crosslinking 
procedure similar to methods previously described [171, 257]. Using a 2 mm x 2 mm 
cylindrical teflon mold, the subchondral layer was first partially crosslinked, then the 
chondral layer was crosslinked on top of the subchondral layer. Specifically, to prepare 
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the OPF precursor solution, 113 mg of OPF and 37 mg of PEGDA (3,400 Da MW, 
Laysan Bio, Arab, AL) were dissolved in 353 L of PBS and set at room temperature for 
45 minutes to eliminate air bubbles. 46.8 L each of the thermal radical initiators, 0.3 M 
ammonium persulfate (APS, Sigma-Aldrich, St. Louis, MO) and 0.3 M N,N,N',N'-
tetramethylethylenediamine (TEMED, Sigma-Aldrich, St. Louis, MO), were then mixed 
into the polymer solution. The addition of APS and TEMED at the concentrations used 
are expected to have minimal toxic effects on the surrounding tissue post-implantation, 
particularly in consideration of previous studies showing high viability of encapsulated 
cells in OPF-based hydrogels following the fabrication process [87, 256, 353]. Lastly, 45 
mg of GMPs swollen with either 225 L of PBS or a GF solution were added to the 
solution and mixed carefully to avoid the formation of bubbles. The polymer-GMP 
mixture was then injected into the bottom two-thirds of the teflon mold for the 
subchondral layer and partially crosslinked at 37ºC for 5 minutes. A similar polymer-
GMP mixture was then prepared for the chondral layer and injected on the subchondral 
layer and crosslinked at 37ºC for 25 minutes. Table 6.1 highlights the three groups used 
in the study with BMP-2 delivered from the subchondral layer and IGF-1 delivered from 
the chondral layer of the bilayered hydrogel composites. Prior to implantation in an 
osteochondral defect, hydrogels were transferred with a drop of sterile PBS to prevent the 
hydrogel composites from drying. Bilayered hydrogel composites at equilibrium swelling 
were cylinders 3 mm x 3 mm in size (data not shown). 
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6.2.4. Animal surgery 
 A total of 36 male, skeletally mature (i.e., 6 months old)  New Zealand White 
rabbits were used as determined by a power analysis and in consideration of previous 
studies [171, 257, 341, 351]. Each animal received bilateral implants (one per knee) and a 
total of 10-12 hydrogels were implanted in 5-6 rabbits per group per time point. It should 
be noted that one rabbit for the 6 week BMP-2 group had complications on the surgery 
table due to previously undetected Pasteurella infection and was excluded from the 
study. All surgical procedures and subsequent animal care were approved by the 
Institutional Animal Care and Use Committees of Rice University and The University of 
Texas Health Science Center at Houston. Briefly, anesthesia was induced prior to surgery 
by subcutaneous injections of ketamine (25-40 mg/kg) and acepromazine (1-2 mg/kg). 
General anesthesia was maintained by inhalation of isoflurane (2-3%) and oxygen. 
Rabbits were immobilized on their backs and the hair from both hind legs was shaven. 
The medial femoral condyle was then exposed through a medial parapatellar longitudinal 
incision, incision of synovial capsule, and lateral luxation of the patella. An 
osteochondral defect (3mm in diameter and 3 mm in depth) was then created through 
serial drilling (2 mm → 2.75 mm → 3 mm) with a dental drill under irrigation (Osseo 
Scientific, Toms River, NJ). The defect was then flushed with saline, dried with gauze, 
and the hydrogel composite was implanted to allow for swelling to the same dimensions 
of the defect. This procedure was then repeated for the contralateral knee using a 
hydrogel of the same formulation. The synovial capsule and skin on both knees were then 
closed with 3-0 and 4-0 Vicryl sutures, respectively. To minimize post-operative 
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discomfort, Carprofen (4 mg/kg) was administered subcutaneously for two days 
postoperatively. 
 
6.2.5. Tissue processing and histological scoring 
 Rabbits were euthanized at 6 or 12 weeks post-surgery with an intravenous 
injection of Beuthanasia (0.22 mL/kg). The tissue surrounding the medial femoral 
condyle defect was retrieved en bloc, cut with a low-speed diamond saw to isolate the 
medial femoral condyle, fixed in 10% neutral buffered formalin for no more than 72 
hours, decalcified in EDTA solution for 6 weeks, dehydrated through a graded series of 
ethanol baths, and embedded in paraffin. Longitudinal sections of 5 m thickness were 
taken from the center (within the central 1 mm) and the peripheral edges (within the 
medial and lateral 1 mm) with a microtome (Leica RM2165). Sections from each location 
were stained with hematoxylin and eosin (H&E), Safranin O/Fast Green (Saf.O), and van 
Gieson's Picrofuchsin (VGP). Histological sections were blindly and independently 
scored by three evaluators (J.L., J.T., F.K.K.) using a previously established histological 
scoring system for osteochondral defects as shown in Table 6.2 [171, 257, 351]. H&E 
and VGP sections were primarily used for overall defect and subchondral bone evaluation 
parameters while Saf.O sections were primarily used for cartilage evaluation parameters. 
Independent of the histological scoring system, the presence of complete subchondral 
bone plate bridging within the defect and neo-surface depressions below the tidemark 
were also evaluated for each histological section. It should be noted that sections from 
one sample in the 12 week BMP-2 group had large artifacts that resulted in the inability 
to accurately score the histological images and were excluded in the histological analysis. 
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6.2.6. Micro-computed tomography 
 All femoral condyles were scanned using a SkyScan 1172 micro-CT imaging 
system (Bruker, Kontich, Belgium) prior to EDTA decalcification. A voltage of 100 kV 
and a current of 100 A with a nominal resolution of 10 m pixel-1 was used. Image data 
were reconstructed using NRecon v1.6 and analyzed with CTAn v1.10, where 
thresholding levels of gray values (70-255) were set for all samples. A circular region of 
interest 3 mm in diameter was selected for a top-down analysis and transverse images 
were used to position the upper boundary of the volume of interest (VOI) at the surface of 
the cartilage layer of the cylindrical defect. Due to the presence of two distinct bone 
morphologies in the subchondral tissue, the bone plate and trabecular bone, two VOIs 
were analyzed separately: the upper .85 mm for the cartilage and cortical region (C&C) 
and the lower 2.15 mm for the trabecular region. Due to the potential for the subchondral 
bone plate to migrate upward during osteochondral repair, the cartilage region was also 
included for the C&C VOI [354]. Parameters analyzed for the C&C and trabecular VOI 
include bone mineral density (BMD), percent bone volume (BV/TV), intersection surface 
(i.S.), bone specific surface (BS/BV), and object number (Obj.N.). Table 6.3 further 
explains each of these parameters. Independent of the micro-CT parameter analysis, the 
presence of complete subchondral bone plate filling and bridging was also evaluated for 
each sample. 
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6.2.7. Statistical analysis 
 A significance level of p < 0.05 was used for all statistical analysis through JMP 
Pro v10.0.2 . For histological scoring analysis, a one-way analysis was performed to 
analyze the potential effect of experimental group, time point, location within the defect, 
and knee joint. The Kruskal-Wallis test of variance was used and post-hoc analysis done 
with the Steel-Dwass All Pairs test. For micro-CT analysis, a one-way analysis was 
performed to analyze the potential effects of experimental group and time point. A one-
way ANOVA was used to test variance and Tukey HSD All Pairs test was used to 
compare means. 
 
 
6.3. Results 
6.3.1. Histological Observations and Scoring 
 Sections from three locations (lateral edge, medial edge, and center) were 
obtained per sample for histological evaluation. Representative images for all groups at 
week 6 and week 12 are shown in Figure 6.1 and Figure 6.2, respectively. Figure 6.3 
displays the mean histological scores from the 11 parameters examined as described in 
Table 6.2, and the distribution of scores for bone morphology, cartilage morphology, and 
cartilage thickness are shown in Figure 6.4.  
 Following histological scoring of all images, the potential effects of experimental 
group, time point (week 6 vs. week 12), location within the defect (edges vs. center), and 
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knee joint (right vs. left) were evaluated. Location within the defect and knee joint did 
not have any statistical impact on the 11 histological parameters scored, indicating that 
there was no major intra-defect variability nor bilateral implant variability. However, it 
should be noted that neo-tissue formation was seen to develop most commonly from the 
defect margins in the subchondral and chondral regions. The effect of time point for all 
samples for the histological parameters scored is shown in Table 6.4. 
 
6.3.1.1. Overall Evaluation 
 In the overall evaluation of the defect, the histological scores for overall tissue 
filling generally mirrored those of overall implant degradation (Figure 6.3a). At week 6, 
there were no differences between groups in overall filling and degradation and none of 
the samples were seen to have complete degradation of the hydrogel composite implant 
as seen by representative images in Figure 6.1. Additionally, the remaining hydrogel was 
located in the subchondral region of the osteochondral defect for all samples. At week 12, 
greater degradation of the implants was seen with 44%, 63%, and 41% of histological 
images showing no presence of remaining hydrogel composite for IGF-1, BMP-2, and 
Both groups, respectively. More specifically, when all three sections from one sample 
had no presence of the remaining implant, 3/12 IGF-1 samples, 4/11 BMP-2 samples, and 
0/12 Both samples showed complete degradation. When all samples at week 12 were 
compared against week 6 samples, there was a significant effect of time point, with week 
12 samples having greater scores for overall filling and degradation than week 6 samples. 
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6.3.1.2. Subchondral Evaluation 
 Similar to overall evaluation, evaluation of the subchondral bone revealed no 
differences between experimental groups at 6 weeks. In the majority of the samples, the 
implant was surrounded by a fibrous capsule (Figure 6.1F), giving the histological image 
a score of 1 for bone morphology. Hypertrophic and calcified cartilage were also seen in 
many of the sections (Figure 6.1G-I), indicative of cartilage resorption and bone 
formation processes. At 12 weeks, while there were no differences for bone filling 
between groups, the BMP-2 group had better bone morphology scores compared to the 
Both group as seen in Figure 6.3B. The BMP-2 group also had the greatest percentage of 
sections with trabecular bone at 36%, whereas 17% and 12% of sections for IGF-1 and 
Both, respectively, showed trabecular bone for the entire subchondral region (Figure 
6.4A). However, the majority of all samples at both week 6 and 12 had cortical and/or 
trabecular bone formation from the subchondral defect margins and all received a score 
of 3 for new tissue bonding with the adjacent bone (Figure 6.3B). The repair of the 
subchondral bone plate was also assessed, with 22%, 22%, and 50% of histological 
sections for IGF-1, BMP-2, and Both groups at week 12, respectively, showing repaired 
bone plate tissue in line with the adjacent bone plate. More specifically, 0/12, 2/11, and 
3/12 samples for IGF-1, BMP-2, and Both groups respectively showed complete bone 
plate bridging with all three sections per samples having presence of a continuous bone 
plate. No repair of the bone plate was seen in any of the 6 week samples. In a comparison 
between 6 week and 12 week samples for subchondral bone histological scores, 12 week 
samples had statistically greater bone filling and bone morphology scores than 6 week 
samples. 
139 
 
6.3.1.3. Cartilage Evaluation 
 Cartilage repair was evaluated with the parameters of cartilage morphology, 
cartilage thickness, surface regularity, chondrocyte clustering, neocartilage 
glycosaminoglycan (GAG) and cell content, and adjacent GAG and cell content (Figure 
6.3C). For neo-cartilage morphology, there was no difference between time points nor 
between groups. However, the 12 week Both group had the greatest percentage of 
samples with articular cartilage repair while many 12 week BMP-2 samples had 
fibrocartilage, and the 12 week IGF-1 group had the most sections with fibrous cartilage 
formation (Figure 6.4B). In having the most sections with articular cartilage, the 12 week 
Both group also had the best scores for chondrocyte clustering and a significant 
difference from the 12 week BMP-2 group (Figure 6.3C). Although harvested at an 
earlier time point, many of the 6 week samples had hyaline cartilage formation with 
intense GAG staining. However, these samples also tended to have hypercellularity in the 
neo-cartilage tissue with cell clustering or unorganized cells (Figure 6.1G-I). As a result, 
6 week samples overall had statistically greater neocartilage GAG and cellularity scores 
than 12 week samples.  
 The thickness of neo-cartilage was also greater at 6 weeks compared to 12 weeks 
with approximately 80% of all 6 week samples having similar or thicker neo-cartilage 
tissue with respect to surrounding cartilage (Figure 6.4C). In contrast, approximately 70% 
of all 12 week samples had similar or thinner neo-cartilage tissue. In examining surface 
regularity, there were no differences among all groups. However, the nature of the 
surface regularity differed between 6 and 12 week samples. 12 week samples generally 
exhibited more irregularities on the repaired tissue surface (e.g., small fissures, bumps, 
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etc.), while 6 week samples had more depressions in the cartilage compared to the 
surrounding tissue (Figure 6.1). 30%, 21%, and 34% of IGF-1, BMP-2, and Both 
sections, respectively, at 6 weeks had the surface of the neo-tissue below that of the 
surrounding tidemark. On the other hand, 8%, 16%, and 21% of IGF-1, BMP-2, and Both 
sections, respectively, at 12 weeks had surface depressions that dipped below the adjacent 
cartilage. In evaluating the GAG and cell content of the adjacent cartilage, normal GAG 
staining and cellularity was seen in most 12 week samples, with some sections 
demonstrating normal GAG staining on one side of the defect, and reduced staining on 
the other side. This was more apparent for 6 week samples as seen in Figure 6.1G. As a 
result, 12 week samples overall had statistically greater scores for adjacent GAG and cell 
content compared to their 6 week counterparts. 
 
6.3.2. Micro-Computed Tomography Analysis 
 The degree of subchondral bone repair was measured through quantitative 
analysis of two different VOIs (Figure 6.5A), C&C and trabecular, for five morphometric 
bone parameters: BMD, BV/TV, i.S., BS/BV, and Obj.N. (Figure 6.6). The effects of 
time point for all samples was also analyzed (Table 6.4). No differences were seen among 
the three groups at week 6 for BMD, BV/TV and i.S. However, group BMP-2 had greater 
BS/BV in the C&C region and a higher Obj.N. in both VOIs than group IGF-1 at week 6 
(Figure 6.6D-E). Figure 6.5B-C show representative images of the incomplete 
subchondral tissue repair for a 6 week sample (6 week Both). By 12 weeks, micro-CT 
analysis showed that the delivery of both growth factors resulted in greater BMD, 
BV/TV, and i.S. compared to that of the IGF-1 only group for the C&C region. 
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Additionally, the 12 week Both group had greater i.S. and lower BS/BV than the 12 week 
IGF-1 group for the trabecular VOI. Comparison between 6 week and 12 week samples 
revealed that 12 week samples had a higher BMD, BV/TV ratio, and greater i.S. area than 
the 6 week samples, and conversely, 6 week samples had greater BS/BV and Obj.N. than 
12 week samples in both C&C and trabecular regions. The repair of the subchondral bone 
plate was also assessed through observation of the micro-CT images. In accordance with 
the histological images, no bone plate was fully repaired for the 6 week samples and 0, 2, 
and 3 samples at 12 weeks for the IGF-1, BMP-2, and Both groups respectively showed 
complete bridging and filling of the defect area with compact bone. However, the 
regeneration of the bone plate was not complete as seen in Figure 6.5D, with the repair 
bone in the defect showing a marked difference in mineral density compared to the 
adjacent compact bone. 
 
 
6.4. Discussion 
 The primary objective of this study was to determine the effect of dual growth 
factor release using IGF-1 from the chondral layer and BMP-2 from the subchondral 
layer of bilayered OPF hydrogel composites on osteochondral tissue repair. The degree of 
osteochondral repair was evaluated at 6 and 12 weeks and histological scoring and micro-
CT analyses were used. Specifically, we investigated 1) if early subchondral bone repair, 
as measured at 6 weeks, would result in better bone and cartilage repair at 12 weeks and 
2) whether the dual delivery of IGF-1 and BMP-2 in separate layers would act 
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synergistically to improve osteochondral tissue regeneration over the delivery of either 
growth factor alone.  
 As a potent morphogenetic factor, BMP-2 has been delivered for a number of 
ectopic and orthotopic bone regeneration applications and has been used to stimulate 
chondrogenesis of MSCs in vitro as well as improve both cartilage and bone repair in 
osteochondral defects in vivo [249, 344, 345, 355-357]. Since it can directly affect 
osteogenesis and chondrogenesis of MSCs, this study loaded BMP-2 onto GMPs that 
were localized in the subchondral layer of bilayered scaffolds in order to focus the 
morphogenetic potential of BMP-2 on bone repair. However, we acknowledge that BMP-
2 may diffuse into chondral space, or conversely, IGF-1 may diffuse into the subchondral 
space over the course of 6 - 12 weeks. Further research tracking the diffusion of growth 
factors or confining the delivery of growth factors to their respective regions could help 
address this limitation. Even so, previous studies studying subchondral bone repair in a 
trochlear groove defect show that upward migration of the subchondral bone plate and 
thinning of cartilage is the natural course of osteochondral repair [354, 358], and that the 
presence of BMP-2 in the chondral region of the defect does not exacerbate this process 
[348, 349]. In this study, only two samples at week 12, one in the BMP-2 group and the 
other in the Both group, had repair of the subchondral bone extending beyond the 
tidemark of the adjacent tissue but below the joint surface.  
 In order to examine early subchondral bone repair, we evaluated the defects at 6 
weeks with both histological scoring and micro-CT analysis. We saw that there were no 
differences in the quantity of bone formation at 6 weeks, as evaluated by bone filling, 
BMD, and BV/TV. This was most likely due to the incomplete degradation of the 
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implants, which was present in all 6 week samples. Bone morphology scoring, bond 
bonding scoring, and i.S. measurements also showed no differences between the 
experimental groups. However, micro-CT analysis revealed a difference with an increase 
in BS/BV in the C&C VOI and a higher Obj.N. count for group BMP-2 in both VOIs 
over group IGF-1 at 6 weeks. This could signify an increase in the number of woven 
bone islets in the subchondral space, which is a commonly observed phenomenon in early 
bone repair for segmental defects [345, 355, 359].  Other studies delivering BMP-2 to 
osteochondral defects have also demonstrated accelerated subchondral bone formation 
with the delivery of BMP-2 [348, 349]. In particular, Sellers et al. found that when BMP-
2 was delivered in a collagen sponge to a trochlear groove defect, most of the new-bone 
formation took place between two and four weeks, and new subchondral bone tended to 
be more sclerotic between four and eight weeks [348]. Thus, the single delivery of BMP-
2 may have enhanced subchondral ossification over that of the single delivery of IGF-1, 
resulting in a greater number of isolated bony trabeculae at the 6 week time point. 
 Histological and micro-CT analysis revealed greater differences in subchondral 
bone repair at 12 weeks. With histological scoring, the delivery of BMP-2 alone resulted 
in better scores for bone morphology than the dual delivery of IGF-1 and BMP-2. This 
could potentially be due to the increased percentage of samples with complete implant 
degradation in the BMP-2 only group (4/11 samples) compared to the Both group (0/12 
samples), resulting in more sections with trabecular bone and no fibrous tissue present. 
With micro-CT, in-depth scrutiny of the repair bone was provided in both the trabecular 
and cortical regions. Analysis of BMD, BV/TV, i.S., and BS/BV revealed that the 
delivery of both BMP-2 and IGF-1 resulted in better subchondral bone repair than IGF-1 
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alone. Additionally, group Both at 12 weeks had the highest bone mineral density, 
percent bone volume, and bone intersection surface in the cortical region than all other 
groups, regardless of the time point. Compounded with the fact that the dual delivery 
group had the most sections with complete bone plate bridging with the adjacent bone 
plate at 50% suggests that the delivery of IGF-1 and BMP-2 synergistically improved 
subchondral bone plate repair over either growth factor alone. Indeed, the dual delivery 
of IGF-1 and BMP-2 has been shown to enhance alkaline phosphatase expression and 
calcium deposition from periodontal ligament fibroblasts over either growth factor alone 
[360]. The combination of both growth factors has also been shown to improve bone 
formation in a rabbit femoral osteotomy defect over BMP-2 alone at 4 and 8 week time 
points [361].  
 When the extent of cartilage repair at 12 weeks was examined through 
histological scoring, the dual delivery of IGF-1 and BMP-2 resulting in less chondrocyte 
clustering than the single delivery of BMP-2. While group Both had the highest 
percentage of sections with articular cartilage and well-organized chondrocytes in a 
columnar fashion, there were no statistical differences with the other groups. 
Interestingly, the delivery of IGF-1 alone resulted in better adjacent GAG and cell 
content at 12 weeks than all 6 week groups. A similar result was achieved in previous 
studies where the delivery of IGF-1 alone also gave the highest scores for adjacent GAG 
and cell content [171, 257]. This may highlight the importance of IGF-1 in regulating the 
homeostasis of native cartilage tissue and balancing proteoglycan synthesis and 
breakdown.  
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 Overall, with minimal differences in cartilage repair at 12 weeks it is difficult to 
identify a correlation between early bone repair and improved cartilage repair at 12 
weeks. Additionally, the delivery of IGF-1 together with BMP-2 from bilayered OPF 
hydrogel composites did not improve cartilage repair over either growth factor alone. 
This could be due to the different layers from which IGF-1 and BMP-2 were delivered. 
Previous in vitro research has demonstrated the synergistic effects of BMP-2 and IGF-1 
on chondrocytes seeded in agarose gels in increasing aggregate modulus and GAG 
production over either growth factor alone [356]. However, in a porous silk scaffold with 
reverse gradients of BMP-2 and IGF-1, seeded human MSCs exhibited chondrogenic and 
osteogenic differentiation along the BMP-2 gradient, with the greatest changes in human 
MSC differentiation occurring in the region with the highest BMP-2 concentration [362]. 
In contrast, cells in the region with the highest IGF-1 and lowest BMP-2 concentration 
retained MSC morphology (spindle-shaped). With this in mind, the improved 
subchondral bone repair with IGF-1 and BMP-2 and the lack of statistical differences in 
cartilage repair between experimental groups suggests that the BMP-2 delivered from the 
subchondral layer of bilayered OPF composites had a greater direct effect on bone repair 
than on cartilage repair. 
 
 
6.5. Conclusion 
 IGF-1 and BMP-2 were loaded into GMPs in the chondral layer and subchondral 
layer, respectively, of bilayered OPF hydrogel composites either separately or together. 
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These three formulations were tested for osteochondral repair in a rabbit model at 6 and 
12 weeks. While histological scoring showed no differences in cartilage and bone repair 
at 6 weeks, micro-CT revealed that the single delivery of BMP-2 increased bone specific 
surface and the number of bony trabecular islets over the single delivery of IGF-1. At 12 
weeks, micro-CT also showed an increase in bone mineral density, percent bone volume, 
and intersection surface, and a decrease in bone specific surface for the dual delivery of 
IGF-1 and BMP-2 over the single delivery of IGF-1. However, there was no significant 
difference between the three groups on cartilage morphology at 12 weeks. These results 
demonstrate that the delivery of BMP-2 can accelerate bone formation at an early time 
point and that the delivery of both growth factors in separate layers has a synergistic 
effect on subchondral bone repair, but not on cartilage repair, in an osteochondral defect. 
Finally, the outcomes of this study can help inspire future spatially-controlled, multiple 
growth factor delivery strategies for osteochondral tissue regeneration. 
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6.6. Tables and Figures 
 
Figure 6.1 Representative histological sections of osteochondral tissue repair after 6 
weeks of implantation for all three groups. Sections were stained with hematoxylin and 
eosin (H&E) (A-C), van Gieson's Picrofuchsin (VGP) (D-F), or Safranin O/Fast Green 
(Saf.O) (G-I).  All 6 week samples had incomplete degradation of the implant, evidenced 
by a light gray staining of the hydrogel surrounded by a yellow fibrous capsule in the 
VGP stains. The neo-cartilage formed was generally thicker than the surrounding 
cartilage with intense Saf.O staining and was present in the subchondral region. (scale 
bar: 1000 m) 
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Figure 6.2 Representative histological sections of osteochondral tissue repair after 12 
weeks of implantation for all three groups. Sections were stained with hematoxylin and 
eosin (H&E) (A-C), van Gieson's Picrofuchsin (VGP) (D-F), or Safranin O/Fast Green 
(Saf.O) (G-I).  12 week samples generally had greater degradation than 6 week samples 
and a smaller fibrous capsule. Group IGF-1 had the most sections with fibrous tissue 
(D,G), group BMP-2 had the most sections with fibrocartilage (E,H), and group Both had 
the most sections with articular cartilage (F,I). (scale bar: 1000m) 
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(A) (B) 
 
(C) 
  
Figure 6.3 Histological scores for the overall defect evaluation (A), subchondral bone 
evaluation (B), and articulating cartilage evaluation (C).  Data are shown as average 
scores with error bars representing standard deviation. (*) indicates a significant 
difference between groups regardless of time point and (&) indicates a significant 
difference between a 12 week group and all 6 week groups (p < 0.05). 
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(A) (B) 
 
(C) 
 
Figure 6.4 Distribution of histological scores for subchondral bone morphology (A), 
cartilage morphology (B), and cartilage thickness (C) for the three groups investigated at 
both 6 and 12 weeks. 
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Figure 6.5 Micro-CT images showing a transverse section of the osteochondral defect in 
a medial femoral condyle (A), sections of a 6 week Both sample in the cortical (B) and 
trabecular (C) region, and sections of a 12 week BMP-2 sample in the cortical (D) and 
trabecular (E) region. (A) also demonstrates the two volumes of interest used, cartilage 
and cortical (C&C) and trabecular, when analyzing the subchondral bone. (scale bar: 3 
mm) 
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(E) 
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Figure 6.6 Morphological parameter analysis for both trabecular and cartilage and 
cortical (C&C) volumes of interest (VOI). Bone mineral density (A), percent bone 
volume (B), intersection surface (C), bone specific surface (D), and object number (E) 
were measured for all groups at both time points. Data are shown as average scores with 
error bars representing standard deviation. (*) indicates a significant difference between 
groups regardless of time point, (&) indicates a significant difference between a 12 week 
group and all 6 week groups, and (#) indicates a significant difference between a 6 week 
group and all 12 week groups (p < 0.05). 
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Table 6.1 Experimental groups investigated in this study. Growth factors were loaded 
into gelatin microparticles prior to encapsulation within bilayered OPF hydrogels. 
Experimental 
Groups 
IGF-1 BMP-2 Both 
Chondral Layer 
(Top 1mm) 
IGF-1 Blank IGF-1 
Subchondral Layer 
(Bottom 2mm) 
Blank BMP-2 BMP-2 
6 Week Repetitions 12 10 12 
12 Week Repetitions 12 11 12 
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Table 6.2 Histological scoring system for the evaluation of (a) overall tissue, (b) 
subchondral bone, and (c) cartilage in rabbit osteochondral defects. 
 Score 
(a) Overall defect evaluation (throughout the entire defect depth)  
1. Percent filling with newly formed tissue  
100% 3 
>50% 2 
<50% 1 
0% 0 
2. Percent degradation of the implant  
100% 3 
>50% 2 
<50% 1 
0% 
 
0 
 
(b) Subchondral bone evaluation (within the bottom 2 mm of defect)  
3. Percent filling with newly formed tissue  
100% 3 
>50% 2 
<50% 1 
0% 0 
4. Subchondral bone morphology  
Normal, trabecular bone 4 
Trabecular bone, with some compact bone 3 
Compact bone 2 
Compact bone and fibrous tissue 1 
Only fibrous tissue or no tissue 0 
5. Extent of new tissue bonding with adjacent bone  
Complete on both edges 3 
Complete on one edge 2 
Partial on both edges 1 
Without continuity on either edge 
 
0 
 
(c) Cartilage evaluation (within the upper 1 mm of defect)  
6. Morphology of newly formed surface tissue  
Exclusively articular cartilage 4 
Mainly hyaline cartilage 3 
Fibrocartilage (spherical morphology observed with ≥ 75% of cells) 2 
Only fibrous cartilage (spherical morphology observed with < 75% of 
cells) 
1 
No tissue 0 
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7. Thickness of newly formed cartilage  
Similar to the surrounding cartilage 3 
Greater than the surrounding cartilage 2 
Less than the surrounding cartilage 1 
No cartilage 0 
8. Joint surface regularity  
Smooth, intact surface 3 
Surface fissures (<25% of new surface thickness) 2 
Deep fissures (≥25% of new surface thickness) 1 
Complete disruption of the new surface 0 
9. Chondrocyte clustering  
None at all 3 
<25% chondrocytes 2 
25-100% chondrocytes 1 
No chondrocytes present (no cartilage) 0 
10. Chondrocyte and GAG content of new cartilage  
Normal cellularity with normal Safranin O staining 3 
Normal cellularity with moderate Safranin O staining 2 
Clearly less cells with poor Safranin O staining 1 
Few cells with no or little Safranin O staining or no cartilage 0 
11. Chondrocyte and GAG content of adjacent cartilage  
Normal cellularity with normal Safranin O staining 3 
Normal cellularity with moderate Safranin O staining 2 
Clearly less cells with poor Safranin O staining 1 
Few cells with no or little Safranin O staining or no cartilage 0 
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Table 6.3 Explanation of 3D morphometric parameters analyzed within two volumes of 
interest (VOI): the cartilage and cortical region and the trabecular region. 
Bone mineral density 
(g/cm3) BMD 
Volumetric density of bone within a mixed bone-soft tissue 
VOI 
Percent bone volume 
(%) BV/TV 
Proportion of VOI occupied by binarised solid objects (e.g., 
bone) 
Intersection surface 
(mm2) i.S. 
Surface of VOI intersected by bone, useful for evaluating 
bone growth at a defined boundary 
Bone specific surface 
(mm-1) BS/BV 
Ratio of bone surface to bone volume within the VOI, useful 
for characterizing the relative complexity of structures 
Object number 
Obj.N. 
Total number of discreet binarised objects within the VOI, 
where a discreet object is a connected cluster of solid (white) 
voxels fully surrounded by space (black) voxels 
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Table 6.4 Main effects analysis of time point (week 6 vs. week 12) for histological 
scoring and micro-CT morphometric parameters (p < 0.05). 
Histological scoring parameters Micro-CT morphometric parameters 
Overall Filling 12wk > 6wk 
Bone Mineral 
Density 
12wk > 6wk 
Overall Degradation 12wk > 6wk 
Percent Bone 
Volume 
12wk > 6wk 
Bone Filling 12wk > 6wk 
Intersection 
Surface 
12wk > 6wk 
Bone Morphology 12wk > 6wk 
Bone Specific 
Surface 
6wk > 12wk 
Bone Bonding -- Object Number 6wk > 12wk 
Cartilage Morphology --   
Cartilage Thickness 6wk > 12wk   
Surface Regularity --   
Chondrocyte 
Clustering 
--   
Neocartilage GAG & 
Cell 
6wk > 12wk   
Adjacent GAG & Cell 12wk > 6wk   
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Chapter 7 
Technical Report: Correlation between the 
repair of cartilage and subchondral bone in 
an osteochondral defect using bilayered, 
biodegradable hydrogel composites* 
The present work investigated correlations between cartilage and subchondral 
bone repair, facilitated by a growth factor-delivering scaffold, in a rabbit osteochondral 
defect model. Histological scoring indices and micro-computed tomography 
morphological parameters were used to evaluate cartilage and bone repair, respectively, 
at 6 and 12 weeks. Correlation analysis revealed significant associations between specific 
cartilage indices and subchondral bone parameters that varied with location in the defect 
                                                        
 
* This chapter was published as Lu S, Lam J, Trachtenberg JE, Lee EJ, Seyednejad H, van den 
Beucken JJJP, Tabata Y, Kasper FK, Scott DW, Wong ME, Jansen JA, Mikos AG. Technical 
Report: Correlation between the repair of cartilage and subchondral bone in an osteochondral 
defect using bilayered, biodegradable hydrogel composites. Tissue Engineering Part C: Methods. 
21:1216-1225 (2015).  
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(cortical vs trabecular region), time point (6 vs 12 weeks), and experimental group 
(insulin-like growth factor-1 only, bone morphogenetic protein-2 only, or both growth 
factors). In particular, significant correlations consistently existed between cartilage 
surface regularity and bone quantity parameters. Overall, correlation analysis between 
cartilage and bone repair provided a fuller understanding of osteochondral repair and can 
help drive informed studies for future osteochondral regeneration strategies. 
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7.1. Introduction 
 The regeneration of osteochondral tissue remains a difficult challenge due to the 
inability for articular cartilage to self-regenerate and the need to consider the multiphasic 
nature of the osteochondral unit.[328, 329] Although the osteochondral unit comprises 
different tissues, cartilage and bone, homeostasis is predicated by an innate biochemical 
and biomechanical interplay between these two tissue types.[331, 332, 334, 363, 364] 
There is an increasing body of knowledge in the fields of osteoarthritis and osteochondral 
tissue engineering on the importance of the subchondral bone on the pathogenesis, as 
well as regeneration, of the articulating cartilage.[333, 365-370] Yet, while many studies 
have examined the associated structural changes of subchondral bone with changes in 
cartilage tissue morphology in an osteoarthritic model,[300, 371-373] less is known about 
how the repair of subchondral bone and its associated structural changes are related to the 
repair of articular cartilage in an osteochondral defect.  
 Previously, Qiu et al.[374] and Orth et al.[354] investigated the healing of 
subchondral bone and articular cartilage in an empty rabbit osteochondral defect. In 
particular, it was found that there was no significant correlation between upward 
subchondral bone migration and cartilage degeneration over time.[354] Additionally, 
Zhang et al. characterized cartilage and bone repair using a biphasic hydrogel/ceramic 
scaffold in a critical-sized rabbit osteochondral defect in a year-long study and saw that 
the gross appearance of cartilage positively correlated with subchondral bone 
volume.[375] However, the rise of tissue engineering strategies for osteochondral repair 
necessitates further research on the associated changes in bone and cartilage repair, 
especially when facilitated by an implanted biomaterial scaffold. To determine these 
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associations, correlation modeling offers a statistical analysis for these relationships. By 
understanding how specific morphological parameters for bone and cartilage are 
correlated, valuable information can be gathered on the repair process. 
 As a result, the current report utilized growth factor-delivering, bilayered 
hydrogel composites to facilitate osteochondral repair in a rabbit model. Specifically, the 
hydrogel composites were based on the synthetic macromer oligo(poly(ethylene glycol) 
fumarate) (OPF) and contained gelatin microparticles (GMPs) as drug delivery vehicles. 
Insulin-like growth factor-1 (IGF-1) and bone morphogenetic protein-2 (BMP-2) were 
delivered separately or together to facilitate tissue formation. In a previous publication, 
the effect of growth factor treatment option on osteochondral repair was presented as a 
comparison of means between experimental groups, as is typically done in an outcome-
based analysis.[376] In this technical report, correlation analysis is used on the same raw 
data to present direct associations between cartilage and bone repair. While causality 
cannot be determined through correlation analysis (e.g., better bone repair causes better 
cartilage repair), specific relationships between cartilage and bone parameters can be 
discovered. In turn, these specific relationships can be the foundation for future 
mechanistic studies investigating cause-and-effect. 
 Thus, the main objective of this report was to examine correlations between 
cartilage indices as determined by histological scoring and subchondral bone parameters 
as determined by micro-computed tomography (micro-CT). Additionally, correlations 
between cartilage and bone repair were compared at 6 and 12 week time points, and the 
influence of growth factor delivery treatment on trends in tissue repair was investigated.  
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7.2. Materials and Methods 
7.2.1. Experimental study design 
 The materials and methods used for the current report have previously been 
published and can be found in Chapter 5.[376] Briefly, dried GMPs (50-100 µm in 
diameter) were loaded with a growth factor solution, IGF-1 or BMP-2, and encapsulated 
in bilayered OPF hydrogel composites. Three different growth factor-loaded GMP 
combinations were encapsulated in bilayered hydrogel composites: 1) IGF-1 only in the 
chondral layer, 2) BMP-2 only in the subchondral layer, or 3) IGF-1 and BMP-2 in the 
chondral and subchondral layer, respectively. The hydrogel composites were then 
implanted in skeletally mature New Zealand White rabbits using a medial femoral 
condyle osteochondral defect model (3 mm in diameter and 3 mm in thickness). A total 
of 36 rabbits were used, with each rabbit receiving bilateral implants and 10-12 hydrogels 
for each group at each time point (6 or 12 weeks).  
 Following 6 or 12 weeks, rabbits were euthanized and condyle samples including 
the defect site underwent micro-CT imaging and histological preparation. Due to the 
presence of two distinct bone morphologies in the subchondral bone, two volumes of 
interest (VOIs) were analyzed separately for the bone plate and the trabecular bone. The 
upper 0.85 mm of the defect was selected as the cartilage and cortical region (C&C) and 
the lower 2.15 mm was selected as the trabecular region. The cartilage region was 
included with the cortical region to cover all possible neo-bone formation as well as due 
to the potential for upward subchondral bone plate migration during osteochondral 
repair.[354] Morphological parameters analyzed for both the C&C and trabecular VOI 
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include bone mineral density (BMD), percent bone volume (BV/TV), intersection surface 
(i.S), bone specific surface (BS/BV), and object number (Obj.N). Additional parameters 
analyzed for the trabecular VOI include trabecular thickness (Tb.Th), trabecular number 
(Tb.N), and trabecular separation (Tb.Sp). Each of these parameters are further explained 
in Supplementary Table 7.1. For histology, sections from the center and peripheral edges 
were stained with hematoxylin and eosin, Safranin O/Fast Green, and van Gieson’s 
Picrofuchsin. 1 center and 2 opposing peripheral histological sections were then blindly 
and independently scored by three evaluators (J.L., J.T., F.K.K.) using a previously 
established histological scoring system for osteochondral defects as seen in 
Supplementary Table 7.2.[171, 376, 377] 
 
7.2.2. Statistical analysis 
 A significance level of p < 0.05 was used for all statistical analysis through JMP 
Pro v11.0.0. To determine the presence and strength of correlation between key micro-
CT parameters and histological scoring indices, Spearman’s rank correlation test was 
used due to the non-parametric and ordinal nature of the histological scoring data sets. 
For each sample, three histological sections were scored (1 center and 2 peripheral) for 
each of the six cartilage indices. The three histological scores were then averaged for 
each cartilage index (n = 70), and the mean scores for each cartilage index were 
compared with the associated micro-CT measurements for both C&C (n = 70) and 
trabecular VOIs (n = 70). As a result, correlation analysis was performed between 6 
cartilage scores and 5 (C&C) or 8 (trabecular) bone morphological measurements, at each 
time point (n = 34 or 36), and for each growth factor group (n = 10 or 12). Correlation 
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coefficients with a significance level of p < 0.05 were graded on a scale from .00 to |1.00| 
as seen in Table 7.1.[378, 379] 
 
 
7.3. Results 
7.3.1. Correlations between micro-CT and histological scoring parameters for all 
samples 
 Except for cartilage thickness, all other histological scoring parameters had 
significant correlations with one or more micro-CT parameters as seen in Table 7.2. 
Cartilage morphology had a weak correlation with BMD and Tb.Sp in the trabecular 
VOI. Additionally, neocartilage cell & glycosaminoglycan (GAG) content had a weak 
correlation with Obj.N in the C&C VOI. Notably, cartilage regularity exhibited moderate 
correlations with a p < 0.0001 with BMD, BV/TV, and i.S in the trabecular VOI.  
 
7.3.2. Correlations between micro-CT and histological scoring parameters for 6 
and 12 week samples 
 In the C&C VOI, differences in correlations among 6 and 12 week samples could 
be seen (Figure 7.1). Significant 6 week correlations existed between micro-CT 
parameters BMD, BV/TV, i.S, and BS/BV and histological scoring parameters cartilage 
morphology and cartilage regularity. In particular, cartilage morphology had a moderate 
correlation with BMD, and cartilage regularity had moderate correlations with BMD, 
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BV/TV, and BS/BV (p < 0.001). At 12 weeks, neocartilage cell & GAG, had weak 
correlations with all micro-CT parameters, except for Obj.N, and chondrocyte clustering 
had a moderate correlation with Obj.N. 
 The trabecular VOI displayed similar differences with the C&C VOI in 
correlations among 6 and 12 weeks samples, with more significant correlations present at 
6 weeks compared to 12 weeks (Figure 7.2). At 6 weeks, cartilage morphology and 
regularity had moderate correlations with BMD and BV/TV, with cartilage regularity also 
having a significant correlation with i.S. Trabecular-specific parameters, Tb.N and Tb.Sp, 
were seen to have significant associations with cartilage morphology, cartilage regularity, 
and neocartilage cell & GAG. At 12 weeks, cartilage morphology exhibited a significant 
correlation with BMD, and cartilage regularity was moderately correlated with BMD, 
BV/TV, and i.S. (p < 0.01). This trend can also be seen in Figure 7.3 and Figure 7.4 
where the regularity of the neo-cartilage surface is even with the adjacent cartilage in the 
presence of repaired trabecular bone (Figure 7.4), and a depression in the neo-cartilage 
surface is seen with minimal subchondral bone repair (Figure 7.3). Chondrocyte 
clustering was also weakly correlated with BS/BV and Tb.Th, and similar to the C&C 
VOI, was moderately correlated with Obj.N at 12 weeks.  
 
7.3.3. Correlations between micro-CT and histological scoring parameters for 
each experimental group 
 At 6 weeks in the C&C VOI, differences in correlations among the three 
experimental groups are seen (Table 7.3). In general, histological scoring indices had 
positive correlations with BMD, BV/TV, i.S, and Obj.N and negative correlations with 
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BS/BV. Interestingly, there were no correlations between cartilage indices and bone 
parameters for the group delivering IGF-1 only. On the other hand, associations were 
seen only in BMP-2 and Both groups. Cartilage morphology, cartilage regularity, and 
neocartilage cell & GAG had significant correlations with BMD, BV/TV, i.S, and BS/BV 
for groups with BMP-2 only. Additionally, group Both had significant correlations 
between cartilage regularity and BMD, BV/TV, i.S, and BS/BV. Adjacent cell & GAG 
also had significant correlations with BS/BV and Obj.N in the Both group. At 12 weeks 
in the C&C VOI, most correlations occurred in the IGF-1 and BMP-2 groups with the 
exception of a positive correlation between cartilage morphology and i.S in the Both 
group (p < 0.01) (Table 7.4). Additionally, there existed strong negative correlations with 
a p < 0.01 between neocartilage cell & GAG and BMD, BV/TV, and i.S in the BMP-2 
group.  
 At 6 weeks in the trabecular VOI, strong correlations between cartilage scores and 
micro-CT parameters existed predominantly in the BMP-2 group, similar to the C&C 
VOI at 6 weeks (Table 7.5). In particular, cartilage morphology, cartilage regularity, and 
neocartilage cell & GAG were strongly correlated with BMD, BV/TV, and Tb.N in the 
BMP-2 group (p < 0.01). Cartilage regularity was also strongly correlated with i.S and 
Tb.Sp in the BMP group. At 12 weeks in the trabecular VOI, strong correlations are seen 
between cartilage regularity and BMD, B/TV, and i.S. for IGF-1 and Both groups (Table 
7.6). Additionally, adjacent cell & GAG was strongly negatively correlated with Tb.Sp in 
the Both group. 
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7.4. Discussion 
 The primary objective of this report was to examine correlations between the 
repair of articular cartilage and the repair of subchondral bone in an osteochondral defect, 
facilitated by a hydrogel composite scaffold. Osteochondral repair was evaluated at 6 and 
12 weeks with histological scoring indices for cartilage evaluation and micro-CT 
structural parameters for subchondral bone repair. Specifically, we investigated 1) if the 
degree of cartilage repair could be associated with the degree of subchondral bone repair 
through correlation analysis, 2) whether the correlations between cartilage and bone 
would change from an early to a later time point, and 3) if the delivery of different 
growth factor combinations would impact trends between cartilage and bone repair.  
 When all samples at both time points were analyzed, significant correlations were 
found between cartilage histological scoring indices and subchondral bone micro-CT 
parameters. Although most correlations were negligible to weak in strength (< |.50|), 
cartilage surface regularity was moderately correlated with bone volume and bone 
formation at the defect edges in the trabecular region (p < 0.0001). This can be seen in 
histological images where cartilage depressions were seen in samples with low bone 
formation (Figure 7.3), and smooth, intact surfaces were seen with greater bone repair 
(Figure 7.4). Indeed, the subchondral bone provides a mechanical support for the 
overlying cartilage and without sufficient bone formation, fissures can develop in the 
surface cartilage.[349]  
 When this association was examined separately at 6 and 12 weeks, moderate 
correlations still existed between surface regularity and bone formation parameters in the 
trabecular region (p < 0.01). However, similar correlations were only present in the C&C 
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region at 6 weeks. Additionally, significant correlations were present between bone 
formation parameters and cartilage morphology and regularity in the C&C region at 6 
weeks, but not at 12 weeks. These changes in correlations from an early to a later time 
point may be a result of the different rates at which bone and cartilage remodel, as has 
been seen previously.[354, 380] Indeed, the more rapid appearance of skeletal changes 
due to abnormal mechanical loading on cartilage highlights the differential adaptive 
capacity and metabolic activity between bone and cartilage.[300]  
 Interestingly, cartilage thickness did not correlate with any bone parameters, 
possibly indicating that the thickness of neo-cartilage tissue was not related to the volume 
of bone formed or the extent of bone remodeling. However, thinning of neo-cartilage has 
previously been seen to be affected by thickening and upward migration of the 
subchondral bone plate.[369, 381] Additionally, thinning of repaired cartilage was seen at 
16 weeks, but not 8 weeks, in the healing of an empty osteochondral defect.[374] While 
the current study saw only two samples with the presence of the subchondral bone plate 
above the tidemark of the surrounding tissue but below the surface of the articulating 
cartilage at 12 weeks,[376] further study with longer time points may see more 
associations of cartilage thickness with subchondral bone parameters. 
 Correlation analysis for each experimental group at each time point was also 
performed. While the sample size for these analyses were low (n=10-12), prudent 
interpretation of these statistically significant results is still relevant. Additionally, greater 
credence is placed on correlations with a significance level of p < 0.01. However, future 
studies with larger sample sizes would be needed to confirm the significant correlations, 
rule out false positives, or find false negatives. In the C&C VOI at 6 weeks, correlations 
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only existed in the two groups that delivered BMP-2 (i.e., BMP-2 only and both IGF-1 
and BMP-2). Group BMP-2 also predominantly had strong correlations between bone 
parameters and cartilage morphology, regularity, and cell & GAG content in the 
trabecular VOI at 6 weeks. These strong associations could be attributed to the potent 
osteoconductive effects of BMP-2 on early bone formation.[349, 376, 382]  
 On the other hand, in the trabecular VOI at 12 weeks, strong positive correlations 
were seen between cartilage regularity and bone formation for the two groups delivering 
IGF-1. Indeed, IGF-1 has been shown to decrease synovial inflammation in comparison 
to growth factor-free controls when delivered with chondrocytes in an equine 
model.[383] IGF-1 can also increase proteoglycan synthesis and slow proteoglycan 
catabolism in a dose-dependent manner.[218, 384, 385] This is corroborated by the strong 
negative correlations between neocartilage cell & GAG content and bone formation at 12 
weeks in the C&C group for the BMP-2 only delivering group. Interestingly, this 
chondroprotective quality of IGF-1 is not clearly apparent in the outcome-based 
publication since a comparison of means for cartilage scoring indices revealed no 
differences between experimental groups at either time point.[376]  
 Overall, correlation analysis gave valuable insight in the repair process of 
osteochondral tissue and can be a useful tool in supplementing traditional outcome-based 
analysis. In the present report, moderate to strong correlations were consistently seen 
between cartilage regularity and bone formation parameters, especially in the trabecular 
region. By simply comparing the means of cartilage and bone repair data sets as 
performed in a previous publication,22 this unique relationship could not have been 
construed. Although causality could not be determined with correlation analysis in the 
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present report (e.g., greater bone formation in the trabecular region improves cartilage 
regularity), knowing specific correlations can be a preliminary step in inspiring informed 
studies for future osteochondral repair strategies. For example, scaffold stiffness in the 
subchondral bone region could be modulated to examine its effects on cartilage 
regularity. In addition, whether or not early bone repair improves cartilage repair could 
be directly tested by using minimally invasive techniques for examining bone and 
cartilage repair, and subsequently performing correlation and/or regression analysis on 
early and late time point measurements.  
 
 
7.5. Conclusion 
 The repair of articular cartilage and subchondral bone, facilitated by a growth 
factor delivering hydrogel composite scaffold, was evaluated in an osteochondral defect 
at 6 and 12 weeks. Associations between specific cartilage indices and bone parameters 
were tested through correlations analysis. Overall, there were significant associations 
between the repair of cartilage and the repair of subchondral bone. Significant 
correlations were consistently seen between cartilage surface regularity and bone quantity 
parameters, which may confirm the role of mechanical support the subchondral bone 
plays for the overlying articular cartilage. Bone and cartilage correlations also changed 
from 6 weeks to 12 weeks of repair, an indication of the different rates at which cartilage 
and bone repair and remodel. Additionally, the three experimental groups had different 
trends in correlations, revealing stronger correlations between cartilage repair and bone 
172 
 
formation at an earlier time point when BMP-2 was involved, and suggesting the 
chondroprotective nature of IGF-1 at a later time point, highlighting the differing effects 
of IGF-1 and BMP-2 on osteochondral repair. Altogether, the repair of cartilage is 
associated with the repair of subchondral bone for specific structural parameters, and 
through correlation analysis, a complete understanding of the repair of both tissues can 
help drive informed studies for future osteochondral repair strategies.  
 
 
173 
 
7.6. Tables and Figures 
 
Figure 7.1 Scatterplot matrix showing density ellipses for 95% of the data between 
cartilage histological scoring indices and bone morphological parameters in the cartilage 
and cortical VOI. Density ellipses were computed from a bivariate normal distribution fit 
to the histological scoring and micro-CT measurements and is a function of the means 
and standard deviations of the variables, as well as the correlation between them. 6 week 
samples are represented by blue ellipses and 12 week samples are represented by red 
ellipses. Significant correlations between cartilage and bone parameters are indicated by 
bolded outlines (p < 0.05), where n = 34 for 6 week correlations and n = 36 for 12 weeks 
correlations. 
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Figure 7.2 Scatterplot matrix showing density ellipses for 95% of the data between 
cartilage histological scoring indices and bone morphological parameters in the trabecular 
VOI. Density ellipses were computed from a bivariate normal distribution fit to the 
histological scoring and micro-CT measurements and is a function of the means and 
standard deviations of the variables, as well as the correlation between them. 6 week 
samples are represented by blue ellipses and 12 week samples are represented by red 
ellipses. Significant correlations between cartilage and bone parameters are indicated by 
bolded outlines (p < 0.05), where n = 34 for 6 week correlations and n = 36 for 12 weeks 
correlations. 
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Figure 7.3 Representative histological section with Safranin O/Fast Green staining of 
osteochondral tissue repair after 12 weeks of implantation (A). (B) and (C) are 
representative transverse micro-CT images of the bone plate and trabecular bone, 
respectively. This sample from the IGF-1 only group demonstrated minimal bone 
formation in both cortical and trabecular regions and had a depressed cartilage surface. 
(scale bar: 1000 µm) 
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Figure 7.4 Representative histological section with Safranin O/Fast Green staining of 
osteochondral tissue repair after 12 weeks of implantation (A). (B) and (C) are 
representative transverse micro-CT images of the bone plate and trabecular bone, 
respectively. This sample from the Both group had well-remodeled trabecular structures 
even with the presence of remaining hydrogel. Additionally, the bone plate has formed 
and the cartilage surface is regular. (scale bar: 1000 µm) 
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Table 7.1 Interpretation of correlation coefficient 
Correlation Coefficient Value Strength of Correlation 
.00 to |.30| Negligible correlation 
|.30| to |.50| Weak correlation 
|.50| to |.70| Moderate correlation 
|.70| to |.90| Strong correlation 
|.90| to |1.00| Very strong correlation 
Note: The sign of the correlation coefficient (i.e., positive or negative) 
indicates the direction of the relationship 
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Table 7.2 Correlations between micro-CT morphological and histological scoring parameters for all samples and both VOIs. 
 
BMD BV/TV i.S BS/BV Tb.Th Tb.N Tb.Sp Obj.N 
C&C Trabec C&C Trabec C&C Trabec C&C Trabec C&C Trabec C&C Trabec C&C Trabec C&C Trabec 
Cartilage 
Morphology 
.30 .33 .25 .27 .27    -  -  - -.35   
Cartilage 
Thickness 
        -  -  -    
Cartilage 
Regularity 
.37 .56 .33 .50 .33 .57 -.35 -.29 - .24 - .40 - -.32   
Chondrocyte 
Clustering 
        -  -  -  .25 .26 
Neocartilage 
Cell & GAG 
  -.27  -.26  .28 .30 - -.30 -  -  .38 .31 
Adjacent Cell 
& GAG 
.32 .29 .26 .30 .27  -.31  -  - .29 - -.30   
* Highlighted cells represent p < 0.0001 
** Blank cells represent non-significant correlations (p > 0.05) 
*** n = 70 
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Table 7.3 Cartilage and Cortical VOI, 6 week correlation between micro-CT morphological and histological scoring parameters for 
each experimental group. 
 
BMD BV/TV i.S BS/BV Obj.N 
IGF BMP Both IGF BMP Both IGF BMP Both IGF BMP Both IGF BMP Both 
Cartilage 
Morphology 
 .75   .75   .70   -.86     
Cartilage 
Thickness 
          -.71     
Cartilage 
Regularity 
 .70 .70  .73 .80  .64 .68  -.96 -.81    
Chondrocyte 
Clustering 
       -.64        
Neocartilage 
Cell & GAG 
 .67   .70      -.78    .67 
Adjacent Cell 
& GAG 
           .61   .77 
* Highlighted cells represent p < 0.01 
** Blank cells represent non-significant correlations (p > 0.05) 
*** n = 10-12 
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Table 7.4 Cartilage and Cortical VOI, 12 week correlation between micro-CT morphological and histological scoring parameters for 
each experimental group. 
 
BMD BV/TV i.S BS/BV Obj.N 
IGF BMP Both IGF BMP Both IGF BMP Both IGF BMP Both IGF BMP Both 
Cartilage 
Morphology 
        .76       
Cartilage 
Thickness 
               
Cartilage 
Regularity 
.62    -.60  .70 -.60        
Chondrocyte 
Clustering 
   -.58         .60 .68  
Neocartilage 
Cell & GAG 
 -.79   -.81   -.82  .62   .69   
Adjacent Cell 
& GAG 
               
* Highlighted cells represent p < 0.01 
** Blank cells represent non-significant correlations (p > 0.05) 
*** n = 12 
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Table 7.5 Trabecular VOI, 6 week correlation between micro-CT morphological and histological scoring parameters for each 
experimental group. 
 
BMD BV/TV i.S BS/BV Tb.Th Tb.N Tb.Sp Obj.N 
IGF BMP Both IGF BMP Both IGF BMP Both IGF BMP Both IGF BMP Both IGF BMP Both IGF BMP Both IGF BMP Both 
Cartilage 
Morphology 
 .86   .82   .76         .89  -.67 -.74     
Cartilage 
Thickness 
       .76                 
Cartilage 
Regularity 
 .92   .80 .59  .88         .80   -.92    -.69 
Chondrocyte 
Clustering 
               .64   -.65      
Neocartilage 
Cell & GAG 
 .82   .79   .79         .87   -.66    .63 
Adjacent Cell 
& GAG 
                       .68 
* Highlighted cells represent p < 0.01 
** Blank cells represent non-significant correlations (p > 0.05) 
*** n = 10-12 
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Table 7.6 Trabecular VOI, 12 week correlation between micro-CT morphological and histological scoring parameters for each 
experimental group. 
 
BMD BV/TV i.S BS/BV Tb.Th Tb.N Tb.Sp Obj.N 
IGF BMP Both IGF BMP Both IGF BMP Both IGF BMP Both IGF BMP Both IGF BMP Both IGF BMP Both IGF BMP Both 
Cartilage 
Morphology 
.63  .62   .58                   
Cartilage 
Thickness 
                      .64  
Cartilage 
Regularity 
.69  .81 .72  .78 .75  .73 -.58               
Chondrocyte 
Clustering 
                     .62   
Neocartilage 
Cell & GAG 
 -.69                       
Adjacent Cell 
& GAG 
                    -.83    
* Highlighted cells represent p < 0.01 
** Blank cells represent non-significant correlations (p > 0.05) 
*** n = 12 
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Supplementary Table 7.1 Explanation of the micro-computed tomography morphometric 
parameters analyzed within the two volumes of interest (VOI). 
Bone mineral density 
(g/cm3) BMD 
Volumetric density of bone within a mixed bone-soft tissue 
VOI 
Percent bone volume 
(%) BV/TV 
Proportion of VOI occupied by binarised solid objects (e.g., 
bone) 
Intersection surface 
(mm2) i.S 
Surface of VOI intersected by bone, useful for evaluating 
bone growth at a defined boundary 
Bone specific surface 
(mm-1) BS/BV 
Ratio of bone surface to bone volume within the VOI, useful 
for characterizing the relative complexity of structures 
Object number 
Obj.N 
Total number of discreet binarised objects within the VOI, 
where a discreet object is a connected cluster of solid (white) 
voxels fully surrounded by space (black) voxels 
Trabecular thickness 
(µm) Tb.Th 
True 3D thickness as determined by an average of the local 
thickness at each point representing bone 
Trabecular number 
(mm-1) Tb.N 
Implication of the number of traversals across a trabecular or 
solid structure made per unit length on a random linear path 
through the VOI 
Trabecular separation 
(µm) Tb.Sp 
True 3D thickness as determined by an average of the local 
thickness at each point representing non-bone 
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Supplementary Table 7.2 Histological scoring system for the evaluation of cartilage in 
rabbit osteochondral defects. 
 Score 
Cartilage evaluation (within the upper 1 mm of defect)  
1. Morphology of newly formed surface tissue  
Exclusively articular cartilage 4 
Mainly hyaline cartilage 3 
Fibrocartilage (spherical morphology observed with ≥ 75% of cells) 2 
Only fibrous cartilage (spherical morphology observed with < 75% of 
cells) 
1 
No tissue 0 
2. Thickness of newly formed cartilage  
Similar to the surrounding cartilage 3 
Greater than the surrounding cartilage 2 
Less than the surrounding cartilage 1 
No cartilage 0 
3. Joint surface regularity  
Smooth, intact surface 3 
Surface fissures (<25% of new surface thickness) 2 
Deep fissures (≥25% of new surface thickness) 1 
Complete disruption of the new surface 0 
4. Chondrocyte clustering  
None at all 3 
<25% chondrocytes 2 
25-100% chondrocytes 1 
No chondrocytes present (no cartilage) 0 
5. Chondrocyte and GAG content of new cartilage  
Normal cellularity with normal Safranin O staining 3 
Normal cellularity with moderate Safranin O staining 2 
Clearly less cells with poor Safranin O staining 1 
Few cells with no or little Safranin O staining or no cartilage 0 
6. Chondrocyte and GAG content of adjacent cartilage  
Normal cellularity with normal Safranin O staining 3 
Normal cellularity with moderate Safranin O staining 2 
Clearly less cells with poor Safranin O staining 1 
Few cells with no or little Safranin O staining or no cartilage 0 
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Chapter 8 
Evaluation of gelatin microparticles as 
adherent-substrates for mesenchymal stem 
cells in a hydrogel composite* 
 Due to the lack of cell-adhesive moieties in traditional synthetic hydrogels, the 
present work investigated the use of degradable gelatin microparticles (GMPs) as 
temporary adherent substrates for anchorage-dependent mesenchymal stem cells (MSCs). 
MSCs were seeded onto GMPs of varying crosslinking densities and sizes to investigate 
their role on influencing MSC differentiation and aggregation. The MSC-seeded GMPs 
were then encapsulated in poly(ethylene glycol)-based hydrogels and cultured in serum-
free, growth factor-free osteochondral medium. Non-seeded MSCs co-encapsulated with 
GMPs in the hydrogels were used as a control for comparison. Over the course of 35 
                                                        
 
* This chapter was submitted to Annals of Biomedical Engineering as Lu S, Lee EJ, Lam 
J, Tabata Y, Mikos AG. Evaluation of gelatin microparticles as adherent-substrates for 
mesenchymal stem cells in a hydrogel composite. (2016) 
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days, MSC-seeded GMPs exhibited more cell-cell contacts, greater chondrogenic 
potential, and a down-regulation of osteogenic markers compared to the controls. 
Although the factors of GMP crosslinking and size had nominal influence on MSC 
differentiation and aggregation, GMPs demonstrate potential as an adherent-substrate for 
improving cell delivery from hydrogel scaffold by facilitating cell-cell contacts and 
improving MSC differentiation. 
 
 
8.1. Introduction 
 Articular cartilage has a limited endogenous ability for self-repair, and since 
current clinical treatments for damaged or diseased cartilage tissue fall short of holistic 
repair, tissue engineering strategies have emerged as an alternative for physiological 
cartilage regeneration. In particular, synthetic hydrogels are appealing as scaffolding 
structures due to their viscoelastic properties, ability to mimic the high water content of 
native tissues, and tunability for greater control over physical properties [386]. Various 
biomaterials have consequently been developed into hydrogel structures [387] and are 
attractive candidates as scaffolds for cell encapsulation and growth [388].  
 In the field of cartilage tissue engineering, stem cells and/or chondrocytes have 
typically been incorporated in such synthetic hydrogels to guide cell and tissue growth. 
Specifically, cell delivery from hydrogels traditionally involves the homogenous 
suspension of cells within a liquid precursor solution and subsequent curing to form a 
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cell-laden scaffold. However, as the field evolves, hydrogels have transitioned from 
merely delivery vehicles to dynamic, bioactive intermediaries of neo-tissue formation 
[388]. In particular, synthetic hydrogels often lack cell-adhesion moieties, and cell-cell 
contacts mediated by N-cadherin cell adhesion molecules have increasingly been shown 
to influence mesenchymal stem cell (MSC) differentiation and cartilage tissue formation 
through condensation [389, 390]. Condensation, a developmental process during 
skeletogenesis, is characterized by MSC aggregation following the establishment of cell-
cell contacts, which in turn can improve chondrogenic differentiation and cartilaginous 
extracellular matrix production [391, 392]. Therefore, the current study seeks to improve 
the differentiation potential of MSCs through the use of enzymatically-degradable gelatin 
microparticles (GMPs) embedded within a poly(ethylene glycol) (PEG)-based hydrogel 
matrix. 
 Synthesized from denatured collagen, gelatin naturally exhibits cell-adhesion 
moieties and has seen numerous applications in cell delivery in a variety of scaffold 
forms [393-395]. Thus, gelatin will be fabricated into microparticles as a medium for cell 
seeding and cell-cell contacts.  Specifically, MSCs will first be seeded onto the surface of 
GMPs, subsequently followed by the encapsulation of MSC-seeded GMPs (MSC-GMPs) 
within a hydrogel scaffold. It is hypothesized that initially seeding GMPs with MSCs can 
improve their differentiation potential, and that the GMPs will serve as enzymatically-
digestible porogens as well as a temporary adherent-substrate for the MSCs. 
Additionally, it is hypothesized that the degradation of the GMPs will result in open 
space for MSC aggregation within the created pores. MSCs are known secretors of a 
number of matrix metalloproteinases (MMPs) [396], and direct extracellular matrix 
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contact can modulate MMP activity through specific substrate-protease responses [397]. 
Moreover, the aggregation of MSCs is modulated by the ratio of cadherin to integrin 
expression; the lower the availability for substrate adhesion, the greater the affinity for 
cell-cell aggregation [398]. Thus, it may be possible to form MSC aggregates following 
degradation of the GMP substrate within the macroporous hydrogel.  
 To investigate the previously stated hypotheses, this study 1) fabricates GMPs of 
varying sizes and degrees of crosslinking, 2) investigates GMP size, GMP crosslinking, 
and seeding method on the activity of MSCs encapsulated within PEG-based hydrogels, 
and 3) cultures the cell-laden hydrogel composites in a serum-free, growth factor-free 
medium to elucidate the sole effect of the aforementioned three variables on MSC 
chondrogenesis, osteogenesis, and condensation. 
 
 
8.2. Materials and Methods 
8.2.1. Experimental design 
 The main design criteria set for fabricating GMPs was a fast-degrading, 
temporary adhesive-substrate for MSC delivery. Thus, GMPs with a very low 
crosslinking density that would still allow for MSC seeding were used. In order to 
determine which GMPs to use for MSC seeding, GMPs with different crosslinking 
densities were degraded in phosphate-buffered saline (PBS) with a range of collagenase 
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1A concentrations (Table 8.1). From this study, select GMPs of different crosslinking 
density and diameter sizes were then co-encapsulated or seeded with MSCs in hydrogel 
composites to yield six different experimental groups as outlined in Table 8.2. Cell-laden 
hydrogel composites were then cultured for 35 days in serum- and growth factor-free 
osteochondral medium to assess MSC activity, condensation, and differentiation. 
 
8.2.2. Oligo(poly(ethylene glycol) fumarate) synthesis 
 Oligo(poly(ethylene glycol) fumarate) (OPF) was synthesized from PEG (Sigma-
Aldrich) with a nominal molecular weight of 3,350 according to methods previously 
developed in our laboratory [339]. Gel permeation chromatography was used to 
characterize the OPF macromer to give a number average molecular weight of 7,500 ± 
200 Da and a weight average molecular weight of 36,300 ± 600 Da. Purified OPF was 
stored at -20°C and sterilized with ethylene oxide for 12 h prior to use following 
established methods [102]. 
 
8.2.3. Gelatin microparticle fabrication  
 GMPs were fabricated using acidic gelatin (Nitta Gelatin) with an isoelectric 
point of 5.0 using a modified process of established methods [352, 399]. Briefly, 30 mL 
of a 10 wt% gelatin solution in distilled, deionized water (ddH2O), preheated to 45°C, 
was added drop-wise to 250 mL olive oil (Sigma-Aldrich) (containing 0.5 wt% Span 80) 
stirring at 400 RPM at room temperature. After 10 min, the water-in-oil emulsion was 
chilled on ice and stirred for 30 more min. Following the emulsion step, 100 mL chilled 
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acetone (4°C) were added and stirred an additional 60 min. The resulting microparticles 
were then collected by vacuum filtration and washed with acetone. The collected GMPs 
were then placed in a 0.1 wt% Tween 80 aqueous solution containing different 
concentrations of glutaraldehyde (1, 2, 3, 4, and 5 mM) and stirred at 4°C for 15 h. After 
crosslinking, glycine was added to a concentration of 25 mM to block residual aldehyde 
groups of unreacted glutaraldehyde and allowed to stir for 1 h. Crosslinked microparticles 
were then vacuum-filtered, washed with ddH2O and acetone, dried under low-vacuum 
overnight, and sieved to different size ranges. GMPs of 50-100 µm and 100-150 µm in 
diameter were sterilized with ethylene oxide for 12 h prior to MSC culture and 
encapsulation. 
 
8.2.4. Gelatin microparticle degradation 
 For the degradation study, GMPs of varying crosslinking were placed in PBS with 
different concentrations of collagenase 1A (Sigma-Aldrich) to facilitate enzymatic 
digestion (Table 8.1). The collagenase concentrations used were based on estimations of 
MMP-1 expression from MSCs [400], as well as observed degradation of GMPs when 
incubated with MSCs. 5 mg of 100-150 µm diameter GMPs were added to the bottom of 
cell strainers with a 40 µm mesh size. The cell strainers with GMPs were then placed in 
6-well plates, with each well containing 10 mL of collagenase-containing PBS (CC-
PBS), and incubated at 37°C for up to 35 days (n=3). The CC-PBS was collected and 
changed at day 1 and every third day thereafter. To measure the amount of gelatin in 
solution, a bicinchoninic acid assay (Micro BCA Protein Assay Kit, Thermo Scientific) 
for total protein determination was used with dissolved, uncrosslinked GMPs prepared as 
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standards. Briefly, 150 µL of standard/sample were combined with 150 µL of the 
working reagent in a clear 96-well plate and incubated for 1 h at 37°C. The absorbance at 
562 nm was then measured with a plate reader (PowerWave x340 Microplate Reader). 
The GMPs were considered completely degraded when the amount of gelatin detected 
was within the standard error of the lower detection limit. This was verified via visual 
observation of the absence of GMPs in the cell strainer.  
 
8.2.5. Rabbit marrow mesenchymal stem cell harvest and culture 
 Rabbit marrow MSCs were isolated from the tibias of 6-month-old New Zealand 
white rabbits as previously described [401]. All surgical procedures were approved by the 
Institutional Animal Care and Use Committee of Rice University. Briefly, after 
anesthesia, bone marrow was collected into 10 mL syringes containing 3,000 units of 
heparin. The bone marrow was then plated and cultured in general medium (GM + FBS) 
containing Low Glucose-Dulbecco’s modified Eagle’s medium (LG-DMEM), 10% v/v 
fetal bovine serum (FBS), 100 units/mL penicillin, and 100 µg/mL streptomycin. GM + 
FBS was changed every 3 days and after 2 weeks of culture, the adherent fraction of cells 
was pooled from 6 rabbits to minimize inter-animal variability and cryopreserved in 
freezing medium containing LG-DMEM, 20% v/v FBS, 10% v/v dimethyl sulfoxide, 100 
units/mL penicillin, and 100 µg/mL streptomycin. Prior to use, MSCs were thawed and 
expanded with GM + FBS up to passage three. 
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8.2.6. Mesenchymal stem cell seeding on gelatin microparticles 
 Prior to MSC seeding, 50 mg dry GMPs (50-100 or 100-150 µm diameter) were 
swollen in 2 mL GM without FBS (GM – FBS) for 1 h at 37°C. 6 × 106 MSCs and 50 mg 
GMPs in suspension were then split evenly between two 100 mm ultra-low attachment 
dishes (Corning) containing 20 mL GM – FBS each. The dish was gently swirled at 120 
RPM for 2 min before incubation for 12 h at 37°C. After 12 h culture, aggregates of 
MSCs and GMPs were broken up with a 1000 µL positive displacement pipette, swirled 
at 120 RPM for 2 min, and incubated for 24 h at 37°C. For GMPs without seeded MSCs, 
GMPs were swollen in GM – FBS for 36 h at 37°C in static conditions. After a total of 36 
h, the suspension of GMPs or MSC-seeded GMPs (MSC-GMP) was filtered through a 70 
µm cell strainer to remove any non-adherent cells and washed with PBS to remove 
residual media. The GMPs or MSC-GMPs were then loaded in a 1 mL syringe shortly 
before encapsulation. 
 
8.2.7. Hydrogel composite fabrication 
 Hydrogel composites were fabricated similar to methods previously described 
[399, 402]. To prepare the OPF precursor solution, 50 mg of OPF and 25 mg of PEG-
diacrylate (3,400 Da, Laysan Bio) were dissolved in 112.5 µL PBS and set at room 
temperature for 45 min to eliminate air bubbles. 23 µL each of radical initiators, 0.3 M 
ammonium persulfate (APS) and 0.3 M N,N,N’,N’-tetramethylethylenediamine 
(TEMED), were then mixed into the polymer solution and vortexed. The concentrations 
of APS and TEMED used were expected to have minimal cytotoxic effects and allow for 
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high viability of encapsulated cells in OPF-based hydrogels following fabrication [401, 
402]. After 30 seconds, 100 µL PBS or cell suspension (6 × 106 MSCs) were added 
followed by the MSC-GMPs or blank GMPs, respectively. The solution was mixed 
carefully to create a homogenous distribution of GMPs and to avoid the formation of 
bubbles. Lastly, the polymer-GMP solution was injected into Teflon molds (6 mm 
diameter × 1 mm thickness) and crosslinked at 37°C for 20 min. Teflon molds were 
flipped at 5 min to prevent GMPs from settling. 
 
8.2.8. Hydrogel composite culture 
 The resulting hydrogel constructs were transferred to ultra-low attachment 24-
well plates (Corning) with 1 mL serum- and growth factor-free osteochondral medium 
(OM), which contained LG-DMEM supplemented with ITS + Premix (6.25 μg/mL 
insulin, 6.25 μg/mL transferrin, 6.25 μg/mL selenous acid, 5.35 μg/mL linoleic acid and 
1.25 μg/mL bovine serum albumin) (BD Biosciences), 100 units/mL penicillin, and 100 
µg/mL streptomycin, 50 mg/L ascorbic acid, 10mM β-glycerophosphate, 10-7 M 
dexamethasone, and 1 mM sodium pyruvate [256]. OM was changed every two days and 
cell-laden composites were cultured up to 35 days.  
 
8.2.9. Confocal fluorescence microscopy 
 Confocal fluorescence microscopy was used to visualize MSCs encapsulated in 
the hydrogel composites at day 0 (D0). To assess cell viability, constructs from D0 were 
rinsed in PBS to remove media and then incubated in a dye solution containing 4 µM 
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ethidium homodimer-1 and 2 µM calcein acetoxymethyl ester (Invitrogen) for 30 min as 
reported previously [256]. MSCs complexed with the Live/Dead reagent were then 
imaged using a Zeiss LSM 510.  
 To assess the morphology of MSCs either seeded on GMPs or encapsulated in the 
gel phase, select samples at D7 were stained for nuclei and F-actin. Briefly, samples were 
fixed in 10% neutral buffered formalin for 10 min at room temperature, washed with 
PBS, and stored at 4°C until staining. Hydrogels were immersed in 0.3% Triton X-100 
for 10 min, 2x, to permeabilize cells, then incubated with DAPI (5 µg/mL) and phalloidin 
(1:20 dilution, Alexa Fluor 488 Phalloidin, Life Technologies) in 3% BSA diluted in 
Triton X-100 for 20 min at room temperature. Samples were then washed in PBS for 10 
min and imaged with a Nikos A1-Rsi.  
 
8.2.10. Biochemical assays 
 At each time point (D0, D7, D21, and D35), hydrogel composites were collected 
(n=4), rinsed in PBS to remove media, cut in half, and stored in -20°C until used for 
biochemical analysis. To determine DNA, glycosaminoglycan (GAG), and 
hydroxyproline (HYP) content, 4 hydrogel halves were each digested in 500 µL of 
proteinase K solution (1 mg/mL proteinase K, 10 μg/mL pepstatin A, and 185 μg/mL 
iodoacetamide in tris-EDTA solution (6.055 mg/mL tris(hydroxymethyl aminomethane), 
0.372 mg/mL EDTA, pH 7.6 adjusted by HCl) at 56°C for 16 h. To determine alkaline 
phosphatase (ALP) activity and calcium content, 4 hydrogel halves were each thawed in 
500 µL of ddH2O. All samples were then subjected to homogenization with a syringe and 
needle, three freeze-thaw cycles, and probe sonication. 
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 DNA content was quantified using a Quant-iT PicoGreen dsDNA Assay Kit 
(Molecular Probes) according to the manufacturer’s instructions. Sample supernatant, 
assay buffer, and dye solution were combined in a black, opaque 96-well plate, and 
incubated for 10 min at room temperature. Fluorescence was measured using excitation 
and emission wavelengths of 485 nm and 528 nm (FL x800 Fluorescence Microplate 
Reader), respectively. DNA concentrations were determined relative to a lambda DNA 
standard curve.  
 GAG content was determined with a dimethylmethylene blue colorimetric assay 
as previously described [401]. Sample supernatant and color reagent were combined in a 
clear 96-well plate and the absorbance at 520 nm was measured (PowerWave x340 
Microplate Reader). GAG concentrations were determined relative to a chondroitin 
sulfate standard curve. Synthetic GAG activity was determined by normalizing total 
GAG content to the DNA content for each sample. 
 HYP content, an indicator of total collagen amount, was determined via a 
colorimetric assay as previously described [403]. An aliquot of sample supernatant was 
combined with an equal volume of 4 N NaOH and hydrolyzed by autoclaving for 15 min, 
121°C (approximately 50 min total processing time). The solution was neutralized with 
HCl and acetic acid to pH 5.5-7.0 and divided into duplicate reactions. Chloramine-T and 
p-dimethylaminobenzaldehyde solutions were then added sequentially, incubated at 60°C 
for 30 min, and read at an absorbance of 570 nm with a plate reader. HYP concentrations 
were determined relative to a trans-4-hydroxy-L-proline standard curve. 
 ALP enzymatic activity was determined using alkaline buffer solution and 
phosphatase substrate tablets (Sigma-Aldrich). Sample supernatant and reagents were 
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combined and incubated for 1 h at 37°C. The reaction was stopped by adding 1 N NaOH, 
and the absorbance at 405 nm was measured using a plate reader. ALP activity was 
determined relative to a p-nitrophenol standard curve. Enzymatic activity was normalized 
to the DNA content for each respective hydrogel composite half. 
 Calcium content was measured using a colorimetric assay by adding acetic acid to 
an aliquot of sample supernatant with a final concentration of 0.5 M and incubating at 
room temperature overnight to dissolve the calcium. Samples were combined with 
calcium arsenazo III reagent (Genzyme), and the absorbance at 650 nm was measured 
using a plate reader. Calcium concentrations were determined relative to a CaCl2 standard 
curve and normalized to the DNA content for each respective hydrogel composite half. 
 
8.2.11. Real-time reverse transcription polymerase chain reaction 
 At D7, D21, and D35, hydrogel samples were collected (n=4), rinsed in PBS to 
remove media, and stored in lysis buffer at -20°C until used for real-time reverse 
transcription polymerase chain reaction (RT-PCR) analysis as previously described [102]. 
Additionally, D0 samples were collected from experimental groups containing 4 mM 
GMPs. Briefly, RNA was isolated from hydrogel samples using the RNeasy Mini Kit 
(Qiagen), reverse transcribed to cDNA using superscript III transcriptase (Invitrogen) and 
Oligo dT primers (Promega), and subjected to real-time PCR (Applied Biosystems 7300 
Real-Time PCR System) using SYBR Green detection (PerfeCTa SYBR Green FastMix, 
Rox; Quanta Biosciences) with custom designed primers (Integrated DNA Technologies). 
Primer sequences used are listed in Table 8.3. All target gene expression were normalized 
to the housekeeping gene GAPDH and expressed as the fold change relative to the 
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baseline expression of the Group 1 control at D0. All gene expression data were 
calculated using the 2-ΔΔCt method [404]. 
 
8.2.12. Statistical analysis 
 A significance level of p<0.05 was used for all statistical analysis through JMP 
Pro v11.0.0. All results are presented as means ± standard deviation. Biochemical assay 
data were analyzed using one-way ANOVA to test variance followed by Tukey’s HSD 
All Pairs test, whereas RT-PCR data were analyzed using the Kruskal-Wallis test 
followed by the Wilcoxon Each Pair test to determine significant differences between 
groups at each time point and between time points for each group.  
 
 
8.3. Results 
8.3.1. Gelatin microparticle degradation 
 The main design criterion set for fabricating GMPs was a fast-degrading, 
temporary adhesive-substrate for MSC delivery. Thus, GMPs with a very low 
crosslinking density that would still allow for MSC seeding were used. Of the five 
crosslinking-densities tested, GMPs crosslinked in 1mM glutaraldehyde solution (1mM 
GMPs) dissolved in 37°C PBS within 24 h while 2, 3, 4, and 5mM GMPs remained 
stable. In order to model the degradation of GMPs due to MMPs secreted from MSCs, 
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2mM and 3mM GMPs were initially tested in varying CC-PBS concentrations (Figure 
8.1a,b). However, 2mM and 3mM GMPs completely degraded when cultured with MSCs 
during the seeding period (36 h), whereas 4mM and 5mM GMPs allowed for cell 
adhesion. As a result, 4mM and 5mM GMPs were only tested at 0, 100, and 200 ng/mL 
CC-PBS concentrations for up to 35 days. Both 4mM and 5mM GMPs held their 
spherical morphology in PBS without collagenase during the culture period, and while 
4mM GMPs degraded in CC-PBS within 13 and 16 days, 5mM GMPs degraded within 
19 and 28 days at the 100 and 200 ng/mL CC-PBS concentrations, respectively.  
 
8.3.2. Mesenchymal stem cell seeding on gelatin microparticles 
 After MSCs were seeded onto 4mM and 5mM GMPs, the MSC-GMPs were 
encapsulated in OPF hydrogels, and the viability and morphology of the MSCs were 
qualitatively examined with confocal fluorescence microscopy. At D0 post-fabrication, 
the cell-laden hydrogel composites were evaluated with a Live/Dead assay kit, with live 
cells and dead cells fluorescing green and red, respectively. As seen in Figure 8.2, MSCs 
are viable following hydrogel encapsulation, whether through direct encapsulation or 
initial GMP seeding. The minimal cell death seen in the MSC-GMP groups also points to 
the MSC seeding procedure on the GMPs as cell-friendly. In order to visualize cell 
morphology in the hydrogel composites, MSCs were stained with DAPI (blue) and 
phalloidin (red) for cell nuclei and F-actin, respectively (Figure 8.3). As shown in Figure 
8.3a, the MSCs exhibit a round morphology, while in Figure 8.3b and Figure 8.3c, MSCs 
are attached and spread on the surface of GMPs within the hydrogel scaffold.  
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8.3.3. Biochemical assays 
 OPF hydrogels containing MSCs + GMPs (Groups 1 and 2) or MSC-GMPs 
(Groups 3-6) were cultured in a serum-free, growth factor-free OM for 35 days and 
evaluated for cellularity, synthetic GAG activity, GMP degradation, ALP activity, and 
mineralization potential (Figure 8.4). Cellularity, as assessed by DNA content, is depicted 
in Figure 8.4a for each group and time point. At D0, Groups 1 and 2 had significantly 
greater total DNA content than Groups 3 and 4 (MSC-GMPs, 50-100 µm), which had 
greater DNA content than Groups 5 and 6 (MSC-GMPs, 100-150 µm). All groups 
displayed a decrease in total DNA content from D0 to D7. However, the DNA amount 
remained relatively stable over the course of 35 days following Day 7.  
 Figure 8.4b represents the synthetic GAG activity as produced by encapsulated 
MSCs. Groups 3, 5, and 6 (MSC-GMPs) showed a significantly larger normalized GAG 
amount at D0 compared to the co-encapsulated MSC + GMPs. Additionally, groups with 
MSCs seeded on 4 mM GMPs showed the greatest GAG synthetic activity at Day 35: 
Groups 3 and 5 were significantly greater than the control groups and Group 3 was 
significantly greater than the 5 mM GMP groups. No direct differences were seen 
between larger and smaller sized GMP groups. 
 In order to examine the change in collagen content as an estimation of GMP 
degradation, total HYP content of the hydrogel constructs was determined over time. As 
seen in Figure 8.4c, total HYP amounts dropped overtime with D21 and D35 values 
significantly lower than D0 and D7 values for all groups. A difference between groups 
with 4mM and 5mM GMP groups can be seen at D21 and especially at D35, with 4mM 
groups having less HYP content than 5mM groups. However, the GMPs were still 
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present and had a spherical morphology within the hydrogels after the culture period (as 
verified by light microscopy), which can be seen by remaining HYP content in each 
group at D35. 
 Since MSCs were cultured in an OM without factors for specific chondrogenic or 
osteogenic directed differentiation, ALP enzymatic activity and calcium content were 
also examined as markers of osteogenic differentiation. Figure 8.4d shows a peak in 
normalized ALP enzymatic activity at D7 for Groups 1 and 2, while the groups with 
encapsulated MSC-GMPs decreased in ALP activity over time from D0. MSCs co-
encapsulated with 5mM GMPs (Group 2) specifically exhibited the highest normalized 
ALP activity at D7 among groups. Interestingly, the MSC-GMPs groups with 4mM 
GMPs (Groups 3 and 5) had greater initial ALP activity at D0 compared to their 5mM 
GMP counterparts (Groups 4 and 6). Looking at normalized calcium content (Figure 
8.4e), no significant differences were observed between groups, and calcium levels 
remained relatively low over the course of 35 days. However, a significant increase in 
normalized calcium content was seen from D0 to D21 for Group 1 and from D0 to D35 
for Group 2. 
 
8.3.4. Real-time RT-PCR gene expression 
 In addition to evaluating the synthetic activity of the cell-laden hydrogel 
composites, real-time RT-PCR analysis was also performed to assess chondrogenic 
and/or osteogenic differentiation potential. In examining markers for chondrogenic 
differentiation, certain trends were consistently seen for COL2, ACAN, and SOX9 gene 
expression. Of note, all MSC-GMP groups exhibited greater chondrogenic gene 
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expression at D21 than did the MSC + GMP control groups (Figure 8.5). Differences 
between MSC-GMP (Groups 3-6) and MSC + GMP (Groups 1-2) hydrogel composites 
were also observed at other time points: MSCs seeded on 5mM GMPs demonstrated 
higher ACAN and SOX9 fold change at D35 compared to the MSC + 5mM GMP control 
(Figure 8.5b,c). Similarly, Groups 3 and 5 (4mM MSC-GMPs) had a greater COL2 fold 
change at D35 compared to the MSC + 4mM GMP control (Figure 8.5a). At D7, MSCs 
seeded on 5mM GMPs exhibited greater ACAN gene expression than the MSC + 5mM 
GMP control (Figure 8.5b). Significant differences were also seen between 4mM GMP 
(Groups 1, 3, and 5) and 5mM GMP (Groups 2, 4, and 6) hydrogel composites. Group 1 
had higher COL2, ACAN, and SOX9 expression at D21 and D35 compared to Group 2. 
Additionally, the larger sized, 5mM MSC-GMP group (Group 6) had higher ACAN and 
SOX9 gene expression than its 4mM counterpart (Group 5) at D21. 
 In assessing markers of osteogenic differentiation, COL1 gene expression was 
consistently down regulated over time for all groups (Figure 8.6a). Moreover, MSC-GMP 
groups had decreased COL1 fold change compared to the MSC + GMP controls at all 
time points. RUNX2 expression also revealed similar down regulation for MSC-GMP 
groups compared to MSC + GMP groups at both D21 and D35 (Figure 8.6b). 
Interestingly, minimal differences in osteogenic gene expression were observed between 
smaller and larger GMP size groups. Regarding GMP crosslinking, Group 4 had reduced 
COL1 and RUNX2 expression at D21 compared to Group 3. 
 Lastly, the presence and formation of cell-cell contacts through CDH2 expression 
was investigated (Figure 8.6c). While there was no significant difference between groups 
with MSCs seeded on GMPs and MSCs homogenously encapsulated in the hydrogel at 
202 
 
early time points, D21 and D35 revealed the impact of the GMPs as a cell substrate: 
MSC-GMP groups showed greater CDH2 fold change compared to Group 1 at D21. At 
D35, MSC-5mM GMP groups showed higher N-cadherin expression than the MSC + 
5mM GMP control. Similarly, Group 3 exhibited more CDH2 gene expression than 
Group 1 at D35. 
 
 
8.4. Discussion 
 The primary objective of this study was to utilize enzymatically-degradable 
GMPs as a temporary adherent-substrate for MSCs within a hydrogel matrix. MSCs were 
seeded onto GMPs of different sizes and crosslinking densities and assessed for 
chondrogenesis/osteogenesis as well as their condensation behavior over 35 days. 
Specifically, we investigated 1) whether the GMPs could act as a temporary adherent-
substrate for MSCs, allowing for MSC aggregation following GMP degradation, and 2) if 
the initial seeding of MSCs on the GMPs could improve their differentiation potential. 
 In order to evaluate GMPs as a temporary adherent-substrate, GMPs of varying 
crosslinking densities were fabricated and subjected to MSC seeding tests as well as 
collagenase-containing medium for GMP degradation modeling. Following GMP 
synthesis, 2 and 3mM GMPs were discovered to be unsuitable for MSC seeding and 
disappeared before the end of the seeding period. Since 2 and 3mM GMPs did not 
completely dissolve in the absence of collagenase within 24 h (Figure 8.1a,b), these 
loosely crosslinked GMPs were likely degraded via enzymes secreted by the MSCs 
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during the seeding period. Consequently, 4 and 5mM GMPs were chosen as the 
temporary adherent-substrate for initial MSC seeding. However, this initial enzymatic 
activity on the GMPs may not have lasted throughout the culture period since 
microparticles still remained within the hydrogel scaffolds at D35. Indeed, while MSCs 
are known secretors of MMPs, tissue inhibitors of metalloproteinases (TIMPs) are often 
produced alongside MMPs, and most TIMPs are highly specific for MMPs, binding in a 
1:1 stoichiometric ratio [405]. In a study by Lozito and Tuan, despite secretion of MMP-1 
and MMP-2 (a gelatinase) by MSCs cultured in a serum-free, growth factor-free medium, 
actual MMP activity was significantly lower due to endogenous production of TIMP-1 
and TIMP-2 [406]. However, certain chemokines have been found to modulate the 
expression of MMPs and TIMPs in MSCs: expression of MMP-2 in a serum-free, growth 
factor-free medium was up-regulated with the exogenous addition of transforming growth 
factor-β1 while TIMP expression was not affected [407]. As a result, to fully realize the 
potential of GMPs as a temporary adherent-substrate for cell delivery, the inclusion of 
serum or growth factors may be necessary. 
 Due to incomplete GMP degradation, macropores could not form within the 
hydrogel scaffold, and the space necessary for MSC aggregation was not achieved. 
Certainly, other methods have been developed to induce cell aggregation within a 
hydrogel: MSCs seeded within macroprous OPF hydrogels [408], chondrocytes 
encapsulated within uncrosslinked GMPs and released into a porous hydrogel bulk upon 
GMP dissolution [409], and MMPs used to degrade crosslinked GMPs as hepatocyte cell 
carriers within an alginate hydrogel [410]. Nevertheless, an objective of the current study 
entailed the use of GMPs as temporary adherent-substrates for the anchorage-dependent 
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MSCs, and it is unclear what the effects of a large dose of MMPs to degrade the GMPs 
would be on stem cells, as opposed to a differentiated cell phenotype (e.g., hepatocytes).  
 Despite the lack of MSC aggregation, biochemical and real-time RT-PCR 
analysis revealed that employing GMPs as an adherent-substrate within OPF hydrogels 
resulted in greater MSC chondrogenic potential as compared to MSCs co-encapsulated 
with GMPs. At D35, synthetic GAG activity and type II collagen expression was higher 
for MSC-4mM GMP groups than the MSC + 4mM GMP control. Furthermore, aggrecan 
and SOX9 fold changes were larger for the MSC-5mM GMP groups than for the controls 
at D35. Overall chondrogenic gene expression was higher at D21 for all MSC-GMP 
groups compared to MSC + GMP groups. While expression of these genes did not 
necessarily increase over time, the significant differences are corroborated by enhanced 
N-cadherin expression for MSC-GMP groups at both D21 and D35. Indeed, cell-cell 
contacts provide additional communication that has been demonstrated to improve 
adipogenic, osteogenic, and/or chondrogenic differentiation through cadherin signaling 
[390], and the disruption of such cell-cell adhesion has been shown to reduce MSC 
chondrogenic potential [389]. 
 While MSC-GMPs exhibited marked chondrogenic differentiation potential, 
markers of osteogenesis decreased over time for all groups. Interestingly, type I collagen 
and RUNX2 expression were significantly lower at D35 for MSCs seeded on GMPs 
compared to MSCs co-encapsulated with GMPs in hydrogels. However, substrate 
stiffness and the physical environment also play a large role in determining cellular 
response. Osteoblastic markers such as RUNX2 are often only expressed when the matrix 
stiffness is close to that of native bone tissue [411]. Although mechanical properties of 
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the hydrogel composites were not tested, the soft adherent substrate presented by the 
loosely crosslinked GMPs may have precluded significant osteogenic potential. 
 Lastly, the extent of GMP crosslinking and GMP size were also investigated as 
factors for influencing MSC activity in the hydrogel composites. While the variable of 
GMP size had minimal effects on differentiation and condensation, differences between 
4mM and 5mM GMPs were found. Total HYP amount was consistently greater for 5mM 
GMP groups than 4mM GMP groups at D21 and D35, likely due to the increased 
crosslinking extent of 5mM GMPs. Additionally, differences between Group 1 and 
Group 2 were seen: greater normalized ALP expression was seen at D7 for MSCs co-
encapsulated with 5mM GMPs compared to 4mM GMPs. This was followed by higher 
COL2, ACAN, and SOX9 gene expression for Group 1 compared to Group 2 at D21 and 
D35. Indeed, the microenvironment plays a large role in stimulating the activity of 
encapsulated MSCs and the relatively softer substrate of 4mM GMPs in Group 1 may 
have improved the chondrogenic potential of co-encapsulated MSCs.  
 However, a similar trend was not consistently seen in groups with MSCs-seeded 
on GMPs. 4mM MSC-GMPs groups displayed greater initial ALP activity compared to 
5mM MSC-GMPs groups, yet smaller sized 4mM MSC-GMPs also had greater synthetic 
GAG activity at D35 compared to 5mM MSC-GMPs. In contrast, larger sized 5mM 
MSC-GMPs had higher ACAN and SOX9 expression than its 4mM counterpart at D21. 
Future investigation with a broader range of GMP crosslinking densities would be 
necessary to clarify the effect of GMP crosslinking. Additionally, the variables of size 
and crosslinking are anticipated to play a larger role in influencing MSC aggregation 
following complete degradation of the GMPs. Further studies incorporating serum or 
206 
 
growth factors in the culture medium would be warranted to elucidate the effect of these 
variables on the differentiation and condensation potential of seeded MSCs. 
 
 
8.5. Conclusion 
 In summary, MSCs were seeded onto GMPs of varying crosslinking densities and 
sizes and subsequently encapsulated in OPF hydrogels. MSCs co-encapsulated with the 
GMPs were included as controls, and the cell-laden hydrogel composites were cultured in 
a serum-free, growth factor-free OM for 35 days. Results indicate that the encapsulated 
GMPs did not completely degrade during the culture period, and crosslinking density and 
GMP size had nominal influence on MSC differentiation potential. Nonetheless, MSCs 
seeded on GMPs exhibited greater N-cadherin expression than their MSC and GMP co-
encapsulated counterparts. Additionally, MSCs seeded on GMPs showed greater 
chondrogenic differentiation potential, while osteogenic markers were found to down-
regulate over time. Overall, these results demonstrate the potential of GMPs as an 
adherent-substrate within hydrogel scaffolds for facilitating cell-cell contacts and 
enhancing MSC differentiation. 
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8.6. Tables and Figures 
(A) (B)
(C) (D)
 
Figure 8.1 Degradation profile of GMPs crosslinked with a 2mM (A), 3mM (B), 4mM 
(C), and 5mM (D) glutaraldehyde solution. Cumulative degradation of GMPs was 
measured up to 35 days in collagenase-containing PBS. 2_0, 2_20, 2_100, and 2_200 
designate 2 mM GMPs incubated with PBS containing 0, 20, 100, or 200 ng/mL 
collagenase 1A, respectively. Similar shorthand designations apply for 3mM, 4mM, and 
5mM GMPs. The day of complete degradation is stated and is indicated by a slight 
plateau in the cumulative GMP degradation graph. GMPs that did not degrade within the 
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culture period are denoted with an ND. Error bars correspond to standard deviation for 
n=3 samples.  
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Figure 8.2 Confocal fluorescence microscopy images of MSCs, complexed with live/dead 
reagents, encapsulated in hydrogel composites at day 0. Green fluorescence designates 
live cells, whereas red fluorescence indicates dead cells. Round cells can be seen in 
Groups 1 and 2 (A and B) while flattened cells can be seen in Group 3-6 (C-F). (Scale 
bar: 200 µm) 
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Figure 8.3 Confocal fluorescence microscopy images of MSCs, stained with DAPI and phalloidin, encapsulated in hydrogel 
composites at day 7. Blue fluorescence designates nuclei, whereas green fluorescence indicates F-actin staining of MSCs. Round 
MSCs encapsulated in the gel phase can be seen in a representative sample from Group 2 (A), while elongated MSCs can be seen in a 
representative sample from Group 4 (B). A z-axial projection stack of 30 images (10 µm apart) set against differential interference 
contrast images shows the spread morphology of MSCs seeded on the GMPs (C). (Scale bar: 100 µm) 
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(A) (B) 
 
(C) (D) 
 
(E) 
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Figure 8.4 (A) DNA content, (B) GAG content normalized to DNA content, (C) HYP 
content, (D) ALP activity normalized to DNA content, and (E) calcium content 
normalized to DNA content for each experimental group at various time points. At each 
time point, groups connected with different letters are significantly different (p < 0.05). 
Within each group, time points connected by lines and noted with (*) are significantly 
different. The x-axis labels are denoted by Gel or GMP, representing MSCs co-
encapsulated with GMPs vs seeded on GMPs; 4 or 5, representing the crosslinking extent 
of GMPs at either 4mM vs 5mM; and S or L, representing smaller 50-100µm GMPs vs 
larger 100-150µm GMPs. Error bars correspond to standard deviation for n=4 samples. 
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(A) (B) 
 
(C)  
 
Figure 8.5 (A) Type II Collagen expression, (B) Aggrecan expression, and (C) Sox9 
expression for each experimental group at various time points. At each time point, groups 
connected with different letters are significantly different (p < 0.05). Within each group, 
time points connected by lines and noted with (*) are significantly different. The x-axis 
labels are denoted by Gel or GMP, representing MSCs co-encapsulated with GMPs vs 
seeded on GMPs; 4 or 5, representing the crosslinking extent of GMPs at either 4mM vs 
5mM; and S or L, representing smaller 50-100µm GMPs vs larger 100-150µm GMPs. 
Error bars correspond to standard deviation for n=4 samples.  
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(A) (B) 
 
(C)  
 
Figure 8.6 (A) Type I Collagen, (B) Runx2, and (C) N-Cadherin expression for each 
experimental group at various time points. At each time point, groups connected with 
different letters are significantly different (p < 0.05). Within each group, time points 
connected by lines and noted with (*) are significantly different. The x-axis labels are 
denoted by Gel or GMP, representing MSCs co-encapsulated with GMPs vs seeded on 
GMPs; 4 or 5, representing the crosslinking extent of GMPs at either 4mM vs 5mM; and 
S or L, representing smaller 50-100µm GMPs vs larger 100-150µm GMPs. Error bars 
correspond to standard deviation for n=4 samples. 
215 
 
Table 8.1 Gelatin microparticles (GMP) of varying crosslinking and collagenase-
containing phosphate-buffered saline (CC-PBS) concentrations used to model GMP 
degradation. 
GMP Crosslinking* 2 mM, 3 mM, 4 mM, 5 mM 
CC-PBS Concentration (ng/mL)^ 0, 20, 100, 200 
* GMPs were crosslinked in a solution of glutaraldehyde at the concentrations indicated above at 4°C for 15 
h 
^ 20 ng/mL CC-PBS concentration was only tested for 2 mM and 3 mM GMPs 
 
Table 8.2 Experimental groups tested for the encapsulation of MSCs and GMPs in a 
hydrogel composite. 
 
Experimental 
Group 
Mode of MSC 
Encapsulation 
GMP Size of Dry GMP 
1 Gel Phase 4 mM 50 – 100 µm 
2 Gel Phase 5 mM 50 – 100 µm 
3 GMP-Seeded 4 mM 50 – 100 µm 
4 GMP-Seeded 5 mM 50 – 100 µm 
5 GMP-Seeded 4 mM 100 – 150 µm 
6 GMP-Seeded 5 mM 100 – 150 µm 
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Table 8.3 Forward (F) and reverse (R) primers used for real-time RT-PCR analysis. 
Gene Primer sequence Product length Reference* 
Type II Collagen (COL2A1) 
F: 5’-AACACTGCCAACGTCCAGAT-3’ 
R: 5′-CTGCAGCACGGTATAGGTGA-3’ 
201 [401] 
Aggrecan (ACAN) 
F: 5′-GCTACGGAGACAAGGATGAGT-3′ 
R: 5′-CGTAAAAGACCTCACCCTCCA-3′ 
114 [401] 
(Sex determining region Y)-box 9 
(SOX9) 
F: 5’-GAGCGAAGAGGACAAGTTCC-3’ 
R: 5’-GTCCAGTCGTAGCCCTTGAG-3’ 
72 - 
Type I Collagen (COL1A2) 
F: 5′-CCCAGAATGGAGCAGTGGTTA-3′ 
R: 5′-AGCAGACGCATGAAGGCAAG-3′ 
270 [401] 
Runt-related transcription factor 2 
(RUNX2) 
F: 5’-CCTTCCACTCTCAGTAAGAAGA-3’ 
R: 5’-TAAGTAAAGGTGGCTGGATAGT-3’ 
143 [412] 
N-cadherin (CDH2) 
F: 5’- CTGCTATTGATGCGGATGAC-3’ 
R: 5’-TGAACATGTTGGGAGAAGGA-3’ 
96 - 
Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) 
F: 5′-TCACCATCTTCCAGGAGCGA-3′ 
R: 5′-CACAATGCCGAAGTGGTCGT-3′ 
292 [401] 
* Primers without a reference were custom designed and validated 
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Chapter 9 
Conclusions 
The overall goal of this thesis was to engineer hydrogel composites as a 
regenerative scaffold and delivery vehicle for growth factors and stem cells, and to 
investigate their potential for osteochondral tissue regeneration. 
In the first specific aim, we utilized OPF hydrogel composites for the spatially 
controlled incorporation of IGF-1 and TGF-β3 to the chondral layer of bilayered 
constructs. We showed that the delivery of growth factors enhanced cartilage repair over 
blank hydrogel controls in an osteochondral defect in vivo. Additionally, it was revealed 
that the single delivery of IGF-1 alone elicited similar levels of osteochondral repair 
compared to dual delivery. In demonstrating the potential of hydrogel composites as 
growth factor delivery vehicles for cartilage repair, our next step emphasized improving 
the repair of the subchondral bone, understanding that the osteochondral unit comprises 
distinct cartilage and bone layers.  
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In the second specific aim, IGF-1 and BMP-2 were incorporated in the chondral 
and subchondral layers, respectively, of bilayered hydrogel composites and the effect of 
single or dual release of these growth factors on osteochondral repair was studied. BMP-2 
enhanced early subchondral bone repair and we found that the dual delivery of both 
growth factors improved subchondral bone formation over the delivery of IGF-1 alone. 
Additionally, correlation analysis was performed between specific cartilage and bone 
repair metrics to provide a fuller understanding of the osteochondral repair process. We 
found that there exists a significant correlation between the degree of subchondral bone 
formation and cartilage surface regularity, highlighting the importance of bone as a 
mechanical support for overlying cartilage.  
Although the findings from the first two specific aims demonstrate the utility of 
growth factor delivery as a strategy to augment repair in the wound healing environment, 
the use of stem cells also confer powerful potential to regenerate osteochondral tissue. In 
the third specific aim, we took advantage of GMPs as a temporary adherent-substrate, 
and the differentiation potential as well as condensation behavior of seeded MSCs were 
assessed. Non-seeded MSCs co-encapsulated with GMPs in OPF hydrogel composites 
were used as controls. We discovered that MSCs seeded on GMPs exhibited more cell-
cell contacts, greater chondrogenic potential, and a down-regulation of osteogenic 
markers compared to controls in the absence of exogenous serum or growth factors. Such 
results demonstrate the significance of physical cues in the microenvironment on 
progenitor cells and establish the value of GMPs within hydrogel composites as versatile 
modes for both growth factor and stem cell delivery. Overall, the work in this thesis 
provides insight into growth factor and stem cell delivery strategies for osteochondral 
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tissue engineering with the hope that holistic regeneration of osteochondral tissue may 
one day be realized. 
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